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Abstract 
Inflammation is a beneficial process in the body that involves immune cell migration in the 
tissue in response to injury or infection. Failure to resolve inflammation is seen in chronic 
inflammatory diseases, such as Chronic Obstructive Pulmonary Disease (COPD). Neutrophils 
are at the very centre of this process, where they persist in the tissue due to ongoing 
recruitment and delayed apoptosis. Furthermore, failure to phagocytose and kill important 
clinical pathogens such as the multi-antibiotic resistant Staphylococcus aureus, compounds 
the pathogenesis of inflammatory disease and patients succumb to life-threatening 
infections. The aim of this thesis was to determine whether tetraspanins, a family of 
transmembrane receptors that play roles in cell survival and immune functions, are involved 
in neutrophil lifespan and phagocytosis. 
Primary human neutrophils were isolated from the blood of healthy subjects and COPD 
patients. Anti-CD63 antibodies and Fab fragments delayed constitutive neutrophil 
apoptosis of both healthy and COPD neutrophils as indicated by morphology and Annexin-
V staining. Donors varied in their responsiveness to anti-CD63 antibodies. All subjects 
expressed CD63 and survival rates did not correlate with CD63 regulation.  
Anti-CD151 antibodies significantly reduced neutrophil phagocytosis of heat killed and live 
S. aureus but not S. pneumoniae or H. influenzae. Gentamicin protection assays confirmed 
that anti-CD151 antibodies reduced the number of intracellular viable S. aureus. 
Fluorescent microscopy showed that anti-CD151 antibodies reduced the numbers of 
pHrodo stained S. aureus present in the acidified phagosome.  
The data presents novel and potential roles for tetraspanins in pathways underpinning 
neutrophil survival and interaction with S. aureus. Our findings suggest that CD63 may play 
a role in neutrophil survival while CD151 may play a key role in neutrophil interaction with 
S. aureus. The study provides two potential molecular targets for modulating neutrophil 
lifespan and S. aureus neutrophil interactions.  
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Chapter 1-Introduction 
1.1. Mammalian immunity 
The immune system has a key role in maintaining homeostasis and protecting the organism 
against invading pathogens. The mammalian immune system can be further divided into 
innate and adaptive immunity. The innate immune system is mediated primarily by 
professional phagocytes such as neutrophils and macrophages and represents the first 
cellular line of defense against intruding pathogens (Silva, 2010). An important feature of 
the innate immune system is that it uses highly conserved receptors amongst the animal 
and plant kingdom to recognise specific pathogen structures. Adaptive immunity is 
considered to be more complex and is mediated largely by B and T lymphocytes (Iwasaki 
and Medzhitov, 2010, 2015). Lymphocytes express highly specific target receptors and 
utilise clonal selection and expansion to protect against later stages of infection, as well as 
maintaining an ‘immunological memory’ in case the threat is reencountered (Zinkernagel 
et al., 1996). 
1.1.1. Inflammation 
The concept of inflammation and its clinical symptoms has been known for a long time 
(Rather, 1971). The first four ‘cardinal’ symptoms were first described by Roman Cornelius 
Celsus in the first century as: redness, swelling, heat and pain. However, only in the second 
century the fifth ‘cardinal’ sign of impaired function was added to the list of symptoms. The 
two great microbiologists Louis Pasteur and Robert Koch went on to hypothesise that 
microorganisms can cause inflammation. We now know that invading pathogens can cause 
inflammation as a result of the host trying to contain and clear the infection. This is a highly 
regulated process, at the base of which neutrophil infiltration has a primary role. 
1.1.2. Neutrophils: role in immunity and inflammation 
Neutrophils are terminally differentiated, polymorphonucleated leukocytes, first 
discovered by Elie Metchnikoff in starfish larvae as cells responding to inserted rose thorns 
(Cavaillon, 2011; Korchak et al., 1983). In humans, neutrophils are the largest group of cells 
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in the circulation, comprising up to 70% of the leukocyte pool (Smith, 1994). It takes 14 days 
for the myeloid stem cell progenitor to produce functionally differentiated neutrophils at a 
rate of 108 cells/min (Bainton et al., 1971; Haslett, 1999; Haylock et al., 1992). At any time, 
humans have up to 1010 neutrophils in the circulation but this number can increase 10-fold 
during stress and infection (Cannistra and Griffin, 1988; Summers et al., 2010). Neutrophils 
contain a number of granules with highly toxic contents, packed during neutrophil 
development, with which they can protect against pathogen threats (Borregaard and 
Cowland, 1997a). 
1.1.2.1. Granulocytopoiesis 
The production of mature neutrophils and other granule containing cells from the common 
myeloid progenitor stem cells in the bone marrow is called granulocytopoiesis. The 
differentiation process as well as release into the circulation is tightly regulated. It is mainly 
dictated by the rate of neutrophil apoptosis and it requires a number of transcription 
factors, with PU.1 having a key role in committing the lineage to neutrophil production, and 
a tight regulation of bone marrow stromal cell-myeloid progenitor cytokine production 
(Bjerregaard et al., 2003; Borregaard, 2010; Lapidot and Kollet, 2002). 
Differentiation of stem cells to neutrophils takes several stages to ensure that the cells are 
fully functional. The process starts at the myeloblast stage, progressing through 
promyelocyte, myelocyte, metamyelocyte, band cells, segmented cells and finally to fully 
functional neutrophils (Glasser and Fiederlein, 1987). During these stages, the neutrophil 
will acquire granules and granule proteins, they will stop proliferating and finally they will 
form the segmented nucleus (Borregaard and Cowland, 1997b; Glasser and Fiederlein, 
1987). At the promyelocyte stage the azurophilic/primary granules are formed, containing 
myeloperoxidase, neutrophil elastase, defensins, serine proteases and antimicrobial 
peptides (Borregaard and Cowland, 1997b; Fouret et al., 1989). Secondary/specific granule 
containing lactoferrin, collagenase and haptoglobin as well as tertiary/gelatinase granules 
having gelatinase, ficolin-1 and arginase1 will form in myelocyte, metamyelocyte and band 
cells stages (Borregaard and Cowland, 1997b; Jacobsen et al., 2007; Rorvig et al., 2009; 
Theilgaard-Monch et al., 2006). During the segmented cell stage an additional set of 
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granules, called secretory vesicles are formed. These vesicles contain receptors involved in 
chemotaxis and recognition of conserved pathogen structures, such as complement 
receptor 3 (CR3), Fc receptors (FcR) and formyl peptide receptors (FPR) (Borregaard et al., 
1992; Borregaard et al., 1987; Nordenfelt and Tapper, 2011).  
1.1.2.2. Neutrophil release in the circulation 
Once they mature, neutrophils are released from the bone marrow into the circulation in 
response to cytokine cues. Chemokine receptor 4 (CXCR4), expressed by both mature 
neutrophils and progenitors, has a key role in retaining the cell in the bone marrow. CXCR4 
binds to chemokine ligand 12 (CXCL12) on bone marrow stromal cells and is important in 
regulating neutrophil homeostasis (Lapidot and Kollet, 2002). Deletion of CXCR4 in mice 
resulted in failure of neutrophil recruitment in response to stimuli while genetic mutations 
in the CXCR4 chemokine receptor gene have been positively correlated with neutropenia 
and WHIM immunodeficiency syndrome (Eash et al., 2009; Hernandez et al., 2003). CXCR2 
expression on myeloid cells also has a key role in homing the cells to the bone marrow, as 
shown by knockout studies where a constitutive mobilisation of neutrophils in circulation 
was noticed (Eash et al., 2010). Release of mature neutrophils from the bone marrow is 
pivotally orchestrated by granulocyte colony stimulating growth factor (G-CSF) levels 
(Cannistra and Griffin, 1988). G-CSF production is downregulated in response to neutrophil 
apoptosis as a result of a feedback mechanism. Neutrophil clearance results in interleukin-
23 (IL-23) decreased levels that promote IL-17A downregulation which ultimately induces 
G-CSF decreased production (Cannistra and Griffin, 1988; Schwarzenberger et al., 2000). 
The cytokine has two opposing roles: to disrupt the neutrophil bone marrow retention 
mechanism, by downregulating CXCR4 and its CXCL12 ligand, and to promote neutrophil 
migration by upregulating the production of CXCR2 ligands, CXCL1 and CXCL2, on bone 
marrow endothelium (Eash et al., 2010; Kim et al., 2006; Semerad et al., 2005; Wengner et 
al., 2008). 
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1.1.3. Neutrophil recruitment to the site of inflammation and bacterial clearance 
Under normal circumstances, neutrophils are released from the bone marrow in an 
inactivated state which is maintained until the cells are primed by a stimulus, making them 
ready to elicit an antimicrobial and inflammatory function (Southgate et al., 2008). 
Neutrophil priming often results in a mixed population containing both inactive cells as well 
as partially or fully activated neutrophils, as shown by both in vitro and in vivo studies 
(Gallin, 1984). Neutrophil priming is an essential step in neutrophil recruitment and 
migration to the site of infection/inflammation and is often done by inflammatory cytokines 
released from tissue such as granulocyte macrophage- colony stimulating factor (GM-CSF), 
tumor necrosis factor-α (TNF-α) and IL-1α (Ekpenyong et al., 2015). This is, however, not 
enough to elicit full neutrophil killing potential and a second activating agent or agonist is 
required, usually a bacterial product such as lipopolysaccharide (LPS) (Ekpenyong et al., 
2015).  
1.1.3.1. Movement of neutrophils to the site of inflammation 
Neutrophil priming is enough to start neutrophil adhesion to the blood vessel endothelium 
and subsequent leukocyte extravasation, a process often referred to as the neutrophil 
adhesion cascade (Ley et al., 2007). The first step that allows initiation of neutrophil 
adhesion cascade is the activation of the endothelium. This is driven by either cytokines 
(such as IL-1β, TNF-α, IL-8) released from tissue inflammatory cells, regarded as a slow 
activation, or by inflammatory stimuli ligation (such as histamines, thrombin and 
bradykinin) to the specific endothelial cell receptors, typically to G-protein coupled 
receptors (GPCRs), known as fast activation (Pober and Sessa, 2007). Activated endothelium 
expresses P- and E-selectin to the cell luminal surface, two molecules involved in neutrophil 
adhesion (Pober and Sessa, 2007). Neutrophils then undergo the initial steps of tethering 
and rolling on the endothelial membrane, which requires binding of P-selectin ligand-1 
(PSGL-1), CD44 and E-selectin ligand-1 (ESL-1) expressed by neutrophils to P-selectin and E-
selectin on endothelial cells (Buscher et al., 2010; Hidalgo et al., 2007). The subsequent 
neutrophil firm adhesion step is mediated by the lymphocyte function-associated antigen 1 
(LFA-1) and macrophage-1 antigen (Mac-1)/ αMβ2 integrin binding on neutrophils to 
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Intracellular adhesion molecule-1 and 2 (ICAM-1 or 2) on endothelial cells (Woodfin et al., 
2010; Zimmerman et al., 1992). Neutrophil L-selectin was shown to have role in this process, 
although this is controversial. In vivo study shows that inhibition of L-selectin shedding by 
neutrophils resulted in increased neutrophil firm adhesion and extravasation while in vitro 
study showed opposing result (Allport et al., 1997; Hafezi-Moghadam et al., 2001). 
Tetraspanins CD9 and CD151 can play a role in the endothelial cell membrane structural 
organisation to facilitate this process (Barreiro et al., 2008). This firm adhesion step 
coincides with activation of downstream signalling involved in neutrophil formation of the 
lamellipodium, which is required for the physical transmigration through the tissue, and 
also recruitment of receptors, needed for bacterial recognition and phagocytosis, to the 
surface of the cell (Borregaard, 2010; Van Keymeulen et al., 2006). The neutrophil 
transendothelial migration (i.e. movement through the endothelial layer) can be either 
paracellular, the most common form of extravasation involving movement between 
epithelial cells, or transcellular, which is more uncommon and involves penetration of the 
cell (Woodfin et al., 2010). Paracellular migration is mediated by platelet endothelial cell 
adhesion molecule 1 (PECAM-1), junctional adhesion molecule (JAM) –A,-B and –C; 
endothelial cell-selective adhesion molecule (ESAM), CD99, VE-cadherins (all of these have 
roles in stabilising the endothelial cell-cell junction), while Mac-1, LFA-1 interaction with 
ICAM-1, ICAM-2 are involved in the deeper migration of the neutrophils between the 
endothelium (Alcaide et al., 2009; Diamond et al., 1990; Muller et al., 1993; Woodfin et al., 
2009). The last step is neutrophil passage through the perivascular basement membrane 
into the tissue is mediated by CD99-CD99L2 and CD177-PECAM-1 interactions with the help 
of neutrophil stored matrix metalloproteinases (MMPs), which cleave the basement 
membrane (Bayat et al., 2010; Bixel et al., 2010; Kang et al., 2001).  
1.1.3.2. Bacterial recognition by neutrophils 
Once in the tissue, neutrophil migration to the site of infection is mediated by receptors 
that recognise both conserved bacterial structures and chemoattractants but also 
chemoattractants produced by the organism in response to the infection, such as the 
complement C5a (Foxman et al., 1999; Hopken et al., 1996). Chemoattractants can also fully 
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activate the neutrophil, that is why this process takes place proximal to the infection site to 
prevent unnecessary self-cell damage (Swain et al., 2002). These receptors are called 
‘pattern recognition receptors’ (PRR) and neutrophils contain a wide variety of such 
receptors.  
1.1.3.2a. Formyl peptide receptors 
One type of PRR receptor that neutrophils express are FPRs, involved in the chemotaxis and 
amplification of the phagocytic process. The receptors recognise formylated bacterial 
peptides, such as N-formyl-methionyl-leucyl-phenalanine (fMLP), produced by bacteria in 
high amounts during exponential growth (Bardoel and van Strijp, 2011). Neutrophils also 
contain specific receptors that allow chemoattractant prioritisation and migration towards 
the highest concentration of bacteria chemoattractants (Heit et al., 2008). FMLP binding to 
the FPR, a GPCR, results in Rho/Rac/Cdc42 signalling pathway activation and ROS 
production (Bokoch, 2005). What is more, this interaction is the prerequisite for neutrophil 
migration towards the fMLP gradient because it activates p38 which redistributes the 
chemoattractant prioritisation receptor around the cell, thus eliminating cell polarity and 
allowing specific neutrophil migration (Billadeau, 2008). 
1.1.3.2b. Toll-like and NOD-like receptors 
Toll-like receptors (TLRs) are amongst the most studied PRRs and are involved in the 
recognition of conserved bacterial structures called pathogen-associated molecular 
patterns (PAMPs). Neutrophils express all known TLRs, except TLR3 (Gordon, 2002; Hayashi 
et al., 2003; Takeuchi and Akira, 2010). The most studied is TLR4 which mediates recognition 
of LPS, a Gram-negative outer membrane glycoprotein, with the help of CD14 LPS-binding 
protein and myeloid differentiation factor 2 (Hayashi et al., 2003; Lugtenberg and 
Vanalphen, 1983; Takeuchi and Akira, 2010). TLR4 knockout mouse models show failure of 
neutrophil recruitment in response to LPS (Zhou et al., 2009). TLR2/TLR1 heterodimers can 
recognise diacylated and triacylated lipopeptides, found on the membrane of Gram 
negative and positive bacteria, while TLR2/TLR6 heterodimerisation allows recognition only 
of tryacilated lipopeptides (Bardoel and van Strijp, 2011; Schenk et al., 2009). Downstream 
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signal of TLR4 and TLR2 heterodimers results in the activation of TNFα, IL-1β and IL-6, 
cytokines involved in priming and recruitment of innate immune cells at the site of 
inflammation (Hayashi et al., 2003). TLR5 recognises flagellin, a conserved flagella 
component (Andersen-Nissen et al., 2007). TLR5 knockout studies have shown important 
role of the receptor in neutrophil recruitment and pneumonia development in response to 
Legionella pneumophila (Hawn et al., 2007). TLR7, TLR8 and TLR9, unlike the receptors 
mentioned above, are expressed in the endoplasmic reticulum (ER) (Takeuchi and Akira, 
2010). While TLR9 is involved in recognising unmethylated, CpG motif containing DNA and 
DNA sugar backbone 2’ deoxyribose, TLR8 and TLR9 recognise single stranded RNA (Haas et 
al., 2008; Heil et al., 2004; Takeuchi and Akira, 2010). 
Nucleotide-binding oligomerization domain protein (NOD)-like receptors (NLRs) are 
another type of receptor found in neutrophils, involved in the recognition of muramyl 
dipeptide peptidoglycan and g-D-glutamyl-mesodiaminopimelic bacterial structures 
(Berrington et al., 2010; Theivanthiran et al., 2012). Activation of NLRs will trigger increased 
phagocytosis, oxidative burst and cytokine production (Ekman and Cardell, 2010; Frutuoso 
et al., 2010). 
1.1.3.2c. Phagocytic/Opsonin receptors 
Neutrophils also express opsonin receptors: FcγRIIa, FcγRIIIb and CR3 (Fleit et al., 1982; 
Witko-Sarsat et al., 2000). While FcγRIIIb has a role in recruitment and clustering of FcγRIIa, 
both recognising IgG coated bacteria, the latter receptor has an important role in activating 
downstream signalling processes involved in bacteria engulfment and killing, being the most 
predominant phagocytic receptor in immune complexes (Chuang et al., 2000; Witko-Sarsat 
et al., 2000). CR3 recognises C3bi coated bacteria but does not directly trigger changes 
involved in bacterial killing and phagocytosis, however it promotes FcγRIIa cytoplasmic 
domain phosphorylation to bring about those functions (Schymeinsky et al., 2007; Todd, 
1996). Neutrophils also contain CR1 receptor, recognising C3b, and CR4, recognising C3bi, 
with functions in amplify bacterial phagocytosis and in promoting killing through ROS 
production and enzyme degranulation (Ross et al., 1978). In addition, neutrophils contain 
C-type lectin receptors that bind to and recognise conserved pathogen carbohydrate 
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structures, such as the dectin-1 lectin receptor that recognises fungal β-glucans (Brown, 
2006; McGreal et al., 2004).  
1.1.3.3. Neutrophil phagosome formation 
Neutrophils can kill bacteria through two main mechanisms: the first is phagocytosis which 
involves engulfment of bacteria and killing in a contained intracellular environment and the 
second is via neutrophil extracellular traps (NETs) whereby neutrophils trap and kill 
extracellular bacteria by exuding genetic contents in conjunction with cytosolic and 
antimicrobial peptides (AMPs) (Brinkmann et al., 2004). 
Phagocytosis is the most common mechanism by which neutrophils kill bacteria. It starts via 
FcγR ligation to the Fc region of IgG coated bacteria, triggering downstream signalling 
through the phosphorylation and dimerisation of the cytoplasmic tails containing the 
immunoreceptor tyrosine-based motif (ITAM) (Figure 1.1) (Cox and Greenberg, 2001; 
Swanson, 2008). The process involves a zipper model where the neutrophil membrane 
takes the shape of the ingested target. Initial steps in the process involves recruitment of 
Src-family kinases (SFK) to ITAM, which forms the platform for the recruitment of more 
kinases that will facilitate phagosome formation such as Syk, phospholipase Cγ (PLCγ), 
growth factor receptor-bound protein 2 (GRB2), GRB2-associated-binding protein 2 (GAB2) 
and phosphatidylinositol-3-kinase (PI3-K)(Figure 1.1) (Swanson, 2008). The end result is the 
conversion of the membrane lipid phosphatidylinositol -4,5 bisphosphate (PtdIns(4,5)P2) by 
PI3-K into phosphatidylinositol -3,4,5 trisphosphate (PtdIns(3,4,5)P3) (Figure 1.1) (Cox and 
Greenberg, 2001). The lipid has key role in recruiting kinases involved in actin 
polymerisation and phagosome shaping, including ADP-ribosylation factor 6 (ARF6)- 
guanine nucleotide exchange factor (GEF), ARF6 GTPase-activating protein (GAP), Rac1 and 
Cdc42 and Wiskott–Aldrich Syndrome protein (WASP) family, but also in the recruitment of 
myosin X, an important component in phagosome sealing (Figure 1.1) (Cox et al., 2002; Cox 
and Greenberg, 2001; Miki and Takenawa, 2003). PLCγ can also promote the conversion of 
PtdIns(4,5)P2 to inositol‑1,4,5-trisphosphate (Ins(1,4,5)P3) and diacylgycerol (DAG) (Figure 
1.1) (Swanson, 2008). DAG is a conical shaped lipid, able to flip across the membrane to 
promote membrane curving and advancement around the bacteria (Carrasco and Merida, 
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2007). Ins(1,4,5)P3 allows release of calcium from the ER, a step necessary in phagosome 
maturation by being part of the actin dissolving process, once the phagosome is closed, to 
allow granule fusion (Nunes and Demaurex, 2010). If the target is too big neutrophils can 
bring membranes from other components such as specific and primary granules, late 
endosome and the ER to aid in the process (Swanson, 2008). 
1.1.3.4. Neutrophil antimicrobial mechanism 
To give the phagosome antimicrobial activity, the phagosome must undergo a drastic, 
progressive conversion, known as phagosome maturation. Early phagosome formation 
starts even before its sealing by fusing with early endosomes, a prerequisite in phagosome 
sealing (Bajno et al., 2000; Roberts et al., 2000). This then transitions through the late 
phagosome, characterised by late endosome fusion, to the fully mature phagolysosome 
where it attains catabolic function through its fusion with neutrophil granules (Borregaard 
and Cowland, 1997b; Harrison et al., 2003). Granule fusion is a calcium concentration 
dependent process, taking place in a pre-set order with secretory vesicles being the first 
ones to fuse with it, followed by tertiary granules, specific and primary granules (Figure 1.1) 
(Borregaard and Cowland, 1997b; Nunes and Demaurex, 2010; Sengelov et al., 1993). 
Granule fusion facilitates the assembly of the nicotinamide adenine dinucleotide phosphate 
(NADPH) complex which pumps protons out of the phagolysososme to promote an acidic 
pH environment and ROS generation (Kobayashi et al., 2005; Segal, 2005). It also allows 
protease activation, such as gelatinase and collagenase cleavage by elastase (Delclaux et al., 
1996; Kobayashi et al., 2005; Segal, 2005). 
As a result, granule fusion exposes the organism to a vast array of AMPs and ROS. AMPs 
catabolise bacteria by targeting key bacterial survival components or deactivating highly 
pathogenic bacterial toxins. For example, lysozyme cleaves the bacterial cell wall between 
N-acetylglucosamine and N-acetyl muramic acid while lactoferrin has the double role of iron 
chelation, an important nutrient for bacterial survival, and membrane permeabilisation by 
promoting LPS release (Jenssen and Hancock, 2009; Wecke et al., 1982). Bactericidal 
permeability increasing protein (BPI) and cationic defensins form pores in the bacterial 
membrane to allow cell content leakage (Ooi et al., 1987; White et al., 1995). Other proteins 
- 10 - 
 
such as elastase are able to degrade membrane protein A, an important protein involved in 
the pathogenesis of Staphylococcus aureus (Belaaouaj, 2002). 
Neutrophils ROS vast array can induce severe microbial damage due to their ability to target 
key bacterial processes required for their survival (Hampton et al., 1998). The process of 
ROS production is driven by the NADPH complex, which upon assembly in the phagosome 
and plasma membrane, is able to transfer electrons to oxidise oxygen (Kobayashi et al., 
2005). Superoxide can synergistically interact with hydrogen peroxide to induce iron release 
from the bacterial iron-sulfur clusters, while the iron can be oxidised further to produce 
additional DNA-damaging ROS products (Jang and Imlay, 2007; Keyer and Imlay, 1996). 
Myeloperoxidase catalyses the interaction between hydrogen peroxide and different ions 
to form highly potent acids such as hyperchloric acid (Aiken et al., 2012; Nauseef, 2007). 
The acid, as well as its precursors, can interact with other proteins to oxidise them or to 
abrogate bacterial energy transduction and protein biosynthesis at plasma membrane 
(Hurst, 2012; Witko-Sarsat et al., 2000). Furthermore, superoxide can interact with nitric 
oxide, produced by either nitric oxide synthase (NOS), or inducible NOS to form 
peroxynitrite, a key bactericidal molecule with multiple roles including: DNA damage, ion 
channel inactivation and disruption of signal transduction (Forstermann et al., 1991; 
Marletta, 1993; Ye et al., 1996). 
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Figure 1.1: Bacterial recognition and phagocytosis by neutrophils. 
The IgG opsonised pathogen is recognised by FcγRII dimers which recruit SFK via ITAM 
motifs. This then forms a platform for the recruitment of the Syk kinase which 
phosphorylates (yellow dot) and activates the ITAM. Recruitment of the GRB2 and GAB2 
then takes place to the ITAM region. These kinases activate PI3-K which catalyses the 
conversion of PtdIns(4,5)P2 to PtdIns(3,4,5)P3. The lipid will recruit myosin X as well as ARF1-
GEF and ARF6-GAP. These regulatory proteins in turn promote the activation/ deactivation 
of Rac1/Cdc42 to recruit WASP family kinases. This will have the end result of actin 
polymerisation and membrane advancement around the target. Syk also phosphorylates 
and recruit PLCγ which promotes the conversion of PtdIns(4,5)P2 into Ins(1,4,5)P3 and DAG. 
The latter lipid inserts into the neutrophil membrane and promotes its curving round the 
target while the latter promotes Ca2+ release from the ER. The Ca2+ will then promote 
granule fusion with the phagosome to form the phagolysosome. This will take place in a 
Ca2+ concentration dependent manner, with secretory vesicles being the first to fuse, 
requiring the least amount of Ca2+, followed by tertiary, secondary and primary granules. 
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1.1.4. The molecular mechanism of neutrophil apoptosis 
Kerr et al., 1972 described for the first time the process of apoptosis as a series of events 
comprising of chromatin and cytoplasmic condensation, DNA fragmentation and membrane 
blebbing, allowing subsequent clearance of the cells by macrophages (Bratton and Henson, 
2011). Neutrophils are short-lived cells with a half-life in the circulation of 8 hours or, if 
recruited to the tissue, lifespan can be increased up to 2 days (Bainton et al., 1971; Cronkite 
and Fliedner, 1964; Elbim and Estaquier, 2010; Kim et al., 2011). However, an alternative 
study demonstrated that neutrophil lifespan in circulation is 5.4 days, although this 
discovery is controversial (Pillay et al., 2010; Tak et al., 2013). The main purpose of 
neutrophil apoptosis is to maintain homeostasis and to allow a quick resolution of 
inflammation, therefore it happens even in the absence of extracellular stimuli (Filep and El 
Kebir, 2009). Failure to do so can result in the development of inflammatory diseases which 
will be described later in this chapter. 
The key features that can be observed in apoptotic neutrophils are that they are 
unresponsive to external stimuli, they are unable to phagocytose and that they express ‘find 
me’ and ‘eat me’ signals to allow macrophage recognition and clearance (Bratton and 
Henson, 2011; Haslett et al., 1994; Savill and Haslett, 1995). Diseases such as Kostmann 
syndrome and chronic congenital neutropenia, whereby neutrophil number is dramatically 
reduced, have shown that an imbalance in neutrophil number by accelerated apoptosis 
results in failure of the organism to mount an appropriate immune response against 
invading pathogens (Carlsson et al., 2004; Klein et al., 2007; Rosenberg et al., 2006). This 
suggests that for a system to function adequately and maintain homeostasis, neutrophil 
clearance and turnover must be in perfect equilibrium. 
Neutrophil apoptosis can be induced via an extrinsic pathway, involving extracellular signals 
and death receptors activation, or via an intrinsic/mitochondrial pathway resulting from 
intracellular events such as ROS release, damaged DNA and permeabilisation of the 
mitochondrial membrane (Geering and Simon, 2011; Maianski et al., 2003; Zhang et al., 
2003a). Depending on their location, apoptotic neutrophils are cleared by resident tissue 
macrophages or homed to the spleen, liver or bone marrow for clearance by specialised 
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macrophages such as the Kupffer cells in the liver (Bratton and Henson, 2011; Summers et 
al., 2010). Interestingly, neutrophil clearance in the bone marrow begins when senescent 
neutrophils express high levels of CXCR4 which allows homing back to CXCL12 (Martin et 
al., 2003) The lifespan of neutrophils can be modulated by cytokines such as GM-CSF and 
TNF-α or by factors secreted by pathogens such as LPS and Pyocyanin, and most recently 
evidence has started to emerge about the involvement of granule proteases in modulating 
this function (Benarafa and Simon, 2017; Colotta et al., 1992; Haslett et al., 1985; Lee et al., 
2003; Rapoport et al., 1992; Usher et al., 2002). Such a granule protease is cathepsin D that 
is able to mediate neutrophil apoptosis either through a caspase-dependent or 
independent pathway (Baumann et al., 2013). 
1.1.4.1. The Bcl-2 protein family regulates mitochondrial apoptosis  
Programmed cell death occurs in most vertebrate cells via the intrinsic/mitochondrial 
apoptotic pathway (Adams, 2003; Green and Kroemer, 2004). The intrinsic apoptotic 
pathway depends on the integrity of the mitochondrial membrane. Interestingly, research 
has suggested that the sole purpose of the neutrophil mitochondria is to modulate 
apoptosis and not to be involved in energy generation, the main function of mitochondria 
in other cell types (Maianski et al., 2003). 
The integrity of the mitochondrial membrane is maintained by B cell lymphoma 2 (Bcl-2) 
family of proteins. Although the name of the family comes from the first protein in the group 
discovered, neutrophils do not express Bcl-2 (Moulding et al., 2001). This family contains 
two antagonising groups of proteins, pro- and anti-apoptotic (Martinou and Youle, 2011). 
From these, the anti-apoptotic proteins found in neutrophils are: myeloid leukemia cell 
differentiation protein (Mcl-1) and A1, while the pro-apoptotic one includes: Bcl-2 
associated x protein (Bax), Bcl-2 like 11 (Bim), Bcl-2 associated antagonist/killer (Bak), Bcl-2 
associated death promoter (Bad), Bcl-2 interacting killer (Bik) and BH3 interacting-domain 
death agonist (Bid) (Geering and Simon, 2011; Santos-Beneit and Mollinedo, 2000; van 
Raam et al., 2006) 
The Bcl-2 family regulate cell death via α-helical BH domains (BH1-4) (Zha et al., 1996). The 
BH3 domain is used by pro-apoptotic proteins to bind into the hydrophobic cleft formed by 
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the BH1, BH2 and BH3 domain of the anti-apoptotic group to mediate cell death (Adams 
and Cory, 1998; Chittenden et al., 1995; Zha et al., 1996). In contrast, the BH1 and BH2 
regions of the anti-apoptotic group are required for the heterodimerisation with the pro-
apoptotic Bcl-2 family members to inhibit cell apoptosis (Yin et al., 1994). 
1.1.4.2. The intrinsic/mitochondria neutrophil apoptosis  
In neutrophils, Mcl-1 is probably the best studied Bcl-2 family member and has a key role in 
the regulation of the intrinsic apoptotic pathway. At high levels, the protein inhibits the pro-
apoptotic proteins Bim and Bak, and loss of Mcl-1 in mice results in a profound reduction in 
neutrophil survival (Dzhagalov et al., 2007; Thomas et al., 2010). Mcl-1 half life in 
neutrophils is only 3 hours due to the presence of a VTLISFG motif that targets the protein 
for poly-u-biquitination and degradation, explaining the short neutrophil lifespan (Moulding 
et al., 2001; Xiao et al., 2014). To initiate intrinsic apoptosis, the Mcl-1 levels decrease 
allowing Bax and Bak oligomerization and insertion in the mitochondrial membrane (Figure 
1.2) (Dzhagalov et al., 2007). This results in cytochrome c release which then associates with 
apoptotic-protease-activating factor-1 (Apaf-1) to form the apoptosome complex (Murphy 
et al., 2003; Zou et al., 1997). This complex recruits and activates the apical caspase, 
caspase-9, which then activates caspase-3, leading to the degradation of cellular 
components and apoptosis induction (Figure 1.2) (Adams, 2003; Murphy et al., 2003; Zou 
et al., 1997). Interestingly, caspases have been shown to be involved in regulating Mcl-1 by 
degrading it in aged neutrophils, to promote neutrophil apoptosis, but not at early time 
points (Wardle et al., 2011). This suggests that that Mcl-1 promotes neutrophil apoptosis 
by being both an upstream regulator of the pathway but also by having its turnover 
regulated by downstream caspases. Other members have shown as well important roles in 
the intrinsic neutrophil apoptosis pathway. For instance, Bim pro-apoptotic protein 
knockout in mice resulted in increased neutrophil survival and neutrophilia (Bouillet et al., 
1999). Moreover, A1 knockout mice present neutrophils that have accelerate intrinsic 
apoptosis and diminished survival in response to stimuli as well as inability to trans-migrate 
through the endothelium (Moulding et al., 2001). 
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1.1.4.3. The extrinsic apoptotic pathway  
As mentioned above, extrinsic apoptosis requires an extracellular signal to activate a 
transmembrane death receptor such as Fas, TNF-receptor 1 (TNF-R1) and TNF-related 
apoptosis-inducing ligand receptor 1 or 2 (TRAIL-R1/2) (Guicciardi and Gores, 2009; Park et 
al., 2007). They are activated by the binding of the trimeric ligands of the TNF cytokine 
family, TNF-α and Fas ligand (FasL) (Figure 1.2) (Ashkenazi and Dixit, 1998; Park et al., 2007). 
Upon ligand binding, the death receptor is stabilised and recruits to its C-terminal death 
domain the Fas-associated death-domain containing protein (FADD) and to FADD N-
terminal the death effector domain (DED) to then associate with the procaspase-8 to form 
the death-inducing signalling complex (DISC) (Galluzzi et al., 2012; Guicciardi and Gores, 
2009; Kischkel et al., 1995). In neutrophils, the extrinsic pathway is not enough to initiate 
downstream signalling involved in cell death and the signal must be amplified via the 
intrinsic pathway by the activation of Bid through its truncation by procaspase-8 and of 
consequent processes involved in cell death (Figure 1.2) (Korsmeyer et al., 2000; Scaffidi et 
al., 1998). The extrinsic pathway does not play a role in neutrophil turnover when 
neutrophils are in a functional quiescent state but rather when they are dealing with an 
infection or inflammation (Jonsson et al., 2005; Nadeau et al., 2008). 
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Figure 1.2: Intrinsic and extrinsic neutrophil apoptosis pathways. 
The extrinsic apoptotic pathway starts by the recruitment and cleavage of caspase -8 (gray 
bar) when TNF-α/FasL/TRAIL (blue cube) binds to the Fas/TNF-R1/TRAIL-R1/2 death 
receptor (dark blue cylinder). This in turn truncates Bid and induces release of cytochrome 
c (yellow stars) from the mitochondria. The intrinsic apoptotic pathway is activated upon 
Mcl-1 rapid turnover. As a result, Bax (light red cylinder) and Bak (dark red cylinder) 
oligomerise and insert into the mitochondria membrane, triggering cytochrome c release. 
Both pathways then lead to the formation of the apoptosome through the interaction of 
cytochrome c with Apaf-1 (purple circle with cross). The apoptosome recruits and cleaves 
caspase-9 (brown), leading to the activation caspsase-3 (green). The activation results in 
DNA damage, as a result of caspase-3 activated DNase that will fragment the DNA, action 
which commits neutrophils to irreversible apoptosis. 
- 18 - 
 
1.1.5. Neutrophil clearance and inflammation resolution  
1.1.5.1. Neutrophil efferocytosis 
The clearance of apoptotic cells by macrophages is called efferocytosis. Apoptotic 
neutrophils express ‘find-me’ and ‘eat-me’ signals that are rapidly recognised by tissue 
macrophages, facilitating their ingestion (Bratton and Henson, 2011; Savill and Haslett, 
1995). 
‘Find-me’ signals are diffusible signals that attract macrophages to the site of the apoptotic 
cell(s). Such signals include ATP, lysophosphatidylcoline or damage associated molecular 
patters (DAMPs) (Bournazou et al., 2009; Ravichandran, 2010). Neutrophils also have a wide 
repertoire of cell-surface ‘eat-me’ signals which are recognised by macrophage receptors 
and allow docking of the apoptotic cell. Amongst these, the best characterised is 
phosphatidylserine, found in the inner leaflet of the plasma membrane that becomes 
exposed on the external leaflet during apoptosis (Fadok et al., 1992). Other factors that can 
trigger efferocytosis by macrophages are phosphorylcoline, CRs, calreticulin, ICAM-1 
epitope changes as well as changes in cell surface charge and glycosation (Bratton and 
Henson, 2011; Greenlee-Wacker, 2016; Ravichandran, 2010). 
Efferocytosis enhances inflammation resolution two-fold. In addition to clearing 
inflammatory cells it induces an anti-inflammatory macrophage phenotype whereby they 
secrete anti-inflammatory cytokines such as IL-10 and transforming growth factor-β (TGF-
β), suppress the production of TLRs, IL-6, IL-8 and TNF-α, and promote tissue endothelium 
and epithelium repair by enhancing the production of vascular endothelial growth factor 
(VEGF) (Bratton and Henson, 2011; Fadok et al., 1998; Leibovich et al., 2002). 
1.1.5.2. Neutrophil reverse migration 
There is emerging evidence that neutrophils can be cleared through a process of reverse 
migration, also known as retrograde chemotaxis (Mathias et al., 2006). This process is 
characterised by neutrophil migration away from the inflammation site and into the 
bloodstream during inflammation resolution. Using a rat model, it was shown that more 
than 70% of neutrophils returned to the circulation rather than undergoing apoptosis 
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(Hughes et al., 1997). Zebrafish larvae models have shown that neutrophils reverse migrate 
into the vasculature and factors such as tissue hypoxia can impede this process, thus 
delaying inflammation resolution (Elks et al., 2011; Hughes et al., 1997; Mathias et al., 
2006). The two in vitro studies conducted show quite different results. In the first study 
0.25% of the neutrophil population could reverse migrate through an epithelial monolayer 
while in a second, microfluidics analysis up to 90% of neutrophils could reverse migrate for 
more than 1,000µm from chemoattractants (Buckley et al., 2006; Hamza et al., 2014). 
Despite the fact that reverse migration has been demonstrated both in vivo and in vitro, the 
variation in the number of neutrophils undergoing this process, probably due to the use of 
different systems, fail to give an accurate quantification of the human cells committing to 
this. 
1.1.6. The role of the neutrophil in inflammatory disease 
Neutrophil numbers in tissue have been positively correlated with disease such as chronic 
obstructive pulmonary diseases (COPD), acute respiratory distress syndrome (ARDS), 
rheumatoid arthritis, asthma and chronic granulomatous disease (CGD) (Brusselle et al., 
2011; Louis and Djukanovic, 2006; Pillinger and Abramson, 1995; Plataki et al., 2006; Quie 
et al., 1967; Quint and Wedzicha, 2007). In CGD, an X-linked inherited immunodeficiency 
disease, neutrophils are unable to mount an adequate immune response in infection due 
to a defect in the NADPH oxidase (Baehner and Nathan, 1967a, b; Kuijpers and Lutter, 2012; 
Odell and Segal, 1991; Quie et al., 1967). 
Neutrophils have also been shown to facilitate the progression of rheumatoid arthritis by 
destroying joint cartilage and bone as a result of prolonged neutrophil survival at the site of 
inflammation (Mohr et al., 1981; Ottonello et al., 2002; Pillinger and Abramson, 1995; 
Wittkowski et al., 2007). What is more, the granule enzymes such as lactoferrin, 
myeloperoxidase, gelatinase and others, are able to promote an inflammatory phenotype 
by enhancing neutrophil survival and preventing tissue repair (Wong et al., 2009; Wright et 
al., 2014). Neutrophilic asthma phenotype is encountered in 50% of all asthmatic patients 
with the disease progression being modulated by increased IL-8 production that enhances 
increased neutrophilic chemotaxis to the site of inflammation and augmented neutrophil 
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survival (Baines et al., 2011; Douwes et al., 2002). What is more, patients that suffer from 
neutrophilic asthma, unlike healthy individuals, are often colonised more with bacteria such 
as S. aureus, M. catarrhalis and Haemophilus influenzae (H. influenzae), that have been 
linked to promoting neutrophilic exacerbations (Green et al., 2014; Redinbo, 2014). 
1.1.6.1. Neutrophil implication in COPD pathology 
COPD is one of the leading causes of morbidity and mortality worldwide and according to 
the World Health Organisation (WHO) is predicted to become the third leading cause of 
death by 2030. The disease is characterised by chronic systemic and airway inflammation 
and is mainly initiated by cigarette smoking but it may include other genetic and 
environmental factors (Lowell et al., 1956; Silverman and Speizer, 1996). Interestingly, the 
most prevalent environmental risk factor is internal air pollution, estimated to affect 3 
billion people worldwide, resulted from burning of coal, wood or crop residues for food 
preparation or home heating (Torres-Duque et al., 2016). Genetic factors for COPD are not 
well understood but studies of a number of gene polymorphisms have been positively 
associated with the disease. COPD related gene polymorphisms have been found in the 
antioxidative system, such as the glutathione S-trasferase (GST) gene, and in the protease 
inhibitor system, such as the one in the α1-antitripsin gene family, as well as in the 
inflammation-specific genes, such as the TGF-β1 specific genes (Celedon et al., 2004; de 
Serres and Blanco, 2012; Shukla et al., 2011). Activated neutrophils colonise the bronchial 
wall and lumen as well as lung alveolar space (Koenderman et al., 2000; Ludwig et al., 1985; 
Oudijk et al., 2006; Pesci et al., 1998). Sputum collection from COPD patients has shown 
increased neutrophil survival and a 30% increase in neutrophil numbers while neutrophil 
proteases secretion, such as neutrophil elastase, have been correlated with emphysema 
and mucus hypersecretion in the lungs (Damiano et al., 1986; Nadel, 1991; Perng et al., 
2004; Zhang et al., 2012). 
To date there is not a full understanding of the mechanisms involved in the dysregulated 
function of neutrophils in COPD patients. It is known, however, that the collective role of 
multiple factors such as failure to kill invading pathogens, inability to undergo apoptosis and 
capacity to release enhanced amounts of proteases can drive disease progression 
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(Hoenderdos and Condliffe, 2013). The only well-established mutation that has been linked 
to the development of COPD phenotype is in the α1-antitripsin gene (de Serres and Blanco, 
2012; Laurell and Eriksson, 1963). This mutation prevents α1-antitripsin to bind and inhibit 
neutrophil elastase to protect against tissue damage (Tetley, 1993). Furthermore, bacteria 
such as S. aureus and H. influenzae commonly colonise the respiratory tract of COPD 
patients and have been positively linked to exacerbations (Hoenderdos and Condliffe, 2013; 
Redinbo, 2014). What is more, people suffering from COPD are at a high risk of sepsis 
(Almirall et al., 1999). This is most probably because neutrophils from COPD patients show 
heightened responsiveness to inflammatory mediators such as LPS, TNF-α and GM-CSF 
(Langereis et al., 2011; Richards et al., 1989). 
1.2. Respiratory pathogen Staphylococcus aureus and the threat of MRSA 
S. aureus is a Gram positive cocci, commonly found on many tissues including skin and 
respiratory tract tissues. It causes a range of infections from sub-clinical soft tissue 
infections to the more serious endocarditis and bacteraemia. An NHS report looking at S. 
aureus bacteremia cases between April 2015 and March 2016 showed 11,405 such cases, a 
7.1% increase compared to the previous year. Out of these, 7.2% were caused by methicillin 
resistant S. aureus (MRSA) (Accute Trust et al., Official statistics 2016) . Mortality rates for 
MRSA are three times higher than other S. aureus infections (Blot et al., 2002). This is 
because MRSA is resistant to β-lactam antibiotics as well as other classes of antibiotics, 
comprising even the last resort antibiotics vancomycin and ciprofloxacin (Blumberg et al., 
1991; Roberts et al., 2013; Sieradzki et al., 1999). Initial MRSA cases were only hospital 
acquired but now community acquired MRSA, genetically distinct from the hospital 
acquired strains, are more prevalent (Bishara et al., 2012). From the MRSA diagnosed in 
hospitals, 92.5% are still sensitive to non-lactam based antibiotics. Most alarming, recent 
statistics estimate that by 2050 there will be 10 million deaths per year due to antimicrobial 
resistance attributed to E. coli, Klebsiella pneumoniae and S. aureus (de Kraker et al., 2016). 
This urges the development of new therapies that do not put high selective pressure on the 
bacteria and recent therapeutic target strategies have shown great potential for 
tetraspanins (Ventress et al., 2016). 
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1.2.1. S. aureus evasion of neutrophil defences 
The importance of neutrophils in defending against S. aureus infections was shown in 
disease where alterations in the number and function of neutrophils, such as CGD, resulted 
in the inability of the organism to cope with the infection (Odell and Segal, 1991; Quie et 
al., 1967). Despite the vast antimicrobial repertoire neutrophils employ in the defense 
against intruding pathogens, S. aureus has evolved many mechanisms to evade neutrophil 
defenses. These can range from stopping neutrophil recruitment to evading killing by 
neutrophils, adding to the problem of bacterial resistance. 
Initial steps in neutrophil adhesion and rolling to blood vessels endothelium are targeted 
through two S. aureus secreted proteins: staphylococcal superantigen-like 5 (SSL5) and 
extracellular adherence protein (EAP) that binds to P-selectin and ICAM-1, respectively, on 
endothelial cells to prevent interaction with their equivalent neutrophil ligands (Figure 1.3) 
(Bestebroer et al., 2007; Chavakis et al., 2002). Chemokine recognition and activation of 
neutrophils is also targeted by a number of factors secreted by S. aureus. SSLs family 
members have an important role in the process. SSL5 binds to FPRs and leukotriene B4 
receptor to prevent sensing of chemotactic factors while SSL3 binds to TLR2 to inhibit 
activation of TLR1/TLR2 and TLR2/TLR6 complexes (Figure 1.3) (Bardoel et al., 2012; 
Bestebroer et al., 2009). Chemotaxis inhibitory protein of Staphylococcus (CHIPS) and FPR-
1 like inhibitory proteins (FLIPr and FLIPr-like) also bind to FPRs to prevent chemotaxis 
towards fMLP and phenol soluble modulins (Figure 1.3) (Haas et al., 2005; Prat et al., 2006; 
Prat et al., 2009). CHIPS also binds to C5aR to prevent interaction with C5a (Haas et al., 
2005). Staphopain A is another factor secreted by MRSA to prevent IL-8 binding to its 
neutrophilic receptor, CXCR2 (Figure 1.3) (Laarman et al., 2012). 
S. aureus has also adapted to evade opsonisation. A number of factors are involved in this 
process. Aureolysin prevents opsonisation by inactivating C3 central complement 
component while staphylococcal complement inhibitor (SCIN) binds to the C3 convertase 
to inhibit its enzymatic activity (Figure 1.3) (Laarman et al., 2011; Rooijakkers et al., 2005a). 
Staphylococcal protein A (SpA) and staphylococcal IgG-binding molecule (Sbi) bind to the Fc 
region of IgG to prevent phagocytosis (Figure 1.3) (Forsgren and Nordstro.K, 1974). Other 
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proteins have dual effect such as staphylokinase (SAK) that can cleave both IgG and C3b 
while SSL7 can bind to IgA and C5 to prevent opsonisation and phagocytosis (Figure 1.3) 
(Laursen et al., 2010; Rooijakkers et al., 2005b). 
Interestingly, the mechanisms that S. aureus employs to evade neutrophil killing have also 
evolved to deactivate both ROS and AMPs. To protect itself from ROS S. aureus uses a 
number of factors including staphyloxanthin, golden pigment, catalases and surface factor 
promoting resistance to oxidative killing (SOK) (Figure 1.3) (Liu et al., 2005; Malachowa et 
al., 2011; Mandell, 1975). To protect against lysozyme, the bacteria modifies its 
peptidoglycan wall by introducing an O-acetylation in the wall while defensins protection is 
done by reducing its negative membrane charge to repel the cationic peptides or by using 
SAK to bind α-defensins (Figure 1.3) (Bera et al., 2005; Jin et al., 2004; Peschel et al., 2001). 
Carotenoid pigments are also widely used to protect against cationic AMP (Figure 1.1) 
(Mishra et al., 2011). 
1.3. Tetraspanin overview 
Tetraspanins are a highly conserved superfamily of membrane spanning receptors, 
consisting of 33 members in mammals (Boucheix and Rubinstein, 2001; Garcia-Espana et 
al., 2008; Huang et al., 2005). According to a phylogenetic analysis conducted by (Garcia-
Espana et al., 2008), the tetraspanin family can be divided into four subfamilies: the 
uroplakins, the retinal degeneration slow (RDS) subfamilies, the CD (cluster of 
differentiation) superfamily and the CD63 family. All tetraspanins are membrane spanning 
proteins involved in a wide variety of processes including cell signalling, adhesion, migration 
and proliferation (Charrin et al., 2014; Hemler, 2003, 2005; Jiang et al., 2015; Schwander et 
al., 2003; Termini and Gillette, 2017). Due to the focus of this thesis, the following sections 
will concentrate on the most studied tetraspanins expressed on immune cells: CD9, CD37, 
CD53, CD63, CD81, CD82 and CD151. 
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Figure 1.3: S. aureus evades detection and killing by neutrophils. 
Interaction to the endothelial cells is stopped by the secreted proteins SSL5, which prevents 
interaction of PSGL-1 with P-selectin, and EAP, which prevents interaction of LFA-1 and 
αMβ2 with ICAM-1. SSL3 secreted protein binds to TLR 1/2 and TLR 2/6 while Staphopain A 
prevents recognition of CXCR2 by IL-8. CHIPS, FLIPr and FLIPr-like bind to the N-terminus of 
the FPRs and C5aR receptors, which recognise fMLP, phenol soluble modulins and C5a. S. 
aureus secrets Sbi and SpA proteins on the surface to bind antibodies while SAK and SSL7 
cut and deactivate the Fc part of the antibody. Proteins secreted by S. aureus also deactivate 
members of complement cascade: aureolysin deactivates C3, SSL7 cleaves C5, SCIN binds 
the convertase and SAK cleaves C3b. Protection against killing in the phagosome is mediated 
by golden pigment (yellow spheres), staphyloxanthin (orange spheres) and catalases which 
protect against hydrogen peroxide (H2O2) and singlet oxygen (O2-). Peptidoglycan wall 
changes allows protection against lysostaphin. Additional mechanism used employ 
increasing the positive change of the membrane to repel the positively charged defensins 
or using SAK protein to bind them as well as using carotenoid pigment (yellow-green 
spheres) to bind the positively charged AMPs. 
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1.3.1. The biochemistry of tetraspanins 
Tetraspanins are small proteins of 200-350 amino acids that protrude 3-5nm from the 
membrane, with several common structural characteristics: four transmembrane 
hydrophobic helixes, a small (EC1) and a large (EC2) extracellular domain, a short 
intracellular loop and amino- and carboxyl intracytoplasmic tails (Figure 1.4) (Boucheix and 
Rubinstein, 2001; Stipp et al., 2003). Some tetraspanins (CD63, CD151, CD37, CD82) also 
contain the Yxxⱷ C-terminal tyrosine based internalisation/lysosomal motif, where ⱷ 
represents a bulky hydrophobic amino acid residue, which allows their endocytosis by 
adaptor proteins (AP) (Berditchevski, 2001). The crystal structure of tetraspanins took many 
years to solve due to the requirement of a membrane for the proteins to keep their 
structures. For this reason, only the structure of the soluble EC2 domain was available 
(Kitadokoro et al., 2001). However, recently the full crystal structure of CD81 tetraspanin 
was elucidated. It shows that the tetraspanin adopts a cone like structure with an 
intramembrane cavity that can be occupied by cholesterol and molecular dynamics 
simulations suggest that CD81 can alter between a closed and open conformation, where 
cavity cholesterol binding shifts the state of the tetraspanin into a closed one (Zimmerman 
et al., 2016). The authors also speculate that the open conformation promotes tetraspanin-
partner interactions while the closed conformation may form weaker tetraspanin-partner 
interactions. 
The EC1 and EC2 domains are the most variable regions between tetraspanins and species. 
The EC2 has a mushroom-like structure where the more conserved 3 α-helical regions (A, B, 
E) form the “stalk” (Figure 1.4) (Hemler, 2003; Kitadokoro et al., 2001; Stipp et al., 2003). 
“The head” of the mushroom is the most variable region, containing 2 α-helixes (C, D) as 
well as the conserved signature motif Cys-Cys-Gly (CCG) and, in some tetraspanins, 2-4 
additional Cys residues that form a disulphide bridge network (Figure 1.4). The EC2 domain 
has been shown to be required to form an association with partner proteins while little is 
known about EC1 role in cell function, with some evidence showing a role in cell trafficking 
(Kazarov et al., 2002; Masciopinto et al., 2001; Zhu et al., 2002). 
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The four transmembrane α-helixes have a pocket formed by the parallel association of the 
transmembrane helixes 1 and 4 with 2 and 3 (Zimmerman et al., 2016) The transmembrane 
domains also have polar residues that are involved in hydrogen bond formation with lipid 
alkyl chains, to stabilise the tetraspanin structure (Figure 1.4) (Gratkowski et al., 2001; Zhou 
et al., 2001). Furthermore, the tetraspanins have intracellular palmitoylation sites, ranging 
from 0-6; palmitoylation aids in the orientation of the short intracellular loop and the N and 
the C intracytoplasmic tails (Figure 1.4) (Yang et al., 2002; Yauch et al., 2000). The 
palmitoylation sites can form as well hydrophobic interactions with membrane lipids to 
stabilise the structure of the tetraspanin and confer a level of rigidity to the membrane 
(Yang et al., 2002; Yauch et al., 2000). Palmitoylation also helps tetraspanins to organise 
themselves into “tetraspanins enriched microdomains” (TEMs) (Berditchevski et al., 2002; 
Charrin et al., 2002; Hemler, 2003, 2005). Evidence shows that loss of palmitoylation results 
in failure of tetraspanins to interact with other partner tetraspanins, leading to impaired 
cell signalling and disease formation (Charrin et al., 2002; Stuck et al., 2015; Termini and 
Gillette, 2017; Yang et al., 2002). 
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Figure 1.4: The structure of tetraspanins. 
The tetraspanin is formed of four transmembrane domains, an EC1 and EC2 domains, an 
intracellular loop and two, an N- and a C-, intracytoplasmic tails. The EC2 contains a 
conserved region or “the stalk” comprised of 3 α-helixes and a variable region or “the head”. 
The variable region contains a CCG motif (yellow circles) which form disulfide bridges (red 
line). Other tetraspanins contain additional 2-4 cysteine residues (white circles) which can 
form disulfide bridges (only 2 additional cysteine residues are represented). Tetraspanins 
also have palmitates or intracellular palmitoylation sites. Polar residues are also found in 
the 4 transmembrane domains (red circles). 
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1.3.2. Tetraspanin interactions with partner molecules 
The CD and CD63 tetraspanin family members can laterally interact via the EC2 or 
transmembrane domain with members of the integrin family, major histocompatibility 
complex (MHC), immunoglobulin superfamily and growth factor receptors to induce signal 
transduction as well as modulating fundamental biological processes by binding to 
signalling molecules through their cytoplasmic domains (Table 1.1) (Charrin et al., 2009; 
Hemler, 2003; Yanez-Mo et al., 2009; Yu et al., 2017; Yunta and Lazo, 2003b). The most 
common interactions of tetraspanins are with integrins. Integrins are membrane proteins 
involved in cell adhesion and signalling, comprised of heterodimers formed from one of the 
18 α subunits and one of the 8 β subunits (Laflamme et al., 1994). The most studied integrin-
tetraspanin interactions are with CD151. Direct CD151-integrin interactions have been 
shown with α3β1, α6β1, α6β4 and α7β1 integrins (Berditchevski et al., 1997a; Serru et al., 
1999; Sincock et al., 1999; Sterk et al., 2002; Yauch et al., 2000). This tetraspanin has a 
unique way of affecting cellular structures. CD151 does not have a direct involvement in 
adhesion or migration when interacting with integrins but rather affects its adhesion 
strength by promoting activation of signalling molecules, such as AKT, Src and GTPases, 
according to the cellular context (Hong et al., 2012b; Lammerding et al., 2003; Nishiuchi et 
al., 2005; Puklin-Faucher and Sheetz, 2009; Takeda et al., 2007). Loss of this tetraspanin 
resulted in kidney failure in mice, although this was strain dependent, while additional study 
showed impaired wound healing in mice lacking CD151 (Cowin et al., 2006; Sachs et al., 
2012; Sachs et al., 2006). Additionally, loss of CD151 in tumor cells results in decreased 
tumor progression or onset (Deng et al., 2012; Hemler, 2014; Sachs et al., 2014). Other 
tetraspanin-integrin interactions were not as well studied. However, CD81 and CD37 were 
shown to be required for IgG production by B cells by regulating B cells adhesion to T cells 
via α4β1 ligands (van Spriel et al., 2012). At the same time, regulation of αIIbβ3 expression 
on platelets by CD9 is required in order to prevent excessive platelet recruitment at the site 
of vascular injury (Mangin et al., 2009). 
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Table 1.1: Main immune tetraspanins interacting partners 
Interactions Tetraspanins Evidence 
Integrins: CD9: α1β1, α2β1, α3β1, α4β1, α6β1, 
α5β1, α6β4, α7β1, αIIbβ3 
CD53: α4β1 
CD81: α3β1, α4β1, α6β1, α5β1, αVβ5 
CD82: α3β1, α4β1, α6β1, α5β1, α1β2 
CD151: α2β1, α3β1, α4β1, α6β1, α5β1, 
αIIbβ3, α6β4, α7β1   
CD63: α3β1, α4β1, α6β1, α1β2, αMβ2, 
αIIbβ3 
CD37: β2, α4β1 
(Berditchevski, 2001; 
Berditchevski et al., 1995; 
Chang and Finnemann, 
2007; Hemler, 2005; 
Mannion et al., 1996; 
Schmidt et al., 1996; Skubitz 
et al., 1996; van Spriel et al., 
2012; Wee et al., 2015; 
Yanez-Mo et al., 2011; 
Yauch et al., 1998) 
MHC CD9: - 
CD53: HLA-DR, HLA-DQ 
CD81: HLA-DR, HLA-DQ 
CD82: HLA-DR, HLA-DQ, HLA-DM, HLA-DO 
CD151: - 
CD63: HLA-DR, HLA-DQ, HLA-DM, 
CD37: HLA-DR 
(Angelisova et al., 1993; 
Engering and Pieters, 
2001; Hammond et al., 
1998; Szollosi et al., 1996) 
Growth factor 
receptors: 
CD9: Transforming growth factor α(TGF-
α), heparin-binding epidermal growth 
factor-like growth factor (HB-EGF) 
CD53: - 
CD81: - 
CD82: Epidermal growth factor receptor 
(EGFR) 
CD151: - 
CD63: Vascular endothelial growth factor 
receptor (VEGFR) 
CD37:- 
(Imhof et al., 2008; 
Lagaudriere-Gesbert et 
al., 1997; Odintsova et al., 
2003; Tugues et al., 2013) 
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Immunoglobulin 
superfamily: 
CD9: FPRP, EWI-2, EWI-F 
CD53: - 
CD81: FPRP, EWI-2, EWI-F 
CD82: - 
CD151: - 
CD63: - 
CD37: - 
(Charrin et al., 2003; 
Montpellier et al., 2011; 
Stipp et al., 2001a; Stipp 
et al., 2001b) 
Membrane 
proteins: 
CD9: CD36, CD19, FcγRII, CD46 
CD53: CD20 
CD81: CD9P-1, CD4, CD8, CD21-CD19, 
CD20, CD46 
CD82: CD4, CD8, CD19, CD20, CD46 
CD151: CD46 
CD63: AP-1, AP-2 
CD37: - 
(Charrin et al., 2013; Imai 
et al., 1995; Levy et al., 
1998; Lozahic et al., 2000; 
Mazurov et al., 2013; 
Miao et al., 2001; Pols 
and Klumperman, 2009; 
Szollosi et al., 1996; Todd 
et al., 1996; Worthington 
et al., 1990) 
Signalling 
proteins: 
CD9: Protein kinase C (PKC), 
Phosphatidylinositol 4-kinase (PI4-K), 
heterotrimetric G proteins 
CD53: PKC 
CD81: PKC, PI4-K, heterotrimetric G 
proteins, Rac1 
CD82: PKC 
CD151: PKC, PI4-K 
CD63: PI4-K 
CD37: - 
(Berditchevski et al., 
1997b; Claas et al., 2001; 
Le Naour et al., 2006; 
Little et al., 2004; Tejera 
et al., 2013; Yauch et al., 
1998; Zhang et al., 2001) 
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1.3.2.1. Tetraspanin trafficking of partner proteins 
Tetraspanins containing the tyrosine-based internalisation motif have a primary function in 
facilitating the trafficking of their partner proteins by either promoting their internalisation 
or association with late endocytic organelles(Pols and Klumperman, 2009) CD63 is the best 
studied in this context and is known to have a role in the transport of a number of proteins 
including the membrane repair regulator protein synaptotagmin 7, the H, K-ATPase pump, 
as well as CXCR4, stromal cell-derived factor 1/CXCL12 and neutrophil elastase (Duffield et 
al., 2002; Duffield et al., 2003; Flannery et al., 2010; Kallquist et al., 2008; Yoshida et al., 
2008). 
There are other tetraspanins involved in protein trafficking. The TspanC8 group, comprised 
of tetraspanin (TSPAN) 5, TSPAN10, TSPAN14, TSPAN15, TSPAN17 and TSPAN33, is involved 
in trafficking from the ER to the plasma membrane or late endosomes the 
metalloproteinase domain-containing protein 10 (ADAM10), a regulator of the 
embryogenesis regulator protein Notch (Dornier et al., 2012; Haining et al., 2012; Prox et 
al., 2012). Another example is CD81, which promotes trafficking and organisation into 
clusters of the co-stimulatory molecule of lymphoid B cells, CD19, along the secretory 
pathway (Mattila et al., 2013; Shoham et al., 2003). The importance of CD81 in immunity is 
shown in a patient where CD81 was defective resulting in him having a faulty adaptive 
immune system (van Zelm et al., 2010). Furthermore, CD82 C-terminal deletion results in 
failure of epidermal growth factor receptor to be trafficked to the endocytic organelles 
(Zhang et al., 2003b). CD151 can also regulate integrin α3β1 expression and its silencing in 
carcinoma cells results in reduced internalisation rates and failure to recruit to tetraspanin 
enrich microdomains (TEMs) of the integrin (Winterwood et al., 2006). 
1.3.2.2. Mechanisms of tetraspanin signalling  
There are several proposed tetraspanin signalling mechanisms. The first one suggests that 
tetraspanins act as signal transducing molecular linkers by bringing into proximity partner 
molecules such as integrins and members of the immunoglobulin family with the signalling 
molecules situated in the cytoplasm (Lammerding et al., 2003). The phosphoinositide kinase 
- 33 - 
 
family plays a key role in this signalling mechanism. PKC and PI4-K type II interactions with 
members of the tetraspanin family facilitate cytoskeletal reorganisation and migration, Ca2+ 
dependent signalling, suppression of carcinoma cell motility, angiogenesis and mast cell 
degranulation (Carloni and Mazzocca, 2009; Liu et al., 2011; Qi et al., 2006; Scharenberg et 
al., 2007; Yauch et al., 1998). One such example was elegantly demonstrated in neutrophils 
where CD151 tetraspanin brings in close proximity α3β1 integrin with PI4-K type II to 
facilitate cell migration (Figure 1.4A) (Yauch et al., 1998). 
The second proposed mechanism of action is by clustering partner membrane proteins to 
promote their increased avidity and affinity for their ligands (Kropshofer et al., 2002). Such 
an example was shown in CD4+ T cells, where tetraspanins CD9, CD81 and CD82 brought 
together the MHC type II receptors HLA-DR/DP with the HLA-DM protein, involved in 
peptide presentation to the MHC class II, and the co-stimulatory molecule CD86 to facilitate 
T-cell activation by increasing the avidity of MHC (Figure 1.4B) (Kropshofer et al., 2002).  
The last signalling mechanism proposed suggests that tetraspanins can act as signalling 
regulators by sequestering proteins to prevent inadequate cell signalling or responses. One 
such signalling mechanism was shown using breast cancer cells where CD82 dampened the 
activity and the dimerisation of epidermal growth factor receptor by redistributing it into 
the cell surface ganglioside GD1a microdomains (Odintsova et al., 2003). 
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Figure 1.5: Different ways of tetraspanin signalling.  
A.) CD151 acting as a transduction linker in neutrophils by interacting via its large 
extracellular loop with the α domain of the α3β1 integrin and with the cytoplasmic domain 
with PI4-K resulting in cell migration. B.) Tetraspanin clustering the partner proteins HLA-
DR/DP MHC class II complex with the HLA-DM peptide presenting protein and the CD86 co-
stimulatory molecule to facilitate T cell activation. 
A. 
B. 
Tetraspanin 
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1.3.2.3. Tetraspanin enriched microdomains (TEMs) 
Tetraspanins most often promote association and organisation of proteins that are far apart 
in the membrane into TEMs or a “tetraspanin web”, which serves to bring about cell 
signalling in a more efficient way (Charrin et al., 2003; Hemler, 2008; Levy and Shoham, 
2005a; Zuidscherwoude et al., 2015). The interactions found in TEMs are diverse. Initially 
demonstrated by co-immunoprecipitation studies, they have been classed into 
direct/primary interactions, between tetraspanins and nontetraspanin partners such as 
α3β1 integrin-CD151, while others are indirect and include secondary, between members 
of the tetraspanin family, and tertiary interactions, formed by indirect association of 
tetraspanins with additional proteins (Berditchevski, 2001; Hemler, 2003; Levy and Shoham, 
2005a; Yauch et al., 1998). There are two different proposed models of TEM assembly, 
indicating a controversy in the field. The first proposed model, is more widely accepted, and 
has already been proven by several groups. This models shows that multiple tetraspanins 
and partner proteins co-localise in the membrane to bring about molecular changes and 
induce different functions (Figure 1.5A) (Andre et al., 2006; Andreu and Yanez-Mo, 2015; 
Levy and Shoham, 2005b; Nydegger et al., 2006). The second one recently came from 
(Zuidscherwoude et al., 2015). Using dual colour stimulated emission depletion it was 
demonstrated that CD37, CD53, CD81 and CD82 group in small clusters, with their 
associated binding partners, no bigger than 10 tetraspanins (Figure 1.5B). As opposed to 
previous dogma, the membrane cluster form associations that are less than 120nm wide. 
These clusters can then co-localise with other clusters when they move through the 
membrane. 
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Figure 1.6: The two models of TEMs. 
A) Tetraspanins and interacting partner proteins group together to make a mixed domain 
structure. B) TEMs formed from the interaction of mostly one tetraspanin type and its 
partner proteins. 
  
A. 
B. 
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1.3.3. Tetraspanins and immunity  
The function of tetraspanins is quite diverse in the innate and adaptive immune system 
ranging from the regulation of immune system activation, level of cytokine/chemokine 
release as well as prompt response in inflammation resolution (Jones et al., 2011; van Spriel, 
2011; Veenbergen and van Spriel, 2011). 
Looking at the adaptive immune system, dendritic cells present opposite roles for 
tetraspanins when knockout models were used, probably due to the tetraspanin different 
functions. For instance, while CD9 has a role in clustering MHC class II dimers to enhance 
stimulation of T cell receptors, CD37 regulates peptide/MHC presentation and CD151 has a 
key role in co-stimulation of T-cells (Sheng et al., 2009; Unternaehrer et al., 2007). CD9 
abolition results in reduced dendritic function while, in contrast, CD37 and CD151 removal 
results in T cell hyper-stimulation (Sheng et al., 2009; Unternaehrer et al., 2007). More 
recently, CD37 and CD82 have also been shown to have opposing functions in dendritic 
cells, with CD37 being found in unactivated cells and promoting migration, while CD82 
promotes antigen presentation and activation of T cells (Jones et al., 2016). In B cells, CD81 
has an important role in activation and transport of CD19 and mutation in CD81 results in 
antibody production deficiency (Tsitsikov et al., 1997; van Zelm et al., 2010). CD81 was also 
shown to have key role in regulating natural killer cell recruitment in response to 
cytokines/chemokine stimulation (Kramer et al., 2009). 
With respect to the innate immune system, macrophage CD9 negatively regulates the 
expression of CD14 on the cell membrane in response to LPS to prevent a heightened cell 
response to the LPS stimuli (Suzuki et al., 2009; Takeda et al., 2015). In eosinophils, CD63 
migration to cell surface is positively correlated to cell activation and degranulation 
(Mahmudi-Azer et al., 2002). In fact, CD63 surface expression is widely used as a marker of 
cell activation including platelets, basophils and, most importantly, neutrophils (Azorsa et 
al., 1991; Gamboa et al., 2003; Lopez et al., 1995). Furthermore, CD37 presence positively 
promotes β2-dependent neutrophil cell migration in mice while CD63-αMβ2 association 
promotes neutrophil migration in humans (Skubitz et al., 1996; Wee et al., 2015). 
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1.3.3.1. Bacterial infections and tetraspanins 
There are a few studies that show that bacteria are able to exploit tetraspanins in order to 
adhere to and infect cells, contributing to their pathogenesis. Although not one of the 
immune tetraspanins, Uroplakin 1a is found on bladder cells and is known to be exploited 
by the uropathogenic E. coli to adhere to urothelial cells (Zhou et al., 2001). Regarding 
immune tetraspanins, CD9 increased cell expression renders mouse L cells much more 
susceptible to diphtheria toxin, an important virulence factor for Cornyebacterium 
diphteriae (Iwamoto et al., 1994). In dendritic cells, CD82 is known to be recruited to fungi 
and bacteria containing phagosomes, prior to their fusion with the lysosomes, but its role 
is in this process is yet to be elucidated (Artavanis-Tsakonas et al., 2011). Studies conducted 
here in Sheffield on epithelial cell lines have shown that CD9, CD63 and CD151 have a 
collective role in the adhesion of Neisseria meningitidis, via its type IV pili, as well as S. 
aureus, Neisseria lactamica, E. coli and S. pneumoniae, by presumably organising adhesion 
molecules via TEMs (Green et al., 2011). The group also demonstrated the therapeutic 
aspect of the tetraspanins. By using recombinant peptides representing regions of the EC2, 
the adhesion of S. aureus to keratinocytes via CD9 was greatly inhibited (Ventress et al., 
2016). Furthermore, CD81 is required for the entry of the opportunistic pathogen Listeria 
monocytogenes into epithelial cells (Tham et al., 2010). Recently, it was also demonstrated 
that metalloproteinase ADAM10 bound and internalised less S. aureus pore-forming α 
hemolysin toxin, when cells were deficient in TSPAN14 (Virreira Winter et al., 2016).  
Tetraspanins can also act as initial binding partners for viruses, fungi and even protozoa. 
Detailed descriptions of the interactions and their consequences for the organism have 
been reviewed in several papers (Monk and Partridge, 2012). 
1.3.3.2. Tetraspanin association with disease 
Since their discovery, tetraspanins have been linked to disease as a result of their increased 
expression, abolition or due to various gene mutations. Probably the most studied 
implications of tetraspanins are in the context of cancer, described in depth in a couple of 
recent published reviews (Hemler, 2014; Yang et al., 2016). Furthermore, tetraspanins 
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mutations have been linked to inherited diseases such as X-linked mental retardation and 
familial vitreoretinopathy exudative (Abidi et al., 2002; Yang et al., 2011). 
CD151 has been shown to have a key role in inflammatory disease progression. It is essential 
for normal function of alveolar epithelial cells, its loss resulting in pulmonary fibrosis in mice 
(Tsujino et al., 2012). Similarly, CD151 truncation results in renal failure, deafness and skin 
blistering due to failure in basement membrane assembly (Crew et al., 2004). In addition, 
mutations in the EC2 region of CD81 has also been linked with severe immune deficiency 
due to the inability of B cells to mount an adequate antibody response (van Zelm et al., 
2010). Most importantly, CD9 was shown to have a preventive role in COPD due to the 
ability of CD9 rich TEMs to negatively regulate CD14 expression on macrophage membrane 
(Takeda et al., 2008; Takeda et al., 2015). 
1.3.4. Known roles of tetraspanins in neutrophil functions 
To date, there is limited knowledge on the functions of tetraspanins in human neutrophils. 
There is evidence that neutrophils express CD9, CD151, CD53, CD63, CD37 and CD82 
(Meyer-Wentrup et al., 2007; Tarrant et al., 2003; Tohami et al., 2004). There is, however, 
some controversy in the literature concerning tetraspanin CD81 and its expression by 
neutrophils. The general consensus is that neutrophils do not express CD81 but Tohami et 
al. showed that a small subpopulation of neutrophils do express CD81 at high levels (Andria 
et al., 1991; Tarrant et al., 2003; Tohami et al., 2004). 
Tetraspanins have a key role in neutrophil migration. For instance, fMLP stimulation 
promotes CD63-αMβ2 integrin-serine/threonine kinases recruitment, such as Lyn, Hck and 
Src, which results in the activation of an integrin specific adhesion and migration (Skubitz et 
al., 1996; Skubitz et al., 2000; Toothill et al., 1990). CD151 was also shown to modulate this 
function by forming a stable complex with α3β1 and PI4-K type II in human neutrophils that 
promotes cell activation (Yauch et al., 1998). According to recent mice in vivo studies, CD37 
can positively modulate neutrophil migration by regulating the cell surface expression of β2 
integrin (Wee et al., 2015). Although a β2-CD37 association was not detected, CD37 
presence promoted actin polymerization, neutrophil cell spreading and cell polarization, its 
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loss resulting in increased β2 internalization (Wee et al., 2015). This suggests that neutrophil 
migration possibly requires a tetraspanin-integrin interaction. At the same time it is possible 
that different tetraspanins-integrin interactions mediate different steps in the neutrophil 
migration process. 
Roles for tetraspanins have been shown in neutrophil interaction and defense against 
pathogens. For instance, Leishmania containing vacuoles can fuse with neutrophil CD63+ 
azurophilic granules, in a process orchestrated by the pathogen to ensure its survival 
(Mollinedo et al., 2010). CD63 is also known to be involved in specific HL-60 azurophilic 
granule targeting and trafficking to the phagolysosome of neutrophil elastase (Kallquist et 
al., 2008). Furthermore, neutrophils from patients infected with S. pneumoniae and 
uropathogenic E. coli showed decreased CD81 and CD82 expression (Tohami et al., 2004). 
In contrast, tetraspanin CD53 may also act as pathogenic risk factor in the 
immunodeficiency syndromes characterised by known recurrent infections and 
unidentified pathophysiology (Mollinedo et al., 1997). This suggests perhaps that 
tetraspanins functions depend on the bacterial pathogen the cell encounters. 
There is limited knowledge about tetraspanins and neutrophil cell survival. Biochemical 
techniques indicate that human apoptotic neutrophils express more CD63 and CD53 
compared to healthy cells, suggesting either that it plays a role in the apoptotic process or 
is merely happening in parallel (Beinert et al., 2000; Mollinedo et al., 1998). 
Similarly, involvement of tetraspanins in inflammatory disease is poorly understood. For 
instance, CD9 is overexpressed in periodontal disease, indicating a potential role for this 
tetraspanin in the pathology of this inflammatory disease (Bisson-Boutelliez et al., 2001). 
More is known about CD63. A polymorphism at the CD63 locus has been associated with 
decreased CD63 expression in neutrophils from COPD patients, but not healthy individuals, 
while Lopez et al. findings suggest that this tetraspanin can act as a marker for rheumatoid 
arthritis (Lopez et al., 1995; Zhang et al., 2007). Considering that COPD and rheumatoid 
arthritis patients have increased neutrophil survival, the above data could indicate a 
potential role for CD63 in neutrophil survival in inflammatory disease (Ottonello et al., 2002; 
Plataki et al., 2006; Pletz et al., 2004). 
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1.4. Hypothesis and aims 
Increased neutrophil lifespan and poor bacterial clearance by neutrophils are common 
causes of COPD disease pathology and progression. Available treatment options only treat 
the symptoms but not the cause of the disease. 
Tetraspanins are members of a large protein family that have roles in many cellular 
functions including cell survival, adherence, fusion and membrane trafficking but they can 
also be exploited by bacteria and other pathogens as gateway for infection. Tetraspanins 
functions in neutrophils have been poorly investigated. I therefore hypothesise that 
tetraspanins play a role in neutrophil survival and bacterial interactions. 
Specific aims of this project include: 
1. Identify the specific tetraspanin(s) involved in human neutrophil apoptosis and 
phagocytosis using anti-tetraspanin antibodies (Chapter 3-4). 
2. Investigate the role of tetraspanin(s) in neutrophil survival in the context of COPD 
(Chapter 3). 
3. To understand tetraspanin(s) role in neutrophil interaction with different Gram 
positive/ negative respiratory pathogens using techniques such as light and 
fluorescent microscopy and gentamicin protection assay (Chapter 4). 
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Chapter 2: Materials and methods 
2.1. Ethics 
The experiments conducted using blood taken from healthy human volunteers followed the 
ethics protocol as agreed by the South Sheffield Regional Ethics Committee, study number 
STH13927. COPD patients or their equivalent healthy controls (HC) used in the study were 
under the approval of the Yorkshire and the Humber Regional Ethics Committee-STH15949 
study. All volunteers gave informed consent and donated a maximum of 500mls over a 6 
month period. Any stored human tissue sample (protein, RNA, DNA) were to be destroyed 
in 5 years. The use and storage of human neutrophils was recorded in a user log book. 
2.2. Reagents 
Sterile, preservative free monoclonal antibodies directed against tetraspanins CD9, CD37, 
CD63 and fragment antigen-binding (Fab) fragment directed against CD63, CD151 and the 
Immunoglobulin G 1(IgG1) isotype control (JC1) were provided by Dr. Lynda J. Partridge, 
Department of Molecular Biology and Biotechnology, University of Sheffield, United 
Kingdom (Table 2.1). AHN-16.1 anti-CD63 antibody was a gift from Dr. Keith Skubitz, 
Department of Medicine, University of Minnesota Medical School, Minneapolis, USA and 
anti-CD63 antibody 6H1 clone was a gift from Dr. Martin Hemler, Harvard Medical School, 
Boston, USA (Table 2.1). LEAFTM (Low Endotoxin, Azide-Free) purified anti-human CD151 
(PETA-3) blocking antibody and LEAFTM purified mouse IgG1, κ isotype control were 
purchased (Table 2.1). Allophycocyanin (APC) labeled anti-human CD151 and Mouse IgG1 K 
isotype control were obtained from eBioscience, San Diego, USA. Pyocyanin was a gift from 
Dr. Graham Taylor, Imperial College London (Usher et al., 2002). S. aureus SH1000 (wild 
type-WT), USA300 (JE2), S. aureus SH1000 protein A (SpA) mutant, SRCO11 and SCRCO12 
SH1000 background fibronectin mutants, as well as SH1000 chromosomal (chr)-green 
fluorescent protein (GFP) strains were provided by Prof. Simon Foster, Department of 
Molecular Biology and Biotechnology, University of Sheffield, United Kingdom. S. 
pneumonia D39 strain and Nontypeable Haemophilus Influenzae (NTHi) NCTC 1269 strain 
were obtained from American Type Culture Collection, Manassas, USA and were a gift from 
Dr. Martin Bewley, Department of Infection, Immunity and Cardiovascular disease, Royal 
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Hallamshire Hospital, Sheffield, UK. The purchase origin of other reagents was from various 
companies and listed in the sections bellow when referring to them. 
2.3. Plasma/Percoll purification of neutrophils from whole blood 
2.3.1. Leukocyte isolation and purification from whole blood 
Venous blood was taken from healthy volunteers, age-matched HC or COPD patients (see 
‘ethics’ Section 2.1 above) and transferred to a 50ml falcon tube containing 3.8% sodium 
citrate (Martindale pharmaceuticals, Essex, UK) at 1ml sodium citrate per 9ml of blood. The 
tube was gently rolled to mix. The tube lid was parafilmed and the blood centrifuged at 350 
g for 20 minutes at room temperature (RT) to allow the separation of blood cells from 
platelet rich plasma (PRP). The PRP was carefully aspirated, to avoid cell pellet disruption, 
and transferred to a 50ml falcon tube. Platelet poor plasma (PPP) was obtained by 
centrifuging the PRP at 800 g for 20 minutes at RT. The PPP was subsequently transferred 
to a fresh 50ml falcon tube. 
2.3.2. Dextran sedimentation of red blood cells 
A volume of 6ml of pre warmed 6% dextran T-500 (3g of dextran powder T-500 was added 
to 50 ml of 0.9% saline) (Sigma-Aldrich, Poole, UK) was added to the blood cell rich lower 
layer and topped up to 50ml with pre-warmed 0.9% saline (Baxter, Newbury, UK). The liquid 
was then mixed by gentle rolling. The droplets on the lid and the bubbles on the surface 
were removed with a Pasteur pipette to prevent disruption of the sedimentation process. 
The lid was left loosened and the red cells were allowed to sediment, at RT, until a clear 
interface was visible (approximately 25 minutes). The white cell rich upper layer was then 
transferred to a clean 50ml falcon tube and centrifuged at 320 g for 6 minutes to pellet the 
cells.  
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Target Clone Isotype Source Storage buffer Purity 
CD9 602.29 IgG1 Andrews et al., 
1981 
PBS >95% 
CD37 WR17 IgG1 Moore et al., 
1987 
PBS >95% 
CD63 H5C6 IgG1 Azorsa et al., 
1991 
PBS >95% 
 AHN-16.1 IgG1 Skubitz et al., 
1996 
PBS >95% 
 6H1 IgG1 Berditchevski et 
al., 1995 
PBS >95% 
CD63 Fab 
fragment 
H5C6 IgG1 Obtained in house 
Higginbottom et 
al., 2000 
PBS >95% for old and 
new stock 
CD151 14A2 IgG1 Fitter et al., 1995 PBS >95% 
 50-6-
blocking 
IgG1 Biolegend, 
Cambridge, UK 
PBS Purity not 
specified by the 
manufacturer 
Endotoxin 
level<0.1 EU/μg 
β1 P4C10-
blocking 
IgG1 Novus Biologicals, 
Abington, UK 
PBS containing 
0.02% Sodium 
Azide 
Purity not 
specified by the 
manufacturer 
Control JC1 IgG1 Muranova et al., 
2004 
PBS >95% 
 LEAF 
purified 
IgG1 Biolegend, 
Cambridge, UK 
PBS 
 
Purity not 
specified by the 
manufacturer 
Endotoxin 
level<0.1 EU/μg 
 
Table 2.1: Description of the antibodies used in this thesis  
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2.3.3. Plasma/Percoll-gradient cell isolation 
During the centrifugation stage, the plasma/Percoll (Sigma-Aldrich, Poole, UK) gradient was 
prepared using accurate measurements of 90% Percoll stock solution (9ml of 100% Percoll 
was made up with 1ml of 0.9% saline) and PPP. Two densities of PPP/Percoll were made: 
51% Percoll (1.02ml of 90% Percoll and 0.98ml of PPP) and 42% Percoll (0.84ml of 90% 
Percoll and 1.16ml of PPP). The two Percoll densities were overlaid in a 15ml polystyrene 
tube as follows: 51% Percoll was placed at the bottom of the tube, followed by the 42% 
Percoll. The supernatant from the cell pellet from section 2.3.2 was discarded and the cell 
pellet was gently resuspended in PPP to a final volume of 2ml and carefully overlaid on the 
top of the Percoll gradient (Figure 2.1 left hand panel). The gradient was centrifuged at 320 
g for 11 minutes at RT without a brake. Following centrifugation, three layers were 
observed: red blood cell (RBC) pellet at the bottom of the tube, followed by a middle band 
containing the granulocyte layer (neutrophils/eosinophils/basophils) and an upper band 
containing peripheral blood mononuclear cells (PBMCs) (Figure 2.1 right hand panel). 
2.3.4. Harvesting the gradient 
Using a Pasteur pipette, the PBMC and the granulocyte layers were transferred to 50ml 
falcon tubes containing 10ml PPP. Cell washing was done by topping them with 40mls hanks 
buffer saline solution (HBSS) without Ca2+ or Mg2+ (Gibco life technology, Paisley, UK). A cell 
count was performed using a haemocytometer chamber. A cells pellet was then obtained 
by centrifugation at 320 g for 6 minutes. Neutrophils were afterwards resuspended in pre-
warmed complete media (Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich, 
Poole, UK) + 10% fetal bovine serum (FBS) (Autogen Bioclear, Wilshire, UK) + 1% 
Penicillin/Streptomycin (Pen/Strep) (Life Technologies, Paisley, UK)) or further purified as 
per section 2.3.5. 
  
- 46 - 
 
                                          
Figure 2.1: Separation of the cells on the plasma/Percoll gradient 
The left hand panel shows the construction of the 3 gradient layers. The right hand panel 
shows appearance of the gradient following centrifugation; a red cell pellet, a granulocyte 
intermediate layer containing neutrophils, basophils and eosinophils and a PBMC upper 
layer comprised of monocytes and lymphocytes. 
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Former 2ml cell layer 2ml cell layer 
2ml 42% Percoll 
2ml 51% Percoll 
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2.3.5. Neutrophil ultrapurification using negative magnetic selection 
Granulocytes isolated from the plasma/Percoll gradient were purified further by negative 
magnetic selection. A StemSep Human Custom Enrichment Kit and a magnetic MACS 
column removed contaminating cells (eosinophils, PBMCs, RBCs) by antibody labelling of 
contaminating cells. Resuspension of the cells was done initially at 1x108 cells/ml in 
neutrophil column buffer (HBSS without Ca2+ and Mg2+ and 2% FBS). A 15 minute incubation 
at RT with 70μl antibody cocktail (Stemcell technologies, Meylan, France) per 1ml cell 
suspension (Sabroe et al., 2004) with intermittent gentle mixing was then conducted. The 
antibody cocktail contains antibodies directed against CD2, CD3 (T lymphocytes), CD19 (B 
lymphocytes), CD36 (eosinophils), CD56 (natural killer cells) and glycophorin A (RBCs). A 
further 15 minute incubation was carried out in the presence of 50μl/ml magnetic colloid 
beads (Stemcell technologies, Meylan, France) with gentle mixing. During the second 
incubation, the negative magnetic selection column (Miltenyi Biotec, Surrey, UK) was 
assembled and primed with 10ml neutrophil column buffer. The cells were subsequently 
added to the column. Contaminating cells were bound to the column via the colloid beads 
allowing collection of neutrophils into a clean tube. To enrich the neutrophil population, 
the column was washed further with 10ml of column buffer. The number of neutrophils was 
then counted using a haemocytometer chamber, followed by cell centrifugation at 320 g 
for 6 minutes and their resuspension in complete RPMI 1640 at 5x106 cells/ml. 
2.4. Bacterial growth and storage 
2.4.1. S. aureus strains 
A range of S. aureus strains and mutants, indicative of the functions targeted, were used for 
the work detailed below. The low virulence SH1000 laboratory strain was obtained in the 
laboratory of Professor Simon J. Foster by restoring the rsbU deletion in the RN6390 lineage 
(Horsburgh et al., 2002). The features of this strains make it a good laboratory tool since it 
behaves as a clinical isolate. S. aureus SpA, SRCO11, SRCO12 and chromosomal-gfp mutant 
strains were obtained in the laboratory of Professor Simon J. Foster on the background of 
SH1000. The SpA mutant is protein A deficient (Chan and Foster, 1998). Protein A allows S. 
aureus binding to the Fc immunoglobulin region in humans to avoid recognition and 
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phagocytosis by neutrophils (Dossett et al., 1969). SRCO11 and SRCO12 are mutants that 
lack the ability to bind to the integrin binding extracellular matrix glycoprotein, fibronectin. 
SRCO11 lacks fibronectin binding protein A (fnbA) and fnbB while SRCO12 lacks fnbA, fnbB 
as well as the iron-regulated surface determinant protein A precursor (isdA) (Buck and 
Horwitz, 1987; Clarke et al., 2004; Jonsson et al., 1991). The S. aureus SH1000 chr-GFP strain 
has a kanamycin resistant gfp gene, stably incorporated in the genome and therefore 
constitutively expresses it (data not published yet). The JE2 strain was obtained from the 
USA300, the most common community-associated MRSA strain, by the double removal of 
macrolide resistance and a cryptic plasmid (Kennedy et al., 2008). 
2.4.1.1. Growth and storage of S. aureus strains 
A -80°C S. aureus master bead stock of WT, SH1000 chr-GFP, SRCO11 and SRCO12 were 
obtained from the laboratory of Prof. Simon Foster. Before usage, the bacteria were thawed 
at RT for 30 seconds. One bead from each stock was placed on brain heart infusion (BHI) 
agar (Sigma-Aldrich, Poole, UK) plate and left to melt for 1 minute. To select for SH1000 chr-
GFP, 50µg/ml kanamycin (Gibco life technologies, Paisley, UK) was added to the agar and 
selection for SRCO11 and SRCO12 was done by using 5µg/ml erythromycin (Sigma-Aldrich, 
Poole, UK). No antibiotics were required for the growth of WT strain. The plates were 
incubated overnight at 37°C/ 5%CO2. The following day, a single colony was inoculated into 
5ml of BHI broth (Sigma-Aldrich, Poole, UK) with or without the antibiotics, depending on 
the strain, at the concentrations defined above. The cultures were then grown overnight on 
a shaker at 37°C/ 5%CO2. In order to achieve bacteria in exponential growth phase, the 
overnight culture was subcultured into fresh BHI broth (plus the antibiotics concentrations 
specified for each strain) by placing the bacteria in fresh BHI broth at an OD600 of 0.05. The 
bacteria was then grown to 1X 109 colony forming unit (CFU)/ml (OD600 of 2.2). At this stage 
the bacterial cells were ready to be used in experiments or stock storage was done as 
follows. Equal amounts of bacterial broth with 50% glycerol diluted in water were mixed, 
aliquoted out and stored at -80°C. The CFU/ml of bacteria was confirmed by conducting a 
Miles-Misra test as described by (Miles et al., 1938). In neutrophil experiments conducted 
in this thesis, 6x10 fold dilutions were made for each condition and 3x10µl drops from the 
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last 3 dilutions were plated on BHI agar plates followed by overnight incubation at 37°C/ 
5%CO2. The CFU/ml was determined the subsequent day by using the formula: 
CFU/ml= (colonies at the dilution where they are distinguishable/30)*1000* dilution 
factor.  
S. aureus JE2 and S. aureus SpA strains were grown by Miss. Dingyi Yang, Infection, 
Immunity and Cardiovascular Disease, Medical School, University of Sheffield, UK. 
2.4.1.2. S. aureus strain heat inactivation 
Heat inactivation/ killing (HK) of a bacteria is conducted to remove its ability to kill cells. For 
light microscopy, western blotting and flow cytometry experiments, overnight cultures of 
S. aureus WT, SpA mutant and S. aureus JE2 strains were incubated in the heating block for 
10 minutes at 100°C to inactivate them. For fluorescent microscopy, S. aureus WT 
subculture was incubated for 30 minutes at 70°C, as indicated by the group who published 
initially with the Alexa Fluor 647 and pHrodo stained S. aureus (Ellett et al., 2015). 
2.4.2. Growth and storage of S. pneumoniae and NTHi 
The -80°C S. pneumoniae or NTHi master stock obtained from following the manufacturers’ 
protocol, were thawed for 30 seconds at RT before usage. A bead was placed on the blood 
agar plate (made in house by mixing BHI agar and overlaying horse blood (Thermo Fisher 
Scientific, Loughborough, UK)) for S. pneumoniae and one on chocolate agar (E&O 
Laboratories Limited, Bonny Bridge, Scotland) for NTHi. NTHi cannot synthesise V factor, 
found inside red blood cells, therefore it must be released by cell lysis, which in turn give 
the plates the appearance of chocolate. The colonies were then streaked out and incubated 
overnight at 37°C/ 5%CO2. The following day, 10-20 colonies of S. pneumoniae were placed 
in BHI broth + 20% FBS and placed on the orbital shaker for approximately 4.5 hours, or 
until the OD600 reached 0.6. To grow NTHi, the BHI broth + 20% FBS was supplemented with 
2µg/ml of nicotinamide adenine dinucleotide (NAD) (Sigma-Aldrich, Poole, UK) and 10µg/ml 
of Hemin from stock (Sigma-Aldrich, Poole, UK) (see Appendix I) and placed on the orbital 
shaker until OD600 reached 0.6. The broth was then aliquoted out and the samples stored in 
the -80°C freezer. The CFU/ml of bacteria was determined by conducting a Miles-Misra test 
(see section 2.4.1.2.). 
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Heat inactivation of overnight culture of S. pneumoniae was done by placing the vial for 10 
minutes in the heat block at 100°C. 
2.4.2.1. S. pneumoniae opsonisation 
The method for opsonising S. pneumoniae D39 was first described by (Gordon et al., 2000). 
To opsonise S. pneumoniae, bacterial stocks (see section 2.4.2.) were thawed at RT and 
washed 3 times in 1ml of PBS (Gibco life technologies, Paisley, UK) at 11,000 g for 5 minutes. 
The bacteria were subsequently incubated for 30 minutes at 37°C/ 5%CO2 on an orbital 
shaker with 500µl of RPMI 1640 (without any serum) + 10% serum containing anti-serotype 
antibodies from immunised people. To obtain the serum, blood was taken from healthy 
human volunteers immunised 3-6 months prior to this with Pneumovax vaccine. The plasma 
was separated from the blood by centrifugation, heat inactivated and tested for the anti-
serotype antibodies using flow cytometry or ELISA. The plasma from 3-4 donors was pooled 
together, aliquoted out and frozen at -80 until needed. The serum separation from blood, 
and determination of antibody levels was performed by our in house technician, Mrs. 
Catherine J. Cooke. The opsonised S. pneumoniae were then washed 3 times with PBS 
(Lonza, Veveris, Belgium) by centrifuging the bacteria for 3 minutes at 3,400 g and 
resuspended in RPMI 1640 + 10% FBS at 1x 109 CFU/ml. The low centrifugation speed for 
washing opsonised S. pneumoniae was used to prevent the dissociation of the opsonins 
from the target. 
2.5. Light microscopy 
2.5.1. Preparation of cytospins  
In order to assess purity, apoptosis and phagocytosis, neutrophils were cytocentrifuged 
onto glass slides as monolayers, allowing the observation of subcellular features by oil 
immersion microscopy. To do this, a volume of 100µl containing neutrophils at 5X106/ml, 
incubated under various conditions (see individual experimental detail), were transferred 
to clip-slide-filter-chambers in duplicates. The cells were then centrifuged at 300 g for 3 
minutes using a Shandon Cytocentrifuge (Shandon Cytospin 3, Thermo Scientific, Hemel 
Hempstead, UK). Allowing a few moments to air dry, cells were then fixed on the slides with 
a drop of 100% methanol. Staining (based on hematoxylin and eosin) was carried out by 
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placing the slides in Diff-Quik stain I (orange dye) (Gentaur, London, UK) for 1 minute, to 
stain cell organelles, followed by Diff-Quick stain II (blue dye) (Thermo Fisher Scientific, 
Loughborough, UK) for 2-3 minutes, to stain nucleus and cell membrane. The slides were 
allowed to fully dry before being coverslipped. To coverslip, a drop of distrene-80 plasticiser 
xylene (DPX) (Fisher Scientific, Loughborough, UK) was placed on the slides followed by 
addition of a glass coverslip on top. The slides were visualised using Zeiss Axioplan 
microscope with 100X oil immersion lens. 
2.5.1.1. Assessment of neutrophil purity, apoptosis and phagocytosis 
Healthy and apoptotic neutrophils have characteristically distinct cellular morphologies 
(Haslett et al., 1989). Healthy neutrophils have a textured, multi-lobed, nucleus connected 
by fine chromatin bridges, small granules and a lilac/pink coloured cytoplasm (Figure 2.2A). 
In contrast, apoptotic neutrophils present two main characteristics: some have a very 
dense, round nucleus due to chromatin condensation, while others appear as “ghost cells” 
due to nuclear components leaking out (Figure 2.2B). Other cells were also seen under the 
microscope: eosinophils had a textured, horseshoe-like nucleus with distinct large, salmon 
pink granules (Figure 2.2C); RBC were seen as grey circles (Figure 2.2D) and monocytes and 
lymphocytes (PBMCs) were seen as having a large textured nucleus and blue cytoplasm 
(Figure 2.2E-F). Bacteria under the microscope appeared as small purple spheres (S. aureus) 
(Figure 2.2G) or rods (S. pneumoniae) (Figure 2.2H). 
Neutrophil apoptosis was assessed by counting a total of 300 (apoptotic and viable) cells on 
each of the duplicate slides. Purity slides were prepared from freshly isolated neutrophils 
at 0 hours, and 500 cells (red cells excluded) were counted on each of duplicate slides based 
on their morphology. Phagocytosis was assessed by calculating the phagocytic index (PI) 
using the formula specified below. This formula takes into account not only the percentage 
of neutrophils that phagocytose bacteria, but also the number of bacteria each cell has 
phagocytosed (Sano et al., 2003). 
Phagocytic index: 
((total number of engulfed bacteria/total number of cells)*(number of cells containing 
bacteria/total number of cells))*100 
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Figure 2.2: Cell and bacteria morphology under the light microscope 
Light microscopy visualisation of cells and bacteria: A) healthy neutrophils with multi-lobed 
nucleus; B) Apoptotic neutrophils that underwent chromatin condensation (black arrow) or 
where cytoplasmic cell content leaked out to form ‘ghost cells’ (blue arrow); C) Eosinophils 
with horseshoe-like nucleus and orange cytoplasm; D) Lymphocyte with round nucleus and 
blue cytoplasm; E) Monocyte with horseshoe-like nucleus and blue cytoplasm; F) 
Anucleated Red blood cell; G) Neutrophil containing S. aureus in the clear phagolysosome 
(black arrow); H) Neutrophil with the engulfed, rod-like S. pneumoniae (black arrow). The 
image blurriness was corrected using Fiji program with the ‘Enhance contrast’ feature. Scale 
bar, 5µm. 
  
A. B. C. D. 
E. F. G. H. 
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2.5.1.2. Analysis of neutrophil survival in the presence of anti-tetraspanin antibodies 
Neutrophils obtained from Section 2.3 were resuspended in complete media at 5X106 
cells/ml, as previously determined by our group and others to be an optimal density. 
Neutrophils were added to 96 well flexible plates (Costar, High Wycombe, UK). Monoclonal 
antibodies directed against CD9, CD37, CD63 and CD151 or fragment antigen binding (Fab) 
fragments directed against CD63 were obtained in the laboratory of Dr. Lynda Partridge via 
purification from hybridoma supernatants using protein G Sepharose. The obtain of Fab 
fragments from whole antibodies was done using pepsin digestion and was previously 
described by the Partridge group (Higginbottom et al., 2000). They were individually added 
to the wells following the concentrations on Table 2.2. Each antibody concentration will be 
specified for each experiment in Chapter 3. The JC1 isotype control was used in all 
experiments as a reference. The following provides key information for experiment design. 
All wells were supplemented with complete media followed by incubation for 4 or 20 hours 
at 37°C/ 5%CO2, as specified for each experiment. Comparison between plasma/Percoll-
pure and ultrapure/ column purified neutrophils was done by using only anti-CD63 
antibodies (20µg/ml) and JC1 isotype control (20µg/ml). The neutrophils from age matched 
HC and COPD patients were incubated for 4 and 20 hours with media, JC1 isotype control 
(20 µg/ml) or anti-CD63 antibodies (20µg/ml). In a single dataset, neutrophils were 
incubated for 4 and 20 hours with media, JC1 isotype control (20 µg/ml) and anti-CD63 
antibodies clones AHN-16.1 and 6H1 (20µg/ml), in addition to the H5C6 anti-CD63 antibody 
clone used in all neutrophil survival experiments. For all the above experiments, the 4 hour 
time point was used since that is when neutrophil apoptosis is starting to be seen while the 
20 hour time point was selected because neutrophil apoptosis starts to plateau out at that 
time (Sabroe et al., 2004).  
In key survival experiments, neutrophils were pre-incubated for 1 hour with JC1 isotype 
control or anti-CD63 antibodies at 10µg/ml followed by survival stimulatory/inhibitory 
compounds to modulate neutrophil apoptosis. Neutrophil incubation was then done for 20 
hours with LPS-10ng/ml (Enzo life sciences, Exeter, UK) and GM-CSF-50units/ml (Gibco life 
technology, Paisley, UK) or for 5 hours with Pyocyanin (Pyo) (50µM). The 5 hour time point 
incubation with pyo was selected due to previous evidence in the literature of significant 
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neutrophil apoptosis reduction when the cells were incubated for 5 hours with the 
apoptosis acceleration stimuli (Usher et al., 2002). Light microscopy assessment and 
cytospins preparation was done as per section 2.5.1. and 2.5.1.1. 
2.5.1.3. Investigation of CD63-GST peptides LPS contamination 
Tetraspanin peptides are small constructs that target the EC2 tetraspanin domain and have 
a GST tag for purification, having been shown recently to have valuable therapeutic 
implications (Higginbottom et al., 2003; Parthasarathy et al., 2009; Ventress et al., 2016). 
Considering that these constructs were obtained in and E. coli system, they were checked 
for endotoxin contamination. Neutrophils obtained from Section 2.3 were resuspended in 
complete media at 5X106 and added to 96 well plates. The cells were then pre-incubated 
with LPS from Rhodobacter sphaeroides (LPS-RS) (10µg/ml) (InvivoGen, Toulouse, France), 
a potent endotoxin inhibitor, for 1 hour followed by a 20 hour incubation with LPS 
(10ng/ml), GST (10µg/ml) and GST-CD63 (10µg/ml). Light microscopy assessment and 
cytospin preparation was done as per section 2.5.1. and 2.5.1.1. 
2.5.1.4. Modulation of neutrophil survival using tissue inhibitor metalloproteinase-1 
Tissue inhibitor metalloproteinase-1 (TIMP-1) is a protein identified via yeast two-hybrid 
system to interact with CD63 (Jung et al., 2006). Neutrophils were resuspended in complete 
media at 5X106 cells/ml. Neutrophils (50µl/well) were incubated in a 96 well plate with 0.05, 
0.1, 0.5 or 1 µg/ml of recombinant human TIMP-1 protein (Insight Biotechnology Limited, 
Wembley, UK) for 20 hours. The recombinant human TIMP-1 protein had 95% purity and 
the endotoxin level <0.1ng/μl. Concentrations were chosen considering the manufacturer’s 
half minimal inhibition value of 0.05µg/ml. Light microscopy assessment and cytospin 
preparation was done as per section 2.5.1. and 2.5.1.1. 
2.5.1.5. Neutrophil phagocytosis of live and HK bacteria in the presence of anti-
tetraspanin antibodies 
Neutrophils have long been known to clear bacterial infections, however we are still 
unaware of all the proteins involved in the process of bacterial interaction, phagocytosis 
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and killing (Holmes et al., 1967). Tetraspanins have been shown in Chapter 1 to be involved 
in bacterial interactions, as a result their roles in neutrophil phagocytosis was investigated. 
Neutrophils (50µl/well at 5x106 cells/ml) obtained from section 2.3. were resuspended in 
complete media (for HK bacteria), or media without antibiotics (for live bacteria) and added 
to 96 well flexiwell plates. Monoclonal antibodies, directed against CD9, CD37, CD63 and 
JC1 isotype control were used at a final concentration of 10µg/ml while anti-CD151 
antibodies were used at 0.5, 1, 5, 10, 20 µg/ml. Biolegend anti-CD151 and matched isotype 
control antibodies were used at 10 µg/ml. The concentrations the antibodies were used at 
will be specified for each experiment in Chapter 4. Cells were pre-treated with media or 
antibodies described above for one hour at 37°C/ 5%CO2. Following this, neutrophils were 
incubated with different multiplicity of infection (MOI) of HK and live S. aureus and 
opsonised HK or live S. pneumoniae (see Sections 2.4.1.2., 2.4.2. and 2.4.2.1. for bacterial 
HK and S. pneumoniae opsonisation) at different time points as described in Table 2.3. The 
incubation time and MOI of bacteria will be specified for each experiment in Chapter 4. In 
a single experiment, neutrophils were incubated with latex beads (Sigma-Aldrich, Poole, UK) 
at MOI10 for 2 hours. The number of latex beads particles was calculated using the formula 
(6.03x1010xS)/ (3.3xd3), where S is % solids and d is the bead diameter. This information is 
batch specific and written on the bottle. Light microscopy assessment and cytospin 
preparation was done as per section 2.5.1. and 2.5.1.1. 
In key experiments, anti-β1 integrin blocking antibodies (see Table2.1) were used to test 
integrin-tetraspanin interactions. The P4C10 antibody clone was used since it has been 
previously shown to act as a blocking antibody (Byron et al., 2009). To test this, neutrophils 
were incubated for 1 hour with media, JC1 isotype control, anti-CD151 antibodies, anti-β1 
integrin antibodies at 5µg/ml or anti-CD151 antibodies + anti-β1 integrin antibodies 
(10µg/ml+ 5µg/ml). Live S. aureus WT at MOI10 was then added to the cells for 45 minutes. 
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Antibodies 
Concentrations 
0.5µg/ml 1µg/ml 5µg/ml 10µg/ml 20µg/ml 
JC1 isotype - - - + + 
CD9 - - - + - 
CD37 - - - + - 
CD151 - - - + - 
CD63-H5C6 + + + + + 
CD63-H5C6-Fab - - + + + 
CD63- AHN16.1 - - - - + 
CD63-6H1 - - - - + 
 
Table 2.2: Tetraspanin antibody concentrations used in the survival experiments. 
Anti-tetraspanin antibodies were used at different concentrations for survival experiments. 
The ‘+’ symbol mark the concentration the antibody is used at in the thesis while the ’-‘ 
symbol indicates the antibody was not used at that concentration. 
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Bacterial strains 
 MOI 
1 2.5 5 10 20 40 
HK  
S. aureus WT 
 
                120 
minutes 
    120 
minutes 
120 
minutes 
30, 60 or 
120 
minutes 
15, 30, 
60, 120, 
180, 240 
minutes 
- 
HK  
S. aureus JE2 
 
- 
- - 
120 
minutes 
- - 
HK  
S. aureus SpA 
 
- - - 
120 
minutes 
120 
minutes 
- 
HK  
S. pneumoniae 
 
 
 
 
 
 
 
- 
- 
120 
minutes 
30,60 or 
120 
minutes 
120 
minutes 
120 
minutes 
Live  
S. pneumoniae 
- 
- - 
60 
minutes 
- - 
Live  
S. aureus WT 
 
- - 
45 or 75 
minutes 
- - - 
Live  
S. aureus 
SRCO11/SRCO12 
 
- - 
45 
minutes 
- - - 
 
Table 2.3.: S. aureus and S. pneumoniae MOI and incubation time used in the phagocytosis 
experiments. 
Neutrophils were incubated for different amounts of time with different MOI of S. aureus 
and S. pnemoniae. The table shows the MOI of each strain of S. aureus and S. pneumoniae 
against the amount of time they were incubated for. The ‘-‘ symbol indicates that the MOI 
was not used for that bacteria. 
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2.6. Flow cytometry 
2.6.1. Determination of CD151 and CD63 expression by flow cytometry 
2.6.1.1. Conjugation of tetraspanin antibodies with Alexa Fluor 488 antibody labelling kit 
The conjugation of JC1 isotype control, anti-CD63 H5C6 antibody clone and anti-CD151 
antibody was done as per manufacturer’s instructions and using the reagents provided in 
the Alexa Fluor 488 antibody labelling kit (Life technologies, Paisley, UK). In brief, a 1M 
solution of sodium bicarbonate was made by adding 1ml of dH2O to the provided vial and 
vortexing until the powder was completely dissolved. The antibody concentration was then 
adjusted to 1mg/ml with sterile PBS by making a dilution from the individual antibody stock 
concentration. To prepare the antibodies for the column, 1/10th volume of 1M sodium 
bicarbonate solution was added to each antibody mixture. One hundred microliters of 
antibody solution was then transferred to individual reaction vials containing Alexa Fluor 
488 dye and incubated for 1 hour with periodical mixing by inversion. A spin column was 
meanwhile prepared for each antibody by adding 1.5ml of resuspended purification resin 
per columns followed by centrifugation at 1,100 g for 3 minutes to remove the excess liquid. 
The 100µl of conjugated antibody was added to individual columns by placing drop by drop 
the liquid into the centre of the column. After the liquid was absorbed into the resin, the 
columns were centrifuged at 1,100 g for 5 minutes to remove the excess dye. The antibodies 
were collected into the provided collection tubes and stored at -20°C until required. 
2.6.1.2. Determination of CD151 and CD63 expression on neutrophils by flow cytometry 
Neutrophils were resuspended in complete RPMI at 5x106 cells/ml and 90µl were added in 
each well in a 96 well plate and topped up to 100µl with complete medium. Neutrophils 
were incubated with media for 0, 4 and 20 hours at 37°C/ 5%CO2. A positive control in which 
neutrophils were incubated for 30 minutes at 37°C/ 5%CO2 with HK S. aureus at MOI10 was 
also set up. S. aureus was used as positive control since it induces degranulation and 
activation of neutrophils (Faurschou and Borregaard, 2003). Following incubation, 
neutrophils were centrifuged at 300 g for 2 minutes. The pellets were then washed in 200µl 
of PBS by centrifugation at 300 g for 2 minutes. Depending on the experimental 
requirements, cells were resuspended in 20µl of PBS and then stained at RT in the dark with 
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different antibodies which will be specified for each experiment in Chapters 3 and 4. These 
are as follows: Alexa Fluor 488-labeled antibodies (JC1, anti-CD63 and anti-CD151) (see 
section 2.6.1.1.) incubation was done for 30 minute using 10µg/ml of the antibodies; APC 
labeled isotype and anti-CD151 antibody incubation was done for 30 minutes using 5µl of 
the commercially available antibodies; when unlabeled primary antibodies were used 
initially, neutrophils were pre-blocked for 15 minutes with 10% goat serum (Biolegend, 
Cambridge, UK) followed by a 20 minute incubation with primary JC1 isotype control or anti-
CD151 antibodies at 10µg/ml followed by a further 20 minute incubation with an equal 
volume, to the primary antibody, of secondary fluorescein 5-isothiocynate (FITC) labelled 
anti-mouse IgG antibody (Sigma-Aldrich, Poole UK). The labeled cells were then added to 
fluorescent activated cell sorting (FACS) tubes containing 300µl of PBS. The tubes were then 
analysed in duplicate using the FACScalibur flow cytometer (BD Biosciences-Pharmingen) 
and Cell Quest Pro program. The neutrophils were gated on the forward scatter (FSC)/ side 
scatter (SSC) parameter based on their size and granularity and any contaminating cells 
were excluded (Figure 2.3). Gain of FITC and Alexa Fluor 488 fluorescence was measured by 
a right shift on the FL1-H (Ex=490nm, Em=525nm) parameter while the binding of APC-
labeled antibodies was measured on the FL4-H (Ex=650nm, Em=660nm) parameter. 
Analysis of data was conducted using Flowjo analysis software version Vx0.7 (Tree Star, Inc).  
2.6.1.3. Determination of anti-CD63 Fab fragment binding to A549 cells 
To validate the anti-CD63 Fab fragments binding to CD63, the A549 adenocarcinomic 
human alveolar basal epithelial cell line, expressing stably CD63 on plasma membrane, was 
used (Funakoshi et al., 2003). A549 cells were dissociated from an 80% confluent flask 
(obtained from general laboratory stocks) by incubation for 20 minutes with 2ml of non-
enzymatic cell dissociation solution (Millipore, Watford, UK). The reaction was stopped by 
adding 6ml of Dulbecco’s modified eagle medium (DMEM) (Lonza, Veveris, Belgium). A 5 
minute centrifugation at 200 g was subsequently done, followed by cell resuspension in 
10ml of PBS. A haemocytometer chamber was then employed to count the number of cells. 
To conduct the experiment, the cells were centrifuged as previously and 1x106 
cells/condition were resuspended in 50µl PBS. Blocking of Fc receptors on cell surface was 
then conducted for 15 minutes with 10% goat serum followed by 1 hour incubation on ice 
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with JC1 isotype control or anti-CD63 Fab fragments at 10µg/ml. A further 20 minute 
incubation with 1µl of FITC labeled anti-mouse antibody was conducted on ice. Unstained 
and a second antibody only negative controls were used. The conditions were analysed 
using the LSRII flow cytometry machine (BD Biosciences). Separation of cell/debris was done 
on the FSC/SSC and gain of FITC fluorescence was analysed using the Blue 530/30 channel 
(Ex=490nm, Em=525nm). Analysis of data was carried out using Flowjo analysis software 
version Vx0.7. 
2.6.1.4. Determination of anti-CD151 antibody binding to HEC-1-B cells 
To check anti-CD151 antibodies binding, the human endometrial adenocarcinoma cell line 
HEC-1-B that expresses CD151 was used (Green et al., 2011). To conduct the experiment, 
an 80% confluent flask was obtained from the laboratory of Prof. Peter Monk- Medical 
School, Sheffield, UK- and 2 ml of non-enzymatic cell dissociation solution was added for 20 
minutes. The reaction was stopped by adding 6ml of DMEM. A 5 minute centrifugation of 
the cells at 400 g was then conducted, followed by their resuspension in 10ml PBS. Counting 
of the cells was done using a haemocytometer chamber. After a subsequent centrifugation 
for 5 minutes at 400 g, 1x106 cells/condition were resuspended in 10µl of PBS. Blocking of 
extracellular Fc receptors was initially conducted for 15 minutes with 10% goat serum. A 30 
minute staining on ice was initially done with 10µg/ml of Alexa Fluor 488 labeled JC1 isotype 
control and anti-CD151 antibodies; and with primary, unstained anti-CD151 antibodies 
(10µg/ml) or with 5µl of commercially obtained APC labeled isotype and anti-CD151 
antibodies. Where the primary, unstained anti-CD151 antibody was used, a further 20 
minute incubation with equal volume, to the primary antibody, of FITC labeled anti-mouse 
antibody was done. An unstained and a secondary antibody only controls were used. 
Separation of cells/debris was done based on their FSC/SSC parameters. Gain of FITC and 
Alexa Fluor 488 fluorescence was measured by a right shift on the FL1-H (Ex=490nm, 
Em=525nm) parameter while the binding of APC-labeled antibodies was measured on the 
FL4-H (Ex=650nm, Em=660nm) parameter. Analysis of data was carried out using Flowjo 
analysis software. 
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Figure 2.3: Distribution of cells on a flow cytometry dot plot. 
Diagram shows FSC parameter (indicator of cell size) and SSC parameter (indicator of cell 
density/granularity) profile of a plasma/Percoll-pure granulocyte preparation. Distinct 
populations of neutrophils can be seen on the FSC/SSC parameter. Neutrophils appear more 
granular than monocytes. A small population of monocytes and lymphocytes can be seen, 
as well as some debris. Due to the high purity in our neutrophil population the monocytes 
cannot be seen clearly. 
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2.6.2. Determination of neutrophil death using Annexin V/ToPro-3 staining 
Neutrophils obtained from plasma/Percoll gradient centrifugation (see section 2.3.) were 
resuspended in complete media at 5x106 cells/ml and 50µl neutrophils/well were added to 
a 96 well plate. Following the addition of 20µg/ml of JC1 isotype control or anti-CD63 
antibodies, the wells were topped to 100µl with complete media and incubated for 20 hours 
at 37°C/ 5%CO2. After incubation, the cells were centrifuged at 300 g for 2 minutes, the 
supernatant removed and the pellet resuspended in 50µl of 1x Annexin V buffer (BD 
Biosciences, Oxford, UK). Annexin V-phycoerythrin (PE) (2.5µl/reaction, BD Biosciences, 
Oxford, UK) was then added to reaction tubes and incubated for 20 minutes in the dark at 
RT. Annexin V binds to phosphatidylserine groups that become permanently exposed on 
the outer membrane as cells undergo apoptosis (Babiychuk et al., 2008; Cantinieaux et al., 
2004; Solito et al., 1998). The cells were subsequently added to FACS tubes containing 300µl 
of 1x Annexin binding buffer with ToPro-3 (Life technologies, Paisley, UK) at 1:10,000 
dilution. A negative control of cells incubated with neither Annexin V nor ToPro-3 was used 
and was kept at RT for the duration of staining protocol. The samples were then analysed 
using LSRII flow cytometer using the Blue575/26 laser to detect PE fluorescence (Ex max-
496nm, Em max-578nm) and Red 660/20 to detect ToPro-3 fluorescence (Ex max-642nm, 
Em max-661nm). Analysis of data was carried out using Flowjo analysis software. 
2.6.3. Determination of neutrophil lysis by S. aureus using flow cytometry 
Neutrophils obtained from plasma/Percoll gradient centrifugation (see section 2.3.) were 
resuspended in RPMI+ 10% FBS at 5x106 cells/ml. A volume of 90µl/well was added per 
condition to a 96 well plate. A 1 hour incubation in the presence of 10µg/ml JC1 control or 
anti-CD151 antibodies at 37°C/ 5%CO2 was initially conducted, followed by a 2.5 hours 
incubation with live S. aureus WT MOI5 at 37°C/5% CO2. After a 2 minute centrifugation at 
300 g, the supernatants were discarded and the pellet resuspended in 200µl of PBS and 
transferred to a clean 96 well plate. A positive control was used where 200µl neutrophils 
resuspended in PBS were incubated at -80°C for 8 minutes, followed by their thawing at RT 
and lysing by vigorous vortexing. ToPro-3 was then added to the wells at 1:10,000 dilution 
and the samples were immediately run using the Attune flow cytometer (Applied 
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biosystems, Loughborough, UK). The cells were separated on FSC/SSC and gain of ToPro-3 
fluorescence (Ex -642nm, Em -661nm) was visualised on the RL1-A channel. Analysis of data 
was carried out using Flowjo analysis software. 
2.6.4. Extracellular bacterial fluorescence quenching using trypan blue  
Trypan blue (TB) is a dye that is commonly used in research to quench fluorescence of 
external particles due to its light absorbing properties in the green spectrum (Nuutila and 
Lilius, 2005). Freshly isolated neutrophils were resuspended in RPMI-1640+ 10% FBS at 5x 
106 cells and 90µl/well of these were added for each condition to a 96 well plate. 
Neutrophils were then incubated for 1 hour in the presence of media at either 37°C/ 5%CO2 
or 4°C and with JC1 isotype control (10µg/ml) or anti-CD151 antibodies (10µg/ml) only at 
37°C/ 5%CO2. Media treated neutrophils were then incubated for a further 45 minutes with 
live S. aureus (WT chr-GFP) MOI 5, 10 or 20 at both 37°C/ 5%CO2 and 4°C. Antibody treated 
neutrophils were further incubated for 45 minutes with live S. aureus (WT chr-GFP) at an 
MOI10 at 37°C/ 5%CO2. S. aureus (WT chr-GFP) has a GFP that can be detected in the green 
portion of the spectrum at 509nm. A 2 minute centrifugation of the cells at 300g was 
subsequently conducted, followed by supernatants removal and pellet resuspension in 125-
150µl of PBS and addition to FACS tubes. For media only incubated neutrophils, TB solution 
0.4% (Sigma-Aldrich, Poole, UK) was then added to tubes at either 1:4 or 1:2 dilutions for 1 
or 15 minutes while for antibody incubated cells a 1:2 dilution of the dye for 15 minutes 
was used. ToPro3 (1:10,000 dilution in PBS) was used as a control to determine membrane 
leakage and was added to cells just before their running on the flow cytometer. The 4°C 
incubated samples were kept on ice until they needed to be run on the flow cytometer. 
Detection of GFP (Ex -488nm, Em -509nm) fluorescence gain was seen as a right shift in the 
FL1-H channel of FACSCAlibur flow cytometer while ToPro-3 (Ex -642nm, Em -661nm) 
fluorescence gain was indicated on the FL-4 channel. Analysis of data was carried out using 
Flowjo analysis software. 
2.6.5. Determine HK S. aureus WT staining with Alexa Fluor 647 and pHrodo 
PHrodo is known for some years as a dye that can be used to measure phagocytosis since it 
can be activated at low pH while Alexa Fluor 488 has recently been used to co-conjugate 
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bacteria with pHrodo to study bacterial interaction and localisation in cells (Aziz et al., 2013; 
Ellett et al., 2015). To investigate fluorescent microscopy results outcome (see section 2.9), 
the intensity and uniformity of HK S. aureus WT conjugation with Alexa Fluor 647 (Life 
technologies, Paisley, UK) and red pHrodo (Life technologies, Paisley, UK) was checked. 
Conjugated HK S. aureus WT with both Alexa Fluor 647 and red pHrodo obtained as per 
Section 2.9.1 were analysed for their fluorescence using LSRII flow cytometer. Unstained HK 
S. aureus WT was used as a negative control. The bacteria were separated on a FSC/SSC plot 
using a logarithmic scale to account for the bacterial size of 1-2µm. Red pHrodo (Ex -560nm, 
Em -585nm) staining was assessed by a right fluorescence shift on the Blue 610/20 channel 
while a right shift on the Red 660/20 axis represented staining with the Alexa Fluor 647 (Ex 
-650nm, Em -565nm) dye. Analysis of data was carried out using Flowjo analysis software. 
2.7. Western Blot  
2.7.1. Preparation of neutrophil and bacteria whole cell lysates 
Neutrophils were centrifuged at 300 g for 2 minutes while HK S. aureus WT and SpA were 
centrifuged at 16,100 g for 3 minutes. Followed by washing with 200µl ice cold PBS, the cells 
were lysed by adding 10 µl lysis buffer (see Appendix II) per 106 cells, vortexing them 
vigorously and placing them on ice for 1 minute. Equal amounts of hot 2X sodium dodecyl 
sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) (see Appendix II) loading dye was 
added followed by heating to 95°C for 10 minutes to denature and linearise protein. 
Samples were frozen at -20°C until used (average storage 1-2 months). 
2.7.2. SDS-PAGE gel preparation and electrophoresis 
To make SDS-PAGE gels, glass moulds and plates were cleaned with 70% IMS, and 
assembled into clamps (Bio-Rad, Berkeley, CA). The resolving gel (12%) was made using the 
reagents specified in Appendix II. N,N,N',N'-Tetramethylethylenediamine (TEMED) was 
added last to the mixture and immediately preceding pouring, since in conjunction with 
ammonium persulfate (APS), it catalyses acrylamide polymerisation to form a gel matrix for 
protein sieving. The gels were poured into each apparatus. Butan-1-ol/isopropanol was 
placed on top, to prevent evaporation, and the gels were let to set at RT for 10-20 minutes. 
The stacking gel was made using the reagents in Appendix II. After the butan-1-
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ol/isopropanol was rinsed off with distilled water, the stacking gel was layered on top of the 
resolving gel. The combs were subsequently inserted in each apparatus, preventing bubble 
formation, and allowed to set for 10-15 minutes. The gels were transferred to the gel 
running apparatus (Protean 2 gel assembly, Bio-Rad, Berkeley, CA) and immersed in 1X 
Running buffer (10X Running buffer made as described in Appendix II and diluted with 
distilled water). The combs were removed and 40µl of neutrophil cell lysates, S. aureus cell 
lysates equivalent of an MOI10, 10µl PLB-985 (obtained by Dr. Pranvera Sadiku) as well as 
5µl of CSL-BBL prestained protein ladder (11-245kDa) (Geneflow, Lichfield, UK) or 7µl of 
ColorPLus Prestained Protein Ladder (11-245kDa) (New England Biolabs, Hitchin, UK) were 
loaded to individual lanes. The ladder ensured sizing of the sample protein. The gels were 
run at 100 volts, using the Power Pac 300 (Bio-Rad, Berkeley, CA), until the samples entered 
the resolving gel, after which the voltage was increased to 150 volts until the blue dye front 
reached the very bottom of the gel. 
2.7.3. Wet transfer of the protein 
A Geneflow wet transfer kit was used for protein transfer. The Transfer buffer (see Appendix 
II) was pre-cooled at 4°C. Just before complete protein electroporation, 4 filter cards, 2 fibre 
pads and one Polyvinylidene difluoride (PVDF) (Merckmillipore, Watford, UK) membrane 
were soaked for each blot in Transfer buffer. The PVDF membrane was previously activated 
by soaking for 5 minutes in 100% methanol. This allows the membrane to switch from 
hydrophobic to hydrophilic, helping the membrane to expose its full protein binding 
capacity. Following electrophoresis, the stacking gel was removed and the cassette holder 
was assembled as follows: black side cassette, fiber pad, 2 filter cards, PVDF membrane, gel, 
2 filter cards, fiber pad and red side cassette. The assembled cassette was placed in the tank 
so that the red side faced the black side of the tank and its black side faced the red side of 
the tank. The tank was immersed on ice during protein transfer to prevent overheating of 
the transfer assembly. Membrane transfer was then conducted at 120V for 70 minutes. 
2.7.4. Antibody incubation 
Following the transfer, the PVDF membrane was removed and placed in a plastic container. 
The membrane was blocked for 2 hours in 5% milk powder (Sigma-Aldrich, Poole, UK)/ 1x 
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TBS (Tris-buffered saline) (see Appendix II). The primary antibodies (see Appendix II) were 
diluted in 4ml 5% Milk/ 1xTBS-0.1% Tween-20 (see Appendix II) and incubated with the 
membrane in a 50ml Falcon tube on a roller overnight at 4°C. The blot was rinsed three 
times in 1xTBS-0.1% Tween-20 for 10 minutes. The use of the Tween-20 detergent in low 
concentrations allows the dissociation of the nonspecifically bound antibodies. The 
secondary anti-rabbit or anti-mouse antibodies were diluted in 5mls of 5% milk powder/ 
TBS-0.1% Tween-20 as described per Appendix II and incubated for 1 hour at RT on the 
shaker. The blot was rinsed three times in TBS-0.1% Tween-20 for 10 minutes. 
2.7.5. Blot developing  
During the final wash, blot developing was started by mixing equal parts of solution A and 
B from the EZ-ECL imaging kit (Bio Rad Laboratories, Hercules, California), followed by a 5 
minute incubation in the dark. The mixture was added to the membrane for a further 2 
minutes. The membrane was transferred to a plastic pocket and all the air bubbles and 
excess liquid removed. Depending on the antibody, imaging of the blot was done for 1-50 
minutes, taking intermediate images, using the Bio-Rad ChemiDoc imaging machine. 
2.7.6. Membrane stripping and reprobing with p38 loading control antibody 
Membrane stripping is done to remove the antibodies used to visualise a target and probe 
for another target, usually a protein loading control. To strip a membrane, 2X10 minutes 
wash with distilled water was conducted followed by a 15 minutes wash with 0.2M sodium 
hydroxide (NaOH) (Alfa Aesar, Heysham, UK) and 2X10 minutes with distilled water. A 2 
hour blocking in 5% milk powder/ 1xTBS was conducted after which the membrane was 
reprobed for the unphosphorylated p38 housekeeping protein as per section 2.7.4, using 
the dilution from the antibody table in the Appendix II. Unphosphorylated p38 was 
previously used by our group as control due to its steady expression in neutrophils 
(Walmsley et al., 2011). Blot developing was subsequently done using the protocol 
described at section 2.7.5.  
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2.8. Bacterial viability assays 
2.8.1. Neutrophil infection 
Neutrophils obtained from plasma/Percoll-gradient centrifugation (see section 2.3) were 
resuspended at 5x106 cells/ml in RPMI 1640 + 10% FBS and 90µl/well was added to a 96 
well plate. Neutrophils were initially incubated for 1 hour with 10µg/ml of JC1 isotype 
control or anti-CD151 antibodies. Meanwhile, bacterial stock of NTHi obtained from section 
2.4.2.1 was thawed at RT and centrifuged at 11,000 g for 5 minutes and the S. aureus WT 
stock obtained from section 2.4.1. was thawed on ice and centrifuged at 16,100 g for 3 
minutes. Thawing was done differently due to the different preservation protocols used for 
the two bacteria while the centrifugation methods were used following the in house 
protocols. The supernatants were discarded and the NTHi was washed 3 times in 1ml PBS 
at 11,000 g for 5 minutes while S. aureus WT was washed only once in 1ml PBS at 16,100 g 
for 3 minutes. The bacteria were then resuspended in RPMI 1640 + 10% FBS at 1x109 
CFU/ml. S. aureus WT was incubated with neutrophils for 45 minutes at an MOI5 while 
neutrophil incubation with NTHi was done for 1 hour at an MOI10 at 37°C/5% CO2.  
2.8.1.1. Determination of viable intracellular bacteria using gentamicin protection assay 
This method allows quantification of internalised viable bacteria after killing extracellular 
bacteria using antibiotics that cannot penetrate the eukaryotic cell (Vaudaux and 
Waldvogel, 1979). Gentamicin (20µg/ml for S. aureus WT and 60µg/ml for NTHi) (Sanofi, 
Surrey, UK) was added for 30 minutes or 75 minutes (S. aureus only) to the infected 
neutrophils from section 2.8.1.1. Gentamicin is a compound that stops protein synthesis by 
binding to the 30S eukaryotic, ribosomal subunit in both Gram positive and Gram negative 
bacteria (Yoshizawa et al., 1998). A subsequent centrifugation of the cells for 2 minutes at 
300 g was conducted. Following supernatant discard, neutrophils were incubated for 10 
minutes with 100µl of 1% saponin (Sigma-Aldrich, Poole, UK), a detergent known to 
associate with cholesterol and permeabilise the eukaryotic cell membrane by forming pores 
in it (Bangham et al., 1962). A volume of 900µl of sterile PBS was then added to each tube. 
Additional six 10 fold dilutions were conducted and plated by placing 3x10µl 
drops/condition on BHI agar (S. aureus) or chocolate agar (NTHi) plates using the Miles-
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Misra dilution techniques (Miles et al., 1938). Plates were incubated overnight at 37°C/ 
5%CO2 .The colonies were counted the following day and the CFU/ml calculated as per 
section 2.4.1.1. 
2.8.2. Monocyte derived macrophages (MDMs) viability assay with S. aureus 
2.8.2.1. Differentiation of PBMCs into MDMs  
In vitro differentiated MDMs have been shown to be a good model for alveolar 
macrophages (Daigneault et al., 2010). PBMCs obtained from plasma/Percoll purification 
(see section 2.3.) were resuspended in RPMI 1640+ 1% Pen/Strep at 4x106 cells/ml. In a 24 
well-plate (Costar, High Wycombe, UK) 500µl of the resuspended cells were added to each 
well and incubated at 37°C/ 5%CO2 for an hour. By starving the cells of FBS for an hour, the 
monocytes adhere to the bottom of the plate. Following this, the non-adherent cells 
(predominantly lymphocytes) were removed by vigorous pipetting and 500µl of RPMI+ 
1%Pen/Strep+ 10% FBS was added to each well. The media was changed the day after and 
then every other day for 14 days. The number of differentiated, adherent MDMs after the 
2 weeks was typically 2x105/well. 
2.8.2.2. Infection of MDMs with S. aureus 
MDMs were incubated for 1 hour with RPMI 1640+ 10% FBS containing 10µg/ml JC1 isotype 
control or anti-CD151 antibodies. In the meantime, a stock vial of S. aureus WT was thawed 
on ice followed by cell centrifugation at 16,100 g for 3 minutes. The supernatants were 
discarded and the S. aureus WT washed once with sterile PBS. The bacteria were 
resuspended in RPMI 1640+ 10% FBS at 1x109 CFU/ml. An MOI5 of S. aureus WT was then 
added to each well. The plates were placed on ice for 1 hour to allow the S. aureus WT to 
adhere to the MDMs followed by a further 1 hour incubation at 37°C/ 5%CO2.  
2.8.2.3. Determination of viable intracellular bacteria in MDMs using gentamicin 
protection assay 
Following the S. aureus WT incubation, the cells were washed 3 times with 1ml ice cold 
sterile PBS. A volume of 500µl fresh RPMI 1640+ 10% FBS containing 60µg/ml gentamycin 
was added to each well and the plate placed at 37°C/ 5%CO2 for 30 minutes. This step 
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allowed the killing of the extracellular and surface bound bacteria. The wells were washed 
3 times with sterile PBS. For a second time point, half of the cells were incubated for a 
further 90 minutes in 500µl fresh RPMI 1640+ 10% FBS containing 6µg/ml gentamycin 
followed by 3 times PBS wash. The lower gentamycin concentration was chosen to avoid 
bacterial growth in the wells. After each time point, MDMs plasma membrane was 
permeabilised by adding 250µl of 2% saponin for 15 minutes. The wells were subsequently 
topped to 1ml with sterile PBS. MDMs were further permeabilised by scraping the bottom 
of the well with a pipette tip and vigorous pipetting. Three 5 fold dilutions were conducted 
and 3x 10µl drops/condition were placed on BHI agar plates. Plates were incubated 
overnight at 37°C/ 5%CO2. Next day colony count and CFU/ml calculation was conducted as 
per section 2.4.1.1. 
2.9. Fluorescent microscopy  
Fluorescent microscopy is a useful tool that enables visualisation of protein interactions and 
co-localisation using fluorophores that emit different fluorescence. For the experiment, 
Alexa Fluor 647 and pHrodo red succinimidyl esters were chosen. The succinimidyl ester 
feature of the dyes allows binding to the amine groups to form highly stable amide bonds 
(Brinkley, 1992). The succinimidyl ester is susceptible to hydrolysis, however if the 
conjugation reaction is done under alkaline conditions, this setback can be overcome 
(Lomant and Fairbanks, 1976). PHrodo is a dye that can be activated at acidic pH, therefore 
it can be useful tool for studying bacterial phagocytosis due to its activation upon bacterial 
entrapment in the phagolysosome (Aziz et al., 2013; Segal, 2005). Alexa Fluor 647 is a highly 
stable dye, from acid to basic pH, that has been recently used to co-stain bacteria with 
pHrodo to study bacterial interaction and localisation in cells (Ellett et al., 2015). The fact 
that pHrodo (Ex -560nm, Em -585nm) and Alexa Fluor 647 (Ex -650nm, Em -665nm) dyes 
have non-overlapping excitation and emission spectra, allows their simultaneous use 
without interference. 
2.9.1 Fluorescent labelling of S. aureus with Alexa Fluor 647 and pHrodo 
Both HK and live S. aureus WT were used for this protocol. S. aureus was centrifuged at 
6,200g, 4°C for 10 minutes and resuspended in sterile PBS at pH9 to achieve 2.5x103CFU/nl. 
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To a clean 1.5ml eppendorf tube, 200µl of the resuspended S. aureus WT was added 
followed by Alexa Fluor 647 succinimidyl ester (10mg/ml) addition at 1:200 dilution and/or 
pHrodo succinimidyl ester (10mM) at 1:1000 dilution. The tube was incubated in the dark 
for 30 minutes at 37°C/ 5%CO2 with gentle shaking. The mixture was subsequently washed 
by adding 1ml of PBS pH8 or PBS pH8+ 1% bovine serum albumin (BSA) (Melford 
Biolaboratories, Ipswich, UK)/ 1% FBS and centrifuging at 16,100 g for 3 minutes. The 
bacteria was afterwards washed using 1ml of 25mM Tris pH8.5 or 25mM Tris pH8.5+ 1% 
BSA/1% FBS by centrifugation at 16,100 g for 3 minutes. A last wash with 1ml of PBS pH8 or 
PBS pH8+ 1% BSA/1% FBS was conducted by centrifugation at 16,100 g for 3 minutes. The 
buffers were used at alkaline pH to allow adequate staining of the S. aureus WT, while 
BSA/FBS were added to prevent bacterial loss during centrifugation. The use of the buffers 
will be specified for each of the fluorescent microscopy experiment in Chapter 4. After 
supernatant removal, the bacteria were resuspended in 100µl of PBS pH 7.4. 
2.9.2. Neutrophil incubation with Alexa Fluor 647 and pHrodo stained S. aureus 
Neutrophils obtained from healthy volunteers as per section 2.3. were resuspended at 
5x106 in complete RPMI 1640 (HK S. aureus WT) or RPMI 1640+ 10% FBS (live S. aureus WT). 
The cells (90µl/well) were incubated in 96 well plates with media or 10 µg/ml of JC1 isotype 
control or anti-CD151 antibodies for 1 hour at 37°C/ 5%CO2. Following this, neutrophils 
were either incubated for 45 minutes at 37°C/ 5%CO2 with MOI10 of HK S. aureus WT or for 
30 minutes at 37°C/ 5%CO2 with MOI5 of live S. aureus WT that were previously stained 
with Alexa Fluor 647 and/or pHrodo. 
2.9.3. Neutrophil membrane labelling 
Following S. aureus incubation, neutrophil membrane labelling was done using PKH67 green 
fluorescent cell linker kit (Sigma-Aldrich, Poole, UK). Staining of the membrane could affect 
cell properties to phagocytose bacteria, therefore the staining protocol was carried out (as 
indicated by the manufacturer) following phagocytosis. In brief, duplicate wells from each 
condition specified in Section 2.9.2 were pulled together and centrifuged at 400 g for 5 
minutes. The supernatant were then discarded and pellet washed once using RPMI 1640 
without FBS or Pen/Strep. The supernatant was carefully aspirated making sure that no 
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more than 25µl of liquid remained. The cells were resuspended in 1ml/ 2x107 cells of Diluent 
C. Following this, 4µl of PKH67 ethanolic dye solution was resuspended in 1ml of Diluent C 
and an equal volume of this solution was added to the Diluent C resuspended cells. A 
prompt mixture by pipetting was conducted, to allow even staining, followed by incubation 
at RT for 5 minutes. The reaction was stopped with an equal volume of FBS and incubated 
for 1 minute. Centrifugation was subsequently conducted at 400 g for 10minutes. To 
remove excess dye, the cells were washed twice in 1.5mls sterile PBS by 400 g centrifuging 
for 5minutes. Cells were resuspended in 200µl of complete RPMI 1640. 
2.9.4. Preparation of fluorescent microscopy slides  
Cytospins of labeled neutrophils were made following the protocol on the Section 2.5.1., 
with the exception that cells were cytocentrifuged on a glass coverslip of 0.13mm that was 
placed between the glass slide and the filter card. The thin coverslip was used to enable 
better resolution during microscopy. Cell fixing was done by adding 50µl of 4% 
paraformaldehyde (PFA) (Sigma-Aldrich, Poole, UK) (see Appendix III) for 15 minutes. PFA 
was used instead of methanol because it preserves the physiology of the cells. The coverslip 
was then washed 3x 5minutes in 50µl of PBS. The stock solution of 50mg/ml of DAPI (4,6-
diamidino-2-phenyl-indolehydrochloride, Biolegend, Cambridge, UK) was diluted 1:10,000 
in PBS and 50µl was added to each slide for 15 minutes to stain neutrophil nucleus. DAPI is 
a dye that intercalates into DNA, therefore staining the nucleus of cells (Manzini et al., 
1985). A 3x 5 minutes wash with 50µl/coverslip of PBS was conducted. The cover slips were 
afterwards inverted using tweezers and fixed on glass slides by being placed directly over 
10µl of the nonfluorescing mounting medium fluoromount G (SouthernBiotech, 
Birmingham, USA). Tweezers were used to push out air bubbles trapped under the coverslip 
by pushing gently on it. Great care was taken not to move the coverslip, to prevent cell loss 
and smearing. The slides were dried in the dark, in the fume cupboard and then kept at 4°C 
for up to 1 month. The slides were imaged using the Olympus upright epifluorescence 
system BX63 (Olympos, Essex, UK). 
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2.9.4.1. Count of pHrodo stained S. aureus internalised by neutrophils 
To analyse the fluorescent microscopy data, Fiji software (free software, Rasband, 1997) 
was used. Dr. Darren Robinson, Department of Biomedical Science, University of Sheffield, 
UK has designed the specific coding program (Figure 2.4A) to be run via Fiji software to 
count the pHrodo stained S. aureus WT inside the neutrophils. Before the program could be 
run, individual neutrophil borders were delimitated by hand (Figure 2.4B). The multi-lobed 
neutrophil nucleus shape does not allow the program to delimitate the cells accurately, 
confusing it with multiple cells (Figure 2.4B). Cells that did not fit completely in the frame 
or had a nuclear structure that was not specific to the neutrophil one were excluded from 
the count. The first 3 commands in the software were performed manually due to varying 
nature of the samples. Initially, the ‘Unsharp Mask’ command was used to correct the 
blurriness of the image (Figure 2.4C). The ‘Enhance contrast’ function was removed because 
the samples were bright enough to be picked up by the program. Following this, the ‘Find 
maxima’ function was used. This function allows the noise to value ratio to be adjusted so 
that an accurate number of bacteria can be picked by the program (Figure 2.4D). The output 
box in the ‘Find maxima’ function was set to ‘point selection’ to allow the display of multiple 
points with a point per each maxima. Once these commands were set, they were excluded 
from the program using two forward dashes (Figure 2.4E). The threshold was then set by 
the program. Based on these setting, the program created a mask by using the ‘Create 
Mask’ function (Figure 2.4F). This function allowed the counting of the bacteria inside the 
region of interest (ROI), which in this instance was the neutrophil. The ‘for’ function (for 
(i=0, i<n, i++)) is a common function used in programming that allowed bacterial counting 
in each neutrophil by giving a number to the neutrophil of 0 to n. A summary of the analysis 
was generated at the end containing the number of bacteria in each neutrophil (Figure 2.4F-
summary panel). The program was run for each individual image. A number of 100 cells 
were counted per each conditions.  
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Figure 2.4: Fiji program print screens of the steps involved in the counting of pHrodo 
stained S. aureus WT within neutrophils 
A) The step by step coding program that determines the number of pHrodo stained S. 
aureus WT inside neutrophils. B) Manual individual neutrophil border delimitation. C) The 
‘unsharp mask’ function is used to reduce the blurriness of the image (left-before, right-
after). D) The ‘Find maxima’ function was used to mark each bacteria with a yellow cross by 
adjusting the noise tolerance. The output type will have ‘point selection’ command to allow 
selection of individual points. E) The green lines in the program represent manually 
excluded steps. F) Output after the program was run. Yellow line represents a Mask for each 
neutrophil. This will change from cell to cell as the program counts the bacteria in each one. 
Only the last cell analysed can be viewed. A summary is produced giving the number of 
bacteria in each cell, the average bacteria size, the % area occupied by the bacteria, and the 
mean intensity. 
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2.10. Statistical analysis of the data 
Statistical analysis was performed using GraphPad Prism version 6 (San Diego, California). 
Data sets were analysed using paired student’s t-test when there were only two groups or 
One way ANOVA with Bonferroni’s post-test with repeated measure or Dunnett’s test when 
there were three or more groups. The Bonferroni correction with repeated measures 
accounts for the variability in the donors by allowing the control in each donor to be 
compared to its equivalent condition. The Dunnett’s test was used when the Bonferroni test 
could not be used due to uneven repeats between the groups compared. When statistical 
analysis was conducted on responsive and nonresponsive donors, the test used was One-
way ANOVA with non-parametric distribution and Dunn's post-test to account for the fact 
that the samples din not assume a uniform, Gaussian distribution. Statistical significance is 
represented by *p<0.05, **p<0.01 and ***p<0.001. 
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Chapter 3: The expression and role of the tetraspanin, CD63, during 
neutrophil apoptosis 
3.1. Introduction 
3.1.1. Neutrophil survival 
Neutrophils are released from the bone marrow into the blood stream as terminally 
differentiated cells (Haslett et al., 1989; Nathan, 2006). Representing 45-70% of the total 
leukocyte pool, these cells can survive in the circulation for up to 8 hours or, if they migrate 
in the tissue, their lifespan can increase to 1-2 days, after which they die by programmed 
cell death (apoptosis) (Bainton et al., 1971; Cronkite and Fliedner, 1964). Apoptotic cells are 
then cleared in the liver, spleen, bone marrow and inflamed tissue by phagocytosis by the 
resident macrophages (Savill et al., 1989). Neutrophils are produced at a rate of 108 
cells/min, therefore regulation of neutrophil apoptosis is of great importance in maintaining 
homeostasis (Haslett, 1999). 
3.1.2. Neutrophil involvement in inflammatory disease 
Failure of neutrophils to undergo apoptosis and clearance by macrophages can result in 
abnormal healing and chronic inflammation (Ariel and Timor, 2013; Nathan and Ding, 2010). 
This is due to the formation of a prolonged inflammatory feedback loop where neutrophils 
release tissue damaging ROS and proteolytic granule contents that induce the release of 
DAMPs, which are involved in attracting additional immune and inflammatory cells (Nathan, 
2006; Nauseef and Borregaard, 2014; Soehnlein et al., 2009). Neutrophilia has been 
positively correlated with diseases such as COPD, rheumatoid arthritis and asthma 
(Brusselle et al., 2011; Louis and Djukanovic, 2006; Pillinger and Abramson, 1995; Plataki et 
al., 2006; Quint and Wedzicha, 2007). These diseases pose a major economic burden and 
are a major cause of morbidity and mortality, since the treatments presently available only 
alleviate the symptoms rather than targeting the underlying cellular inflammation. In the 
event of the sustained current trends, 400 million asthmatics are predicted to exist 
worldwide by 2025 and, according to the WHO, COPD will become the third leading cause 
of death worldwide by 2030 (Bahadori et al., 2009). Design of effective treatments that 
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actually treat the disease rather than the symptoms is, therefore, of paramount 
importance. However, considering the fragile, infection prone state of these patients, 
designing a neutrophil-targeted treatment has been slow due to potential 
immunosuppressive effects. 
3.1.3. The role of tetraspanins in neutrophil survival 
The 33 highly conserved tetraspanin members have wide-ranging functions including cell 
adherence and fusion, cell motility, protein membrane trafficking, endocytosis and bacterial 
adherence as well as cell survival (Charrin et al., 2014). Most cell survival implications are 
positively correlated with disease progression. For instance, tetraspanin-2 promotes 
diabetes mellitus progression by contributing to regulation of glucotoxic apoptosis in 
human pancreatic cells, while CD151 induces survival of A549 lung adenocarcinoma cells 
and CD53 activates the AKT pathway responsible for radioresistant tumor survival (Hwang 
et al., 2016; Li et al., 2015; Yunta and Lazo, 2003a). In the context of immunity, CD37 has a 
dual role in B cell survival by being able to activate opposite pathways involved in apoptosis 
and cell survival (Lapalombella et al., 2012; van Spriel et al., 2012). 
The role of tetraspanins in neutrophils, and more precisely in neutrophil survival, is poorly 
understood. Tetraspanin CD53 and CD63 expression has been linked to the onset of 
neutrophil apoptosis as a consequence of their increased expression with age (Beinert et 
al., 2000). In addition, tetraspanin expression is also linked to neutrophil-dominant 
inflammatory disease. For instance, a polymorphism at the CD63 locus was shown to result 
in decreased expression of CD63 at mRNA and plasma membrane protein level in 
neutrophils from COPD patients (Zhang et al., 2007). CD63 was also demonstrated to be a 
potential suitable marker for rheumatoid arthritis due to its up regulation on neutrophil 
membrane, while CD9 expression was shown to be increased in periodontal disease (Bisson-
Boutelliez et al., 2001; Lopez et al., 1995). Other evidence of tetraspanin involvement in 
neutrophil functions show that CD63 has a role in modulating neutrophil adhesion to 
endothelial cells by associating with tyrosine kinase activity to regulate this process (Skubitz 
et al., 1996; Skubitz et al., 2000). 
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These studies indicate a potential association between the tetraspanin family and 
neutrophil survival as well as neutrophil-dominant inflammatory disease. Therefore, my 
hypothesis is that tetraspanins play a role in neutrophil survival. The first aim of the project 
is to test my hypothesis by determining if tetraspanin(s) are involved in the survival process 
by targeting them using anti-tetraspanin antibodies. Secondly, the aim is to investigate the 
potential correlation between neutrophil survival and tetraspanin(s) expression. 
Furthermore, I aim to confirm key findings in neutrophils isolated from patients with COPD. 
3.2. Results 
3.2.1. Neutrophil purity from plasma/Percoll-pure and ultrapurified neutrophils via 
magnetic selection 
Data from our group and others show that neutrophil purity from plasma/Percoll 
purification is typically >95%, while neutrophils further purified using magnetic selection 
(ultrapurified) resulted in purities above 99% due to elimination of PBMCs (Haslett et al., 
1985; Sabroe et al., 2002). PBMC contamination has been shown to alter neutrophil survival 
by producing neutrophil-activating molecules such as cytokines and lipid mediators, and 
therefore achieving a highly pure neutrophil population is important when studying 
neutrophil function (Sabroe et al., 2004). Neutrophil purity from the experiments was 
therefore analysed to see if it is in accordance with the published literature. Cytospins of 
freshly isolated neutrophils from both plasma/Percoll purification and ultrapurification 
were analysed via light microscopy (Figure 3.1). Plasma/Percoll purification resulted in 
neutrophil mean±SD purity of 92.45±3.54 (Figure 3.1A) while ultrapurification resulted in 
neutrophils with a mean±SD purity of 98.92±1.15 (Figure 3.1B). The average value from 
plasma/Percoll purification is lower than expected because some donors were eosinophilic 
and eosinophils are not separated from neutrophils via Percoll gradients. PBMCs were not 
present at levels >2%. The data from these experiments would be considered accurate since 
previous literature shows that eosinophils do not influence neutrophil survival (Sabroe et 
al., 2004). 
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Figure 3.1: Neutrophil purity following plasma/Percoll and negative magnetic selection 
purification. 
Neutrophils were isolated from whole venous blood of healthy volunteers via 
plasma/Percoll gradient centrifugation (A) or further ultrapurified using negative magnetic 
selection (B). Purity was assessed by using light microscopy and calculating the percent 
neutrophils from 500 cells. The mean±SD purity of plasma/Percoll pure neutrophils was 
92.45±3.54 (n=98, A) while ultrapurification resulted in neutrophils with purity of 
98.92±1.15 (n=7, B). 
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3.2.2. Neutrophil apoptosis increases over time 
Previous results from our group and others show that neutrophil apoptosis increases over 
time, plateauing at around 20 hours (De Souza et al., 2002; Mecklenburgh et al., 2002; 
Sabroe et al., 2004). Current results show that incubation of neutrophils from 0-26 hours 
results in an increase in apoptosis with time. This can be seen in the photomicrographs 
where a predominantly viable population with multi-segmented nuclei, can be seen at 0 
hours while at 20 hours there are mainly apoptotic neutrophils (Figure 3.2 A-B). Neutrophil 
apoptosis reaches a mean±SD of 68.65±6.73 at 20 hours while at 26 hours apoptosis reaches 
a mean±SD of 70.46±2.91 (Figure 3.2C). These changes can be distinguished due to 
differences in neutrophil morphology between apoptotic and viable neutrophils, as 
described in Section 2.5.1.1. The results show that the plasma/Percoll purified neutrophils 
obtained in our experiments undergo apoptosis in vitro over time in accordance with time 
courses in the published literature.  
3.2.3. Anti-CD63 antibodies inhibit neutrophil apoptosis 
To test the hypothesis that tetraspanins play a role in neutrophil survival, neutrophils were 
incubated for 20 hours with anti-tetraspanin antibodies directed against CD9, CD37, CD63 
and CD151 at 10µg/ml. These particular tetraspanins are found more commonly on immune 
cells and this is the reason for selection in this project (Jones et al., 2011). The concentration 
was chosen because it was found by the group of Dr. Lynda Partridge to give saturating 
binding with cells that express these tetraspanins. Media and an IgG1 isotype antibody (JC1, 
10µg/ml) were used as controls. Photomicrographs of media (Figure 3.3A) and JC1 isotype 
control (Figure 3.3B) show higher numbers of apoptotic neutrophils in culture compared to 
the anti-CD63 antibody treated cells (Figure 3.3C). There is a significant reduction in 
neutrophil apoptosis in the presence of anti-CD63 antibodies, however the anti-CD9, CD37 
and CD151 antibodies had no effect on neutrophil apoptosis (Figure 3.3D). Different 
individuals show a high variability in the donor response in the presence of anti-CD63 
antibodies, as shown in the table in Figure 3.3E. Neutrophil apoptosis in some donors was 
not affected by anti-CD63 antibodies while others donors showed a profound inhibition. 
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Overall, the data indicated a potential role for CD63 in neutrophil survival and this 
hypothesis was tested in further experiments. 
3.2.4. Anti-CD63 antibodies inhibit neutrophil apoptosis at 10 and 20µg/ml 
Considering the effect of anti-CD63 antibodies on neutrophil apoptosis, their working 
concentration was further refined to determine the optimal use in the current study. To do 
this, neutrophils were incubated for 20 hours with low (0.5-1µg/ml) and high (5-20µg/ml) 
concentration ranges of anti-CD63 antibodies (Figure 3.4). While the low concentrations of 
anti-CD63 antibodies had no effect on reducing neutrophil apoptosis (Figure 3.4A), higher 
concentrations of 10 and 20µg/ml significantly reduced neutrophil apoptosis (Figure 3.4B). 
To ensure optimal inhibition, anti-CD63 antibody was used at 20µg/ml in all further 
experiments. 
3.2.5. Alternative anti-CD63 antibody clones inhibit neutrophil apoptosis 
Since a number of factors can influence the efficacy of antibodies, such as affinity, epitope 
and isotype class, a panel of different anti-CD63 antibody clones were used in the neutrophil 
survival assay. In Figures 3.3 and 3.4 the anti-CD63 antibody was clone H5C6. Two additional 
clones were used, AHN-16.1 and 6H1. These clones were used by other groups to study 
tetraspanin-integrin interaction, AHN-16.1 being also used to show a link between CD63, 
tyrosine kinase activity and αMβ2 in promoting neutrophil migration (Berditchevski et al., 
1995; Skubitz et al., 1996). Neutrophils were incubated for 4 and 20 hours with H5C6, AHN-
16.1 and 6H1 anti-CD63 antibody clones and JC1 isotype control at 20µg/ml (Figure 3.5). 
Although at 4 hours there was visible reduction in apoptosis with AHN-16.1, significance in 
reducing neutrophil survival was reached only with H5C6 (Figure 3.5A). At 20 hours, 
apoptosis was significantly inhibited with AHN-16.1 (Figure 3.5B). Although at 20 hours 
AHN-16.1 resulted in a more profound inhibition of apoptosis than H5C6, all further 
neutrophil apoptosis modulation experiments will be conducted using H5C6, since this 
antibody clone is effective and readily available via Dr Lynda Partridge. 
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Figure 3.2: Constitutive neutrophil apoptosis time course.  
Freshly isolated neutrophils from venous blood of healthy volunteers were cultured for 0, 
2, 4, 6, 8, 20 and 26 hours. Apoptosis was assessed by light microscopy. (A-B) Representative 
photomicrographs of neutrophils incubated for 0 hours (A.) and 20 hours (B.). Apoptotic 
neutrophils - red arrow, viable neutrophils -black arrow, eosinophils - green arrow. Scale 
bar 10µm. C.) Time course from 3 independent donors expressed as mean±SD. 
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Donor Media JC1 CD9 CD37 CD63 CD151 
D1 79.72 73.38 77.79 79.98 29.72 81.06 
D2 77.85 78.13 83.71 84.65 76.59 63.33 
D3 89.73 90.21 91.43 92.16 78.44 91.33 
D4 80.45 80.10   23.10 64.94 
D5 84.26 84.28   80.95 89.04 
Mean±SD 82.40±4.71 81.22±6.37 84.31±6.84 85.59±6.14 57.76±28.76 77.94±13.18 
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Figure 3.3: The effect of different anti-tetraspanin antibodies on neutrophil apoptosis. 
Freshly isolated neutrophils from venous blood of healthy volunteers were cultured for 20 
hours with media or 10µg/ml of anti-tetraspanin antibodies directed against CD9, CD37, 
CD63, CD151 or JC1 IgG1 isotype control. Survival was assessed by light microscopy. (A-C) 
Photomicrographs of neutrophils incubated with media (A), JC1 isotype control (B) and anti-
CD63 antibodies (C). Apoptotic cells -red arrow, 'ghost cells' - blue arrows, viable neutrophils 
- black arrow. Contaminating cells are eosinophils (green arrow) and lymphocytes (yellow 
arrow). Scale bar 10µm. (D) Quantification of the data from 3-5 independent experiments 
expressed as Mean±SD. Statistical analysis carried out by one-way ANOVA with Dunnett's 
post-test (*p<0.05). (E.) Table of data points for each condition, used in chart D. 
- 86 - 
 
M e d ia J C 1 5 u g /m l 1 0 u g /m l 2 0 u g /m l
0
2 0
4 0
6 0
8 0
1 0 0
%
 A
p
o
p
to
s
is
***
**
C D 6 3
C o n d itio n s
M e d ia J C 1 0 .5 u g /m l 1 u g /m l
0
2 0
4 0
6 0
8 0
1 0 0
%
 A
p
o
p
to
s
is
C D 6 3
C o n d itio n s
A . B .
 
Figure 3.4: Anti-CD63 antibodies inhibit neutrophil apoptosis at higher concentrations. 
Freshly isolated neutrophils from venous blood of healthy volunteers were cultured for 20 
hours with media, JC1 isotype control (10µg/ml) and low concentrations (0.5-1µg/ml) (A) or 
high concentrations (5-20µg/ml) (B) of anti-CD63 antibodies. Survival was assessed by light 
microscopy. Data representative of at least 3 (A) or 7 (B) independent experiments is 
expressed as mean±SD. Statistical significant differences are highlighted as **p<0.01 and 
*** p<0.001 (ANOVA, Bonferroni's repeated measures post-test). 
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Figure 3.5: The effect of different anti-CD63 antibody clones on neutrophil apoptosis. 
Neutrophil isolated from venous blood of healthy volunteers were incubated for 4 (A) or 20 
hours (B) with different anti-CD63 antibody clones (H5C6, AHN-16.1, 6H1) (20µg/ml) and 
JC1 isotype control (20µg/ml). Apoptosis was assessed by light microscopy. Data from 4 
different donors is expressed as mean±SD. Statistical analysis carried out by one-way 
ANOVA with Bonferroni's repeated measures post-test (*p<0.05 and **p<0.01). 
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3.2.6. Flow cytometry confirmation of the survival effects of anti-CD63 antibodies 
Although assessing neutrophil apoptosis by light microscopy is considered the gold 
standard, it is important to validate these findings with a biochemical measurement of 
apoptosis. Annexin V/ToPro3 staining and assessment by flow cytometry is a more objective 
measurement. Phosphatidylserine (PS) is irreversibly exposed on the neutrophil surface 
during apoptosis and can be quantified by binding to the fluorescent probe, Annexin V 
(Nusbaum et al., 2005). ToPro3 is a vital dye that intercalates between double stranded DNA 
when cells become permeable and therefore necrotic (Babiychuk et al., 2008; Cantinieaux 
et al., 2004; Solito et al., 1998; Vanhooijdonk et al., 1994). Neutrophils incubated for 20 
hours with media, JC1 isotype control (20µg/ml) or anti-CD63 antibodies (20µg/ml) were 
stained with Annexin V-PE and ToPro3 (Figure 3.6). A shift of the cells into the top left 
quadrant represents Annexin V-PE+ cells, visualised using Blue 575/26 channel, while a shift 
into the bottom right quadrant is indicative of ToPro3+ events, detected on the Red 660/20 
channel (Figure 3.6A). The top right quadrant represents Annexin V-PE+/ToPro3+ dual 
stained cells. Quantification of percentage apoptotic cells showed that neutrophil apoptosis 
is significantly inhibited in the presence of anti-CD63 antibodies (Figure 3.6B). These data 
support the previous results that CD63 plays a role in neutrophil survival. 
3.2.7. Anti-CD63 antibody-mediated neutrophil survival is not affected by low levels of 
contaminating PBMCs 
Evidence from the literature showed that PBMC contamination of neutrophil preparations 
can alter neutrophil survival in in vitro cultures (Lee et al., 1993; Sabroe et al., 2004). 
Therefore, the next hypothesis was to test if neutrophil survival in the presence of anti-
CD63 antibodies is mediated by contaminating cells. To test this, neutrophils from the same 
donor were purified by plasma/Percoll centrifugation or further ultrapurified using negative 
magnetic selection to remove PBMCs. The cells were subsequently incubated for 20 hours 
with media, JC1 isotype (20µg/ml) control or anti-CD63 antibodies (20µg/ml). Apoptosis of 
both plasma/Percoll-pure (Figure 3.7A), mean±SD purity of 98.26±1.05, and ultrapure 
neutrophils (Figure 3.7B), mean±SD purity of 99.26±0.9, was significantly inhibited in the 
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presence of anti-CD63 antibodies. This data therefore indicates that low levels of PBMCs 
contaminations do not affect neutrophil survival in the presence of anti-CD63 antibodies. 
3.2.8. H5C6 anti-CD63 antibody clone detects and binds to CD63 
Neutrophils are known to express CD63 in the lysososmal granules which can be mobilised 
to the cell surface (Ageberg and Lindmark, 2003; Metzelaar et al., 1991). In order to validate 
that the H5C6 antibody was indeed binding to CD63, immunoblotting was used. Neutrophil 
whole cell lysates from 3 independent donors were subjected to SDS-PAGE and 
immunostained with the H5C6 clone anti-CD63 antibody or JC1 isotype control. The staining 
confirmed CD63 expression in all 3 donors (Figure 3.8), due to the presence of bands 
between 45-60kDa and 30-35kDa. CD63 is a highly glycosylated protein capable of yielding 
immunoreactive products of different sizes, depending on the amount of glycosylation, 
ranging from 27-60kDa (Ageberg and Lindmark, 2003). As a control, the same neutrophil 
lysates were probed with JC1 isotype control antibodies, and this showed a very faint band 
at 30-35kDa (Figure 3.8), suggesting possible nonspecific binding of the isotype control. No 
bands between 35-60kDa were detected with the isotype control. 
Antibody binding was further verified by flow cytometry. Binding of anti-CD63 antibodies 
on the neutrophil surface in cells incubated with media or HK S. aureus (known to cause 
degranulation of neutrophils and externalisation of CD63) was then investigated. Freshly 
isolated neutrophils were incubated for 15 minutes with media or HK S. aureus at MOI10, 
followed by a 30 minute incubation with Alexa Fluor 488 conjugated JC1 isotype control 
(10µg/ml) or anti-CD63 antibodies (10µg/ml). FSC/SSC dot plots showed a right and 
upwards shift of neutrophils in the presence of HK S. aureus, indicative of both neutrophil 
phagocytosis of bacteria and activation (Figure 3.9A). FL-1H histograms also showed a right 
shift in CD63+ fluorescence in HK S. aureus treated neutrophils when compared to JC1 
control but no right shift in CD63+ fluorescence is seen in neutrophil only incubated cells 
when compared to the control (Figure 3.9B). Overall, these data confirms CD63 expression 
by neutrophils from whole cell protein extracts but does not confirm surface expression of 
CD63 on unstimulated neutrophils.  
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Figure 3.6: Flow cytometry evidence of anti-CD63 antibodies inhibition of neutrophil 
apoptosis. 
Neutrophils from venous blood of healthy volunteers were isolated and cultured for 20 
hours in the presence of media, JC1 isotype control (20µg/ml) or anti-CD63 antibodies 
(20µg/ml). A) Representative plots of unstained neutrophils and media, JC1 isotype control 
and anti-CD63 antibody treated cells. Neutrophil apoptosis and necrosis was assessed using 
Annexin V-Pe and ToPro3 stain, respectively. Gain of far red fluorescence (Red 660/20) 
indicates ToPro3 positivity while gain of blue fluorescence (Blue 575/26) represents Annexin 
V-PE positivity staining. B) Quantification (top two quadrants) of neutrophil apoptosis from 
7 independent experiments is shown as mean±SD. Statistical significant differences are 
highlighted as *p<0.05 (ANOVA, Bonferroni's repeated measures post-test). 
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Figure 3.7: Anti-CD63 antibodies inhibit apoptosis of plasma/Percoll-pure and ultrapure 
neutrophils. 
Freshly isolated neutrophils from venous blood of healthy volunteers were purified via 
plasma/Percoll gradient centrifugation (A) or further ultrapurified using a negative 
magnetic selection column (B). The cells were subsequently incubated for 20 hours with 
media, JC1 isotype (20µg/ml) control or anti-CD63 antibodies (20µg/ml). Survival was 
assessed by light microscopy. Data from 4 different donors is expressed as mean±SD. 
Statistical significant differences are highlighted as *p<0.05 and **p<0.01 (one-way ANOVA, 
Bonferroni- repeated measures post-test). 
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Figure 3.8: Evidence of CD63 expression by neutrophils. 
Whole cell lysates from freshly isolated neutrophils from three independent donors were 
run on a 12% SDS-PAGE gel. Protein lysates from 2X106 neutrophils were loaded in each 
lane. Identical blots were probed for CD63 (left) or for JC1 isotype control (right) (1:600). 
On the CD63 blot there are two bands: one between 60-45kDa and one between 30-35kDa. 
On the JC1 blot there is a faint band between 30-35kDa. Red line at 60kDa and 30kDa 
represents the expected molecular weight range of CD63. 
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Figure 3.9: Evidence of CD63 expression by neutrophils on their surface upon incubation 
with HK S. aureus. 
A) Representative FSC/SSC dot plots of freshly isolated neutrophils from venous blood of 
healthy volunteers incubated for 15 minutes with media or HK S. aureus at MOI10 and 
probed for Alexa Fluor 488 conjugated JC1 isotype control (10µg/ml) or anti-CD63 
antibodies (10µg/ml) for 30 minutes. (B) Histogram overlay of neutrophils from a single 
experiment: unstained-red, JC1 isotype control-orange, JC1+ S. aureus-blue, anti-CD63 
antibody- light green, anti-CD63 antibody+ S. aureus- dark green. FACScalibur was used to 
detect a right shift in fluorescence on the FL1 parameter. 
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3.2.9. LPS contamination of GST-CD63 fusion proteins 
GST-CD63 constructs that correspond to the EC2 domain of CD63 were used previously by 
the Partridge group to confirm the involvement of tetraspanins in bacterial adhesion (Green 
et al., 2011; Hassuna et al., 2009). Glutathione S-transferases (GSTs) are molecular tags that 
aid in the purification process of a recombinant protein by improving their solubility and 
stability (Harper and Speicher, 2011; Ketley et al., 1975). GST fused proteins have been 
previously shown to have activity and were used by Dr. Lynda Partridge group as a tool for 
investigating cell functions (Green et al., 2011; Ho et al., 2006; Parthasarathy et al., 2009; 
Wong et al., 2001). These constructs are obtained in a bacterial expression system, 
therefore contamination with LPS is highly likely. Neutrophils are highly responsive to 
endotoxin, where concentrations of 1ng/ml can influence their functions including lifespan 
(Sabroe et al., 2002). To control for this, the TLR4 antagonist LPS-RS was used, which works 
in this context by preventing LPS-induced survival (Coats et al., 2005). In a single 
experiment, neutrophils were pre-incubated for 1 hour with LPS-RS (10µg/ml), followed by 
a 20 hour incubation with LPS (10ng/ml), GST (10µg/ml) and GST-CD63 (10µg/ml). Results 
confirm that LPS inhibits neutrophil apoptosis which is preventable by LPS-RS (Figure 3.10). 
Both GST and GST-CD63 treatments resulted in a dramatic decrease in neutrophil apoptosis. 
Co-incubation of GST and GST-CD63 fusion proteins with LPS-RS resulted in a moderate but 
visible increase in the apoptosis levels. The experiment therefore indicates that the GST and 
GST-CD63 proteins have moderate endotoxin levels that can influence result outcome. For 
this reason, the constructs will not be used in future experiments. 
3.2.10. Anti-CD63 Fab fragments significantly inhibit neutrophil apoptosis 
Antibodies are large divalent molecular structures that can cause changes by cross-linking 
protein partners causing indirect effects. Consequently, the hypothesis that anti-CD63 
antibodies influence neutrophil survival indirectly by cross-linking partner molecules was 
tested by using Fab fragments. These fragments are monovalent structures and the 
equivalent of 1/3 of the antibody size. They represent only the region of the antibody that 
can bind the target directly, as a result they are less likely to cross-link and any effects are 
more likely to be due to direct binding. Neutrophils were incubated for 20 hours with media, 
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JC1 isotype control (20µg/ml), anti-CD63 antibodies (20µg/ml) or anti-CD63 Fab fragments 
(5-20µg/ml). Apoptosis was significantly inhibited in the presence of anti-CD63 antibodies 
but no effect was seen with any concentration of CD63-Fab fragments (Figure 3.11).  
These data may suggest that the full antibody is required for functional effect because of 
the need for the antibody to cross-link with tetraspanin binding partners. Failure of Fab 
fragments to modulate neutrophil apoptosis also led to the consideration that CD63-Fab 
fragments may have lost their activity in storage. To test this, their target binding capacity 
was investigated using the A549 adenocarcinomic human alveolar basal epithelial cell line, 
that stably expresses CD63 (Funakoshi et al., 2003). Cells from the A549 epithelial cell line 
(1x106/ condition) were incubated for 1 hour with primary JC1 isotype control (10µg/ml) 
antibody or anti-CD63 Fab fragments (10µg/ml) followed by a 20 minute incubation with 
1µl of secondary FITC labeled anti-mouse antibody (Figure 3.12). The full JC1 isotype 
control, in contrast to a Fab fragment, was used to highlight any unintended, non-specific 
and off-target effects of the antibody. FSC/SSC dot plots showed a gated cell population 
which was separated from debris (Figure 3.12A). Blue 530/30 histogram showed little to no 
right shift in CD63+ Blue 530/30 in CD63-Fab incubated neutrophils when compared to JC1 
or secondary antibody only staining controls (Figure 3.12B). This is indicative of a failure of 
CD63-Fab to bind to CD63, potentially because of breakdown during storage. 
For this reason, a newer batch of CD63-Fab fragments was obtained. Fab fragments at 10 
and 20µg/ml showed a significant, concentration dependent inhibition in apoptosis when 
compared to JC1 control (Figure 3.13). 
The binding specificity of the new anti-CD63-Fab to CD63 was checked using the CD63+ A549 
cell line, as previously. The experiment was conducted by Mr. Anesu R. Matamba using the 
in house flow cytometry protocol of Dr. Lynda J. Partridge. FSC/SSC dot plots showed cell 
separation from debris (Figure 3.14A). FL-1H histogram showed a right shift in CD63+ FL1 
fluorescence with both anti-CD63-Fab fragments (dark green) and anti-CD63 antibody (light 
green) stained neutrophils when compared to JC1 (orange) or secondary only (blue) 
antibody controls (Figure 3.14B). This confirms binding of the CD63 Fab fragments to CD63 
exposed A549 cell surface. 
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Figure 3.10: Evidence for endotoxin contamination of GST and GST-CD63 protein 
constructs. 
Freshly isolated neutrophils from venous blood of healthy volunteers were pre-incubated 
with LPS-RS (10µg/ml) for 1 hour followed by a 20 hour incubation with LPS (10ng/ml), GST 
(10µg/ml) and GST-CD63 (10µg/ml). Neutrophil apoptosis was assessed by light microscopy. 
Data obtained from a single experiment. 
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Figure 3.11: Anti-CD63 Fab fragments have no effect on neutrophil apoptosis. 
Neutrophils obtained from venous blood of healthy volunteers were incubated for 20 hours 
with media, JC1 isotype control (20µg/ml), anti-CD63 antibodies (20µg/ml) or increasing 
concentrations of anti-CD63 Fab fragments old stock (5-20µg/ml). Neutrophil apoptosis was 
assessed by light microscopy. Quantification of the data from 4 different experiments is 
expressed as mean±SD. Statistical significant differences are highlighted as *p<0.05 (one-
way ANOVA, Bonferroni- repeated measures post-test). 
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Figure 3.12: Flow cytometry evidence of anti-CD63 Fab fragments inability to bind to 
target. 
A) Cells from the A549 epithelial cell line (1x106 / condition) were stained with primary 
antibody directed against JC1 isotype control (10µg/ml) and anti-CD63 Fab fragments old 
stock (10µg/ml) for 1 hour followed by a 20 minute incubation with 1µl of secondary FITC 
labeled anti-mouse antibody. A549 cells distribution under different conditions was shown 
on FSC/SSC dot plots. B) Histogram of A549 labeled cells: red-unstained, blue-secondary 
antibody only, orange-JC1 isotype control, green-anti-CD63 Fab fragments. Binding to the 
A549 cells of the JC1 isotype control and anti-CD63 Fab fragments was assessed on a right 
shift on the Blue 530/30 channel using LSRII flow cytometer. Data obtained from single 
experiment. 
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Figure 3.13: Anti-CD63 Fab fragments inhibit neutrophil apoptosis in a concentration 
dependent manner. 
Freshly isolated neutrophils from venous blood of healthy volunteers were incubated for 20 
hours with media, JC1 isotype control (20µg/ml), anti-CD63 antibodies (20µg/ml ) or 
different concentrations of anti-CD63 Fab fragments new stock(10 or 20µg/ml). Data from 
3 different donors is expressed as mean±SD. Statistical analysis carried out by one-way 
ANOVA with Bonferroni's repeated measures post-test (*p<0.05). 
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Figure 3.14: Flow cytometry evidence of anti-CD63 Fab fragments ability to bind to target. 
A) Cells from the A549 epithelial cell line (1x106/ conditions) were stained for JC1 isotype 
control (10µg/ml), anti-CD63 antibodies (10µg/ml) and anti-CD63 Fab fragments new stock 
(10µg/ml) using the in house protocol of Dr. Lynda Partridge laboratory. Dot plots of A549 
cells distribution under different conditions on FSC/SSC scatter. B) Histogram of A549 
labeled cells: red-unstained, blue-secondary antibody only, orange-JC1 isotype control, light 
green- anti-CD63 antibodies, dark green-anti-CD63 Fab fragments. Data obtained from 
single experiment by Mr. Anesu R. Matamba, Molecular Biology and Biotechnology 
department, University of Sheffield. 
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3.2.11. Anti-CD63 antibodies do not regulate neutrophil apoptosis in the presence of 
accelerating/inhibitory agents of apoptosis 
To this point, the effect of anti-CD63 antibodies on constitutive neutrophil apoptosis has 
been probed. I next investigated whether anti-CD63 antibodies had the potential to 
regulate neutrophil apoptosis in the presence of agents that either accelerate or inhibit 
apoptosis. Neutrophils were incubated for 1 hour with anti-CD63 antibodies or JC1 isotype 
control followed by a 5 hour incubation with pyocyanin (pyo) or a 20 hour incubation with 
LPS or GM-CSF. Pyocyanin is a Pseudomonas toxin, which accelerates neutrophil apoptosis 
via the production of ROS (Manago et al., 2015; Prince et al., 2008). LPS prolongs neutrophil 
survival via the NFkB pathway (Remer et al., 2003) while GM-CSF binds to GM-CSF receptors 
on neutrophils and activates Lyn pathway to induce neutrophil survival (Rapoport et al., 
1992; Wei et al., 1996). As expected, constitutive neutrophil apoptosis was significantly 
inhibited in the presence of anti-CD63 antibodies (Figure 3.15A, B). Apoptosis was 
significantly increased in the presence of pyocyanin but was not significantly reduced by co-
incubation with anti-CD63 antibodies (Figure 3.15A). Although apoptosis was visibly 
reduced with GM-CSF and even further with LPS, co-incubation of these pro-inflammatory 
stimuli with anti-CD63 antibodies did not significantly potentiate neutrophil survival (Figure 
3.15B). These data suggest that a CD63-mediated survival pathway is most relevant to 
constitutive, rather than induced, survival.  
3.2.12. TIMP-1 does not influence neutrophil survival 
TIMP-1 is a tissue inhibitor of metalloproteinases glycoprotein that has been shown, 
through two-hybrid selection system, to interact with CD63 and to cause cancer cell survival 
(Chirco et al., 2006; Jung et al., 2006; Toricelli et al., 2013). Therefore, we tested the 
hypothesis that TIMP-1 is able to cause neutrophil survival. Neutrophils were incubated for 
20 hours with 0.05, 0.1, 0.5 or 1µg/ml of recombinant human TIMP-1 protein. Following 
light microscopy quantification, no modulation of neutrophil apoptosis was seen with TIMP-
1 human recombinant protein (Figure 3.16). 
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Figure 3.15: Effect of anti-CD63 antibodies on neutrophil apoptosis in the presence of 
inflammatory and apoptosis inducing/inhibitory stimuli. 
Plasma/Percoll-pure neutrophils from healthy volunteers were cultured in the presence of 
media, anti-CD63 antibodies (20µg/ml) and JC1 isotype control (20µg/ml) for one hour. A 
further 5 hours incubation with pyo (50µ) (A) or 20 hour incubation with LPS (10ng/ml) or 
GM-CSF (50 units/ml) was conducted (B). Neutrophil survival was assessed by light 
microscopy. Data from 4 (A) and 6 (B) different donors is expressed as mean±SD. Statistical 
analysis carried out by one-way ANOVA with Bonferroni's repeated measures post-test with 
selected columns, comparing anti-CD63 antibody incubated conditions to the equivalent 
JC1 ones and JC1 to JC1+Pyo (*p<0.05, **p<0.01). 
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Figure 3.16: Effect of different concentrations of recombinant TIMP-1 protein on 
neutrophil survival. 
Neutrophils isolated from venous blood of healthy volunteers were incubated for 20 hours 
with 0.05, 0.1, 0.5 or 1µg/ml of recombinant human TIMP-1 protein. Neutrophil survival 
was assessed by light microscopy. Data from 3 independent donors is expressed as 
mean±SD. Statistical analysis carried out by one-way ANOVA with Bonferroni's repeated 
measures post-test. 
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3.2.13. Cohort analysis indicates different neutrophil survival response to anti-CD63 
antibodies 
The table in Figure 3.3B showed, albeit using a small sample size, that neutrophil survival 
rates in the presence of anti-CD63 antibodies varies between donors. This hypothesis was 
further investigated by performing more experiments and looking at results from a bigger 
cohort of samples. Results obtained from 44 donors incubated for 20 hours with JC1 isotype 
control or anti-CD63 antibodies (20µg/ml), show variable reduction in neutrophil apoptosis 
with anti-CD63 antibodies (Figure 3.17). Some donors have a profound reduction in 
apoptosis (for the purpose of this study, named ‘responsive donors’) that can reach up to 
90% inhibition. Others show little to no reduction in apoptosis (for the purpose of this study, 
named ‘nonresponsive donors’) reaching equal or slightly higher apoptosis rates to the 
control samples. 
As a result, donors were stratified into responders and nonresponders as follows: the 
donors having a ≥25% decrease in apoptosis in the presence of anti-CD63 antibodies 
compared to JC1 control where classed as responders while donors having a ≤25% decrease 
in apoptosis were classed as nonresponders. Out of the cohort, 3 responders and 3 
nonresponders were selected. Neutrophils from these donors were incubated for 4 or 20 
hours with media, JC1 isotype control (20µg/ml) and anti-CD63 antibodies (20µg/ml) in 3 
independent experiments to determine whether variability in the neutrophil isolation 
techniques rather than donor phenotype was the cause of the responsiveness to anti-CD63 
antibodies. Human error was further reduced by maintaining the same phlebotomist and 
scientist for the neutrophil isolation protocol. Data from each donor was expressed as a 
mean of the three independent experiments. Statistical analysis showed no significant 
reduction in neutrophil apoptosis at 4 hours in the presence of anti-CD63 antibodies when 
compared to the JC1 control for both responsive and nonresponsive donors (Figure 3.18A). 
However, significant reduction of neutrophil apoptosis at 20 hours with anti-CD63 
antibodies when compared to JC1 control is seen in responsive donors (Figure 3.18B). The 
triplicates from responsive donors at the 20 hour time point were plotted individually 
(Figure 3.18C.). This data shows minimal variability between the repeats (Figure 3.18C). 
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Figure 3.17: Evidence of differential donor neutrophil survival with the anti-CD63 
antibodies. 
Freshly isolated neutrophils from venous blood of healthy volunteers were cultured for 20 
hours with JC1 isotype control and anti-CD63 antibodies at 20µg/ml. Survival was assessed 
by light microscopy. Data obtained from 44 independent experiments, each line 
representing an individual donor. 
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Figure 3.18: Effect of anti-CD63 antibodies on neutrophil survival of responsive and 
nonresponsive donors. 
Percoll-purified neutrophils from responsive and nonresponsive donors incubated for 4 (A) 
and 20 (B) hours with media, JC1 isotype control and anti-CD63 antibodies at 20µg/ml. 
Neutrophil survival was assessed by light microscopy. (A-B) Each donor value plotted 
represents the mean of 3 repeats. Data is expressed as mean±SD. Statistical analysis carried 
out by One-way ANOVA with non-parametric distribution and Dunn's post-test (*p<0.05). 
(C) Twenty-hour time point individual values from 3 independent, responsive donors. Data 
is expressed as mean±SD. 
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3.2.14. No significant variation in CD63 protein expression is seen between responsive 
and nonresponsive donors and between the time points studied 
Considering there is a difference between responsive and nonresponsive donor survival, I 
hypothesised that responsiveness may correlate with CD63 expression. Hypothesis testing 
was done by western blotting techniques. Whole cell lysates were prepared at 0, 4 and 20 
hours, simultaneously to, and therefore using the same neutrophils as the functional 
experiments carried out in Section 3.2.13. Lysates from 2X106 neutrophils from each 
replicate were loaded per well. Membranes were probed for CD63 using the H5C6 antibody 
clone (Figure 3.19). The blots were imaged at comparable time points: 1289 seconds for the 
responsive donors and 1073 seconds for the nonresponsive ones. A similar band pattern, 
45-60kDa and 30-35kDa, is seen as above in responsive (Figure 3.19 A-C) and nonresponsive 
(Figure 3.19 D-F) donors. Total unphosphorylated p38 was probed as a loading control and 
this showed minor variation in the amount of protein loaded for 3 samples, where 
decreased p38 expression corresponded with lower CD63 protein expression. There is no 
robust time dependent pattern of CD63 protein expression at 0, 4 and 20 hours. Donor 
repeats show an inconsistent protein expression, with no obvious differences between 
responsive and nonresponsive donors. Attempts to quantify the CD63 protein expression 
from western blots via densitometry, using Fiji software, failed to produce reliable results 
due to the inconsistent band pattern on the blots. Considering this, it cannot be concluded 
if there is a difference in CD63 protein expression between responsive and nonresponsive 
donors. 
3.2.15. CD63 expression on neutrophil surface at 4 and 20 hours 
A single study has demonstrated increased expression of CD63 on the neutrophil surface as 
neutrophils age in culture (Beinert et al., 2000). Results from Section 3.2.14. indicated that 
global analysis of CD63 protein expression did not show any differences between the two 
different donor groups investigated and between time points, but western blotting is not 
able to distinguish between intracellular and cell surface expression of CD63. Flow 
cytometry, the same biochemical method employed by Beinert et al, was used to see if 
surface expression was regulated during culture. Neutrophils were incubated for 4 and 20 
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hours, followed by staining with Alexa Fluor 488 pre-stained JC1 isotype control (10µg/ml) 
or anti-CD63 (10µg/ml) primary antibodies. Neutrophils were gated from contaminating 
cells/debris based on FSC/SSC profiles (Figure 3.20 A and C). FL-1H histogram showed little 
to no right shift in CD63+ FL1 with anti-CD63 antibody stained neutrophils when compared 
to JC1 controls at both 0 (Figure 3.20B) and 20 hours (Figure 3.20D). Furthermore, the FL1-
H histogram profile indicates a possible bigger shift in CD63+ fluorescence at 20 hours when 
compared to the 4 hour one. However, no conclusion can be drawn due to the high JC1 FL1 
fluorescence. 
3.2.16. Neutrophil apoptosis is significantly reduced at 4 and 20 hours in the presence of 
anti-CD63 antibodies in age matched HC and COPD patients 
Neutrophils are known to drive the pathophysiology of COPD as a consequence of their 
dysregulated, prolonged survival at the site of inflammation. The literature shows that 
neutrophils from COPD patients have less CD63 mRNA and cell-surface protein expression 
than healthy control patients (Zhang et al., 2007). Considering this, the hypothesis 
investigated was that anti-CD63 antibodies are less effective in inhibiting neutrophil 
apoptosis in COPD patients. Neutrophils from age matched HC with a mean±SD age of 
66±9.42 or from COPD patients with mean±SD age of 63.57±5.29, as indicated in Figure 
3.21C table, were incubated for 4 and 20 hours with media, JC1 isotype control and anti-
CD63 antibodies at 20µg/ml. Age matched controls are desirable because it accounts for 
some of the significant variables in the study, where age is considered as one of the most 
important variable. A great review by Panda et al., 2009 showed that age has been 
correlated with loss of neutrophil functions such as membrane composition, chemotaxis, 
priming, activation and most importantly increased neutrophil apoptosis. This therefore 
shows the importance in considering age as an influential variable in our experiments. 
Contrary to the hypothesis, apoptosis was significantly reduced at 4 and 20 hours with anti-
CD63 antibodies in both age matched HC (Figure 3.21A) and COPD patients (Figure 3.21B). 
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3.2.17. No significant difference in CD63 protein expression is seen between COPD 
patients and age matched HC 
Global CD63 protein expression from age matched HC and COPD patients was also 
investigated to determine whether expression correlated with neutrophilic inflammatory 
disease. Protein extracted from 2X106 neutrophils at 0, 4 and 20 hours from age matched 
HC and COPD patients was loaded on individual SDS-PAGE gels and probed for CD63. A band 
pattern at 45-60kDa and 30-35kDa is seen in all blots, indicative of CD63 protein expression 
(Figure 3.22). However, comparative analysis between age matched HC and COPD patients 
showed 3 blots with similar or no difference in protein expression between the groups 
(Figure 3.22 A-C) and two with higher CD63 protein expression in COPD patients compared 
to the age matched HC (Figure 3.22 D-E).The unphosphorylated p38 control for protein 
expression showed similar protein load in most samples, with low or no expression of the 
control correlating with low CD63 expression between 60-45kDa. Attempts to quantify the 
CD63 protein expression on western blot via densitometry, using Fiji software, failed to 
produce reliable results due to the inconsistent band pattern on the blots. Looking at COPD 
and age matched HC, there is no consistent CD63 expression pattern at any of the time 
points analysed. 
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Figure 3.19: Evidence of CD63 expression in responsive and nonresponsive donors. 
Whole cell lysates from 3 responsive (A-C) and 3 nonresponsive (D-E) donors were run in 
triplicates on a 12% SDS-PAGE gel. Protein extracted from 2X106 neutrophils at 0, 4 and 20 
hours was loaded in replicates for each donor on individual gels and probed for CD63 
(1:600). There are two bands noticeable in both responsive and nonresponsive donors: one 
between 45-60kDa and one between 30-35kDa. Unphosphorylated p38 (1:4000 dilution) 
control was used to verify equally loaded protein levels on each panel. Each blot represents 
an individual donor. 
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Figure 3.20: CD63 expression at 4 and 20 hours. 
Freshly isolated neutrophils from venous blood of healthy volunteers were cultured for 4 
(A-B) and 20 hours (C-D). The cells were subsequently incubated for 30 minutes with Alexa 
Fluor 488 conjugated JC1 isotype control (10µg/ml) or anti-CD63 antibodies (10µg/ml) and 
analysed using the FACScalibur machine. Distribution of cells under different conditions was 
visualised on FSC/SSC dot plot (A, C). Histograms of labeled neutrophils at 4 (B) or 20 hours 
(D): red-unstained, blue-JC1 isotype control, orange-anti-CD63 antibody. Right shift on FL1-
H axis is indicative of fluorescence gain. Plots representative of the data obtained from two 
experiments. 
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Figure 3.21: Anti-CD63 antibodies inhibit neutrophil apoptosis in age matched HC and 
COPD patients. 
Neutrophils from age matched HC (A) and COPD patients (B) were incubated for 4 and 20 
hours with media, JC1 isotype control and anti-CD63 antibodies at 20µg/ml. Neutrophil 
survival was assessed by light microscopy. Data from 7 HC and COPD patients is expressed 
as mean±SD. Statistical analysis carried out by one-way ANOVA with Bonferroni's repeated 
measures post-test ( *p<0.05 and **p<0.01 ). (C) Table showing individual age of age 
matched HC and COPD patient groups used in charts A and B. 
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Figure 3.22: Evidence of CD63 expression in COPD patients and age matched HC. 
A-E) Whole cell lysates from age matched HC and COPD patients were run on a 12% SDS-
PAGE gel. Protein extracted from 2X106 neutrophils at 0, 4 and 20 hours was loaded on 
individual gels and probed for CD63 expression (1:600). Two sets of bands are seen in both 
HC and COPD patients: one between 45-60kDa and one between 30-35kDa. 
Unphosphorylated p38 (1:2000 dilution) control was used to check even protein loading 
levels on each panel. Each blot represents a COPD patient-age matched healthy control pair. 
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3.3. Discussion 
In this chapter it was shown, using light microscopy and biochemical techniques, that anti-
CD63 antibodies significantly inhibit constitutive neutrophil apoptosis. The data was also 
confirmed by the use of CD63-Fab fragments and additional anti-CD63 antibody clones. 
Inhibition of CD63-dependent apoptosis was shown to be donor variable, via a mechanism 
that is yet to be elucidated. The results also indicate similar apoptosis rates between age 
matched HC and COPD patients, with increased survival in the presence of anti-CD63 
antibodies, and no difference in global protein expression. The overall data suggest, 
therefore, a possible role of CD63 in constitutive neutrophil apoptosis. 
The use of antibodies against CD63, but not to the other immune related tetraspanins CD9, 
CD37 and CD151, reduced neutrophil apoptosis by approximately one third. Alternative 
anti-CD63 antibody clones modulated neutrophil apoptosis to different degrees, with the 
most profound seen with the AHN-16.1 clone. The antibodies were derived from different 
hybridoma cell lines. While the H5C6 antibody comes from a P3X653-Ag8 myeloma cell fused 
with splenic cells from mice immunised with human splenic and peripheral blood adherent 
cells, the 6H1 antibody comes from a P3X myeloma cell fused with splenocytes from mice 
immunised with MTSV 1-7 mammary epithelial cells and the AHN-16.1 antibody is derived 
from P3X653-Ag8 myeloma cell line fused with splenic cells from mice immunised with 
eosinophils from a patient with chronic eosinophilia (Azorsa et al., 1991; Berditchevski et 
al., 1995; Hildreth and August, 1985; Hildreth et al., 1991; Skubitz et al., 1996; Skubitz et al., 
1983). Although all of the antibodies come from immunisation with different antigens, all 
three recognise CD63 protein with the most probable cause for different levels of inhibition 
in neutrophil survival to be due to the affinity to the epitope. Considering this, the AHN-
16.1 antibody clone has the highest affinity, followed by the H5C6 and the 6H1 one, the last 
clone appearing to have lost its activity due to lack of effect or would have been degraded 
in storage. In addition, there is evidence in the literature, at least for CD151, that the use of 
different antibody clones can induce different functions or show different expression 
results (Geary et al., 2001; Yamada et al., 2008). Such studies were not conducted for anti-
CD63 antibodies, probably because there are less available clones. Due to availability 
reasons, only the H5C6 clone was taken forward in all experiments but, considering the 
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above information, if more antibody of the potent AHN-16.1 clone could be obtained, it 
would be interesting to repeat the functional and more importantly the expression 
experiments to see if the results are altered. 
Fab fragments specific to CD63 were used in additional experiments in order to determine 
whether the anti-CD63 antibodies inhibited neutrophil apoptosis directly or the whole 
antibody is necessary to produce an indirect effect by cross-linking tetraspanin partner 
proteins. Results show that Fab fragments are enough to reduce neutrophil apoptosis 
indicating the mechanism of altering neutrophil apoptosis is via a direct effect on CD63 and 
not through indirectly affecting antibody cross-linking of CD63 with partner molecules. For 
instance, CD9 antibody crosslinking with partner molecules can promote degranulation of 
platelets, eosinophils and basophils while antibody crosslinking of CD9, CD53, CD81 and 
CD82 mediates activation of T cells (Higginbottom et al., 2000; Kim et al., 1997; Lagaudriere-
Gesbert et al., 1997; Naik et al., 1995; Qi et al., 1996). Interestingly, CD63-Fab fragments 
appear more potent in reducing neutrophil apoptosis, when the opposite is usually the case. 
This could be due to either the Fab fragments being at higher molar concentration relative 
to the intact antibody or the antibody was less potent in this experiment. CD63-Fab 
fragments can also disrupt CD63-partner protein interaction, although at lower magnitude 
to the antibodies, which can lead to changes in signalling or protein distribution in the cell 
membrane. Were we to find that targeting CD63 may be therapeutically useful in patients 
with inflammation, Fab fragments are more desirable in this context since they limit the risk 
of antibody cross-reactivity through the Fc domain or antibody failure to reach a target due 
to their size. However, the most advantageous therapeutics are peptide fragments due to 
their characteristics of being small, highly permeable as well as being fast and cheaper to 
produce compared to whole or fragments of antibodies. What is more, recent published 
data, showed the high efficacy of peptides (~16 amino acids) representing the EC2 region 
of CD9 in preventing bacterial adherence, indicating potential therapeutic benefits for other 
tetraspanins (Ventress et al., 2016). It would therefore be interesting to test in the future 
the effects of synthetic peptides based on CD63 on neutrophil survival.  
Antibodies are comprised of a F(ab)2 region and an Fc region(Murphy, 2012). While the 
F(ab)2 region is involved in antigen recognition, the Fc region can interact with the Fc 
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receptor on neutrophil surface and activate the neutrophil (Murphy, 2012; Porges et al., 
1994; Swanson, 2008). Consequently, anti-CD63 antibodies could inhibit neutrophil 
apoptosis either by direct target binding of the antibody or through the antibody Fc region 
that could potentially interact with the Fc receptors on adjacent cells. The latter mechanism 
could potentially involve pro-survival cytokine activation, such as IL-8, upon Fc region- Fc 
receptor interaction, resulting in decreased apoptosis of neighboring cells (Vogelpoel et al., 
2015). However, the use of anti-CD63 Fab fragments, demonstrated that the Fab antibody 
region is sufficient to reduce significantly neutrophil apoptosis. This suggests that the 
mechanism of reducing neutrophil apoptosis at 20 hours with the anti-CD63 antibodies 
does not depend on the antibody Fc region interacting with the Fc receptors on adjacent 
cells. 
My results show that recombinant TIMP-1 protein does not inhibit neutrophil apoptosis at 
any of the concentrations used. In accordance with our data, a recent in vivo study 
demonstrated that TIMP-1 does not regulate neutrophil apoptosis but regulates neutrophil 
induction of granulopoiesis (Kobuch et al., 2015). However, recombinant TIMP-1 protein 
binding to CD63 must be checked in our experimental model to determine if a lack of 
interaction could have caused the results. TIMP-1-CD63 interaction can be probed using 
fluorescent microscopy to determine their co-localisation.  
Our results show that the GST-CD63 protein constructs are contaminated with LPS. 
Reducing the LPS concentration in the protein construct preparation would allow us to see 
if the effect of the antibodies can be replicated by them as it was done in previous studies 
(Green et al., 2011; O'Driscoll et al., 2013). The GST-CD63 constructs were obtained by Dr. 
John Palmer in the Partridge laboratory via affinity purification, with purities for GST-CD63 
above 0.5ng/µg protein and for GST at 0.16ng/µg protein. This indicates, at least for GST-
CD63 construct, a high contamination with LPS that could alter neutrophil functions. 
Therefore, to use the peptides in future experiments, without altering their survival, 
reduction of LPS levels below the detectable limit of 0.020ng/mL is of key importance 
(Wakita, 2014). While a number of methods can be used currently to reduce LPS levels 
within a sample, none are able to completely remove it (Wakelin et al., 2006). Still, a 
technique was recently published where LPS concentrations could be reduced below 
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detectable limit by using porous supports bearing polymeric lipid membranes (Wakita, 
2014). Alternatively, the endotoxin can be neutralised by adding polymyxin B, a lipid A 
binding agent, however this agent can stimulate cytokine production (Damais et al., 1987). 
In our experiments, neutrophils were incubated only with antibodies and antibody 
fragments directed against a single tetraspanin. However, the literature shows us that 
tetraspanins are more likely to form TEMs where multiple tetraspanins have 
complementary and often redundant role in these complexes (Huang et al., 2005; Sugiura 
and Berditchevski, 1999). There is proof in the literature that CD63 can interact and form 
complexes with other tetraspanins such as CD9, CD151, CD81 and CD82 (Hammond et al., 
1998; Radford et al., 1996; Sincock et al., 1997). It could therefore be hypothesised that a 
more profound neutrophil apoptosis inhibition can be seen by using anti-CD63 
antibodies/fragments in combination with antibodies/fragments against CD63 interacting 
tetraspanins. The sole use of anti-CD9 and anti-CD151 antibodies resulted in no direct effect 
on neutrophil survival. This suggests perhaps that either these tetraspanins are not involved 
directly in mediating neutrophil survival or a function compensation by other tetraspanins 
could take place. However, involvement of other tetraspanins, their collective role as well 
as their redundancy in neutrophil survival pathways, would need to be investigated in the 
future by using a mixture of anti-tetraspanin antibodies/fragments. The advantage of this 
experiment would be that it could allow us to understand the role of tetraspanins in 
neutrophil survival pathways but also hint towards a more universal mechanism of 
tetraspanin rearrangement in TEMs to induce functional changes in cells. 
My data shows that individual donors respond differently when incubated with the anti-
CD63 antibodies with some having a profound inhibition of cell apoptosis while others 
showing little to no effect. When a small cohort of responsive and nonresponsive donors 
were investigated, results reached statistical significance at 20 hours for the responsive 
donors in the presence of anti-CD63 antibodies when compared to JC1 control. However, 
according to current literature, donor variability is not an uncommon phenomenon in 
neutrophils. For instance, in vivo studies show that interferon γ (IFNγ) can induce different 
neutrophilic post-translational modifications which trigger different donor HLA-DR 
expression in neutrophils (Reinisch et al., 2003). This supports the possibility of donor 
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variation in our study. Still, donor variability can be induced by other factors. It is known 
that complement activation during blood sampling procedure causes an increase in 
CD11b/CD18 expression on the neutrophil cell surface (Wehlin et al., 1998). CD63 is also 
known to associate at high levels only with externalised CD11b/CD18 (Skubitz et al., 2000). 
This suggests that if the cells become activated during preparation (and therefore 
upregulate CD11b/CD18) then there is an increased likelihood of CD63 being expressed on 
cell surface. A good way to investigate complement activation and CD11b/CD18 expression 
on neutrophil surface is by conducting the experiments in whole blood. The 20 hour 
triplicates of the 3 responsive donors demonstrate that there is little variability in the results 
between the 3 repeats, due to the use of the same phlebotomist and the same scientist to 
conduct plasma/Percoll neutrophil purification. Furthermore, flow cytometry experiments 
looking at CD63 expression in responsive and nonresponsive donors could be conducted in 
the future in parallel with survival experiments to look if there is different expression of 
CD63 on the neutrophil cell surface of each group. However, other factors such as age, 
gender, diet or environmental factors could potentially alter the survival results, a 
hypothesis that would be interesting to test in the future (Spitzer and Zhang, 1996). The 
ethics for this study prohibited the use of age and sex to correlate with neutrophil apoptosis 
but these factors would need to be investigated in the future to understand the variable 
donor response to anti-CD63 antibodies. To understand the variability between donors I 
explored CD63 expression between responsive and nonresponsive donors. The western blot 
data (Figure 3.19) did not show any visible difference between responders and 
nonresponders or, within the same donor, between the 3 time points studied. Considering 
the fact that neutrophils contain many proteases, it is possible that some of the protein was 
cleaved, which could have resulted in inaccurate results. The lysis buffer used in protein 
extraction contained protease inhibitors, however, a loading control such as the use of the 
PLB-985 or A549 cells was not run alongside the experiment to check for protease cleavage 
(El Azreq et al., 2010). Still, other aspects of protein modification could be investigated to 
see if there is a clear segregation between the two group responses. For instance, literature 
shows that the degree of glycosylation of CD63 or other tetraspanins can impact on their 
function (Metzelaar et al., 1991; Schroder et al., 2009; van Gisbergen et al., 2005; Yoshida 
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et al., 2009). Considering that CD63 is one of the most heavily glycosylated tetraspanins 
with 4 glycosylation sites, it is possible that there will be a variability of glycosylation at 
protein level between responders and nonresponders. While glycosylation results in a 
difference in molecular weight and theoretically can be visualised by western blotting, mass 
spectrometry would be a more quantitative technique. For example, the smear that is 
observed by western blot at the higher molecular weights impairs an accurate 
interpretation of the results. Furthermore, western blotting of whole cell lysates allows only 
an overall view of protein expression and not trafficking, which is a key regulator of 
function. Time-lapse fluorescent microscopy would give a better understanding of the 
localisation of CD63 on the plasma membrane or azurophilic granule of neutrophils in the 
presence of anti-CD63 antibodies. A possible internalisation of CD63 upon the use of 
antibodies could explain the increased neutrophil survival due to internalisation of the 
interacting partners, consequences that will be explained in the following paragraphs. 
The light microscopy data indicated that neutrophil apoptosis at 4 and 20 hours in both 
COPD and age matched HC patients is inhibited by anti-CD63 antibodies. Western blot 
analysis of whole cell lysates from age matched HC and COPD patients at three time points 
showed that there is no obvious difference between the two groups in terms of protein 
expression. This outcome was expected considering the similar apoptosis rates between the 
two groups. In addition, no difference in CD63 protein expression between time points 
within the same donor is seen. The literature shows that CD63 mRNA and plasma 
membrane protein level is reduced in COPD patients compared to HC (Zhang et al., 2007). 
Considering the study used flow cytometry to look at cell surface CD63 protein expression, 
it suggests that although the protein level can be similar between HC and COPD patients, 
there could be variations between plasma membrane and intracellular expression of CD63. 
It is however interesting that neutrophils from COPD patients and HC respond similarly to 
the anti-CD63 antibodies.  
Anti-CD63 antibodies were shown to be more effective in modulating constitutive 
neutrophil apoptosis since incubation with survival/apoptosis modulating factors such as 
pyocyanin, LPS and GM-CSF with anti-CD63 antibodies did not affect neutrophil survival 
further. This may be because the pro-apoptotic/pro-survival stimulus engaged pathways 
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that overrode the function of CD63 in regulating survival. While pyocyanin accelerates 
apoptosis via ROS induction, cathepsin D, cytochrome C release and mitochondria 
permeabilisation; LPS prevents apoptosis by activating the MYD88 pathway and GM-CSF 
activates Lyn pathway to induce neutrophil survival (Manago et al., 2015; Prince et al., 2008; 
Rapoport et al., 1992; Remer et al., 2003; Wei et al., 1996). The lack of anti-CD63 antibodies 
effect to modulate further neutrophil apoptosis when 3 different, important signaling 
neutrophil pathways were targeted suggests that perhaps this tetraspanin is modulating 
constitutive neutrophil apoptosis. Probably other tetraspanins that have not been 
investigated yet could be studied in the context of induced neutrophil apoptosis. For 
instance, in monocytes LPS is able to induce the co-clustering of TLR4, Fcγ-RIIa, CD81 and 
CD14 while in macrophages CD9 can modulate CD14, a TLR4 cofactor, expression on the cell 
membrane in the presence of LPS (Pfeiffer et al., 2001; Takeda et al., 2015). Considering the 
involvement of these 2 tetraspanins in TLR signaling, future experiments could explore if 
they are involved in regulating LPS induced neutrophil survival. 
An important question concerns the mechanism of CD63-mediated neutrophil survival. The 
constitutive neutrophil apoptosis pathway occurs through the intrinsic/mitochondrial 
pathway and is the result of increased pro-apoptotic Bcl-2 factors compared to anti-
apoptotic members which go on to activate apoptosome formation and caspase activation 
(Adams, 2003; Adams and Cory, 1998; Murphy et al., 2003; Zou et al., 1997). Bcl-2 is an anti-
apoptotic factor that was shown in tumor cells to be regulated by AP-2 α-Rb (adaptor 
protein-2 α-retinoblastoma) activation complex (Morales et al., 2011). Despite the fact that 
CD63 can bind to AP-2 it is also know that neutrophils do not express the Bcl-2 anti-
apoptotic factor, therefore leading to a dead end for this mechanism (Hirst et al., 1999; 
Moulding et al., 1998). The pro-apoptotic protein Bax transcription was shown in colonic 
epithelial cells to require the transcription factor AP-1 to initiate apoptosis (Mandal et al., 
2001). According to the literature, there is no evidence of CD63 interacting with AP-1 
protein. Although a mechanism for CD63 involvement in constitutive neutrophil apoptosis 
cannot be proposed yet, it could be speculated that via CD63-AP-2 interaction in other cell 
types the tetraspanin could be involved in modulating cell survival by promoting their 
trafficking. However, it may as well be the case that the tetraspanin may regulate 
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expression of one or more Bcl-2 family members by activating different signalling pathways, 
as seen in acute myelogenous leukemia cells (Nishioka et al., 2015). 
CD63 can be transported to the cell surface from the cytoplasm and recycled back (Pols and 
Klumperman, 2009). However, there is evidence that indicates that antibody binding 
induces rapid internalisation of CD63 via its internalisation/lysosomal C-terminal targeting 
motif (Mantegazza et al., 2004; Rous et al., 2002; Smith et al., 1995). Considering the 
literature, it is plausible that CD63-protein interactions and the formation of TEMs to be 
abrogated by the recycling of the CD63 to the lysosomal compartment. This may result in 
loss of function by abrogating formation of signalling platforms that may be involved in 
promoting neutrophil apoptosis. 
A possible mechanism by which CD63 inhibits constitutive neutrophil apoptosis is by 
affecting the function or transport of protein kinase C (PKC) δ signalling molecule to the cell 
surface. PKCδ is an important pro-apoptotic neutrophil signaling molecule that once 
translocated to the plasma membrane, aids PS externalisation (Nusbaum et al., 2005; 
Pongracz et al., 1999; Webb et al., 2000). Interestingly, Plaszczyca et al., 2014 showed in 
fibrous histiocytoma, that PKCδ catalytic genes can fuse with the CD63 gene resulting in 
constitutive activation of this kinase. It is possible that either anti-CD63 antibodies prevent 
recruitment or translocation of the PKCδ to the cell surface or the antibody-CD63-PKCδ 
complex prevents PS externalisation by preventing kinase activation. A possible way to 
investigate if this interaction takes place in neutrophils is by using fluorescent microscopy 
and fluorescently tagged antibodies in co-localisation studies. Co-immunoprecipitation 
could be another way to investigate CD63-PKC interactions, although this technique causes 
problems in neutrophils due to the proteases that can degrade proteins. In addition, the 
place of interaction, if present, between the tetraspanin and the kinase can be determined 
by using markers for the different endosomal compartments involved in protein trafficking 
such as Ras-related protein 5 (Rab-5) for early endosomes, lysososmal-associated 
membrane protein 1 (LAMP-1) for lysosomes and Rab7 for late endosomes (Chavrier et al., 
1990; Meresse et al., 1995; Peters et al., 1991).  
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In a different neutrophil study, CD63 was also shown to interact with αMβ2 integrin and Src 
and Lyn protein kinases (Skubitz et al., 1996). This resulted in kinase phosphorylation and 
activation leading to neutrophil migration and adhesion to HUVEC epithelial cells. This 
adhesion was increased in the presence of anti-CD63 antibodies. Recent data also shows 
that ligation of SMIP-0166 drug with CD37 protein situated on chronic lymphoid leukemia 
cells led to phosphorylation of the N-terminus immunoreceptor tyrosine-based activation -
like motif of CD37 by Lyn kinase, leading to Src homology region 2 domain-containing 
phosphatase-1 -dependent BIM upregulation and cell death (Lapalombella et al., 2012). This 
suggests a possible mechanism of action for anti-CD63 antibodies in preventing cell death. 
However, one of the antibodies used by Skubitz et al., 1996, was used in a single experiment 
(Figure 3.5) to show a profound inhibition of neutrophil apoptosis. The association of the 
kinases with CD63, in a fairly big complex, was also demonstrated in the presence of Brij 58 
detergent (Skubitz et al., 2000). It is possible that actually the Lyn and Syk kinases to 
associate with other proteins but because they are part of a big complex, to appear as it 
interacts with CD63. The cytokine GM-CSF was also shown to activate Lyn kinase resulting 
to inhibition of neutrophil apoptosis (Wei et al., 1996). Results in this chapter showed no 
cumulative role for GM-CSF and anti-CD63 antibodies (Figure 3.15B) in inhibiting further 
neutrophil apoptosis when compared to separate incubation of neutrophils with the two 
reagents. As a result, in this context, it is improbable a role for CD63 role in Lyn kinase 
activation.  
Another possible mechanism of action CD63 is involved in to modulate neutrophil 
apoptosis, is via PI4-K type II. CD63 is known to interact almost entirely in the intracellular 
compartment with the PI4-K type II kinase (Yauch and Hemler, 2000). PI4-K type II 
participates in phosphoinositide synthesis at the plasma membrane and these lipids are 
involved, amongst many functions, in modulating cell survival (Tolias and Cantley, 1999). 
The binding of anti-CD63 antibodies, as previously described, could promote rapid 
internalisation of CD63 from the plasma membrane which can result in PI4-K type II 
internalisation. This would result in the inhibition of phosphoinositide synthesis or reduced 
production of phosphoinositides that could affect cell membrane properties and as a result 
increase cell survival. 
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Still, CD63 involvement in neutrophil survival may be a more complicated process than 
expected since CD63 acts as a transporter for many proteins, some of which are involved in 
neutrophil survival, degranulation and cell homeostasis. Using a zebrafish model, it was 
shown that CD63 is involved in embryo hatching by altering the function of the secretory 
machinery either by disrupting CD63-integrin function or by failing to deliver the hatching 
enzymes to the granules (Trikic et al., 2011). A similar morphology as the hatching model 
was seen in a neutrophil in vitro model, where the authors showed that CD63 knockout, by 
siRNA in COS cells, resulted in failure to transport the precursor of neutrophil elastase to 
the lysozyme granules (Kallquist et al., 2008). Neutrophil elastase is a key enzyme in 
neutrophil functions since mutations in the neutrophil elastase ELANE gene can result in 
severe congenital neutropenia and cyclic neutropenia, exhibited by fewer than 1.5 × 
109neutrophils/L and lasting for more than 3 months (Dale et al., 2000; Rosenberg et al., 
2006). The mutations in the ELANE gene results in protein unfolding, mislocalisation 
accumulation in the cytoplasm and cell death (Grenda et al., 2007; Horwitz et al., 2007; 
Kollner et al., 2006). However, the in vitro experiments conducted did not show any severe 
neutrophil survival pathology with the anti-CD63 antibodies, nor did the phenotyping of in 
vivo mouse model showed any neutrophil abnormalities (Schroder et al., 2009). These 
results suggest that perhaps modulation of neutrophil apoptosis by CD63 is through a 
different mechanism since tampering with neutrophil elastase would most probably result 
in cell death, considering the known literature, rather than survival. 
Another mechanism CD63 can be involved in regulating to reduce neutrophil apoptosis is 
the transport of the H,K-ATPase. Current literature shows, using COS7 cells, that CD63 
sequential association with the AP-2 and AP-3 adaptor complexes, allows CD63 interaction 
with the gastric H,K-ATPase β-subunit to move it from the cell surface to early and late 
endosomes to lysosomal compartment (Duffield et al., 2003). Western blotting techniques 
also showed that human neutrophils have similar H,K-ATPase β-subunit to the gastric one 
(Ritter et al., 1998). In addition to this, neutrophils have vacuolar H-ATPase that is involved 
in preserving neutrophil homeostatis by pumping protons in the extracellular space and in 
the organelles (Lafourcade et al., 2008). Furthermore, in the presence of G-CSF, β-subunit 
synthesis is upregulated in the cytosolic compartment and increased translocation of the 
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vacuolar H-ATPase to the neutrophil plasma membrane can be seen (Niessen et al., 1997). 
There is also evidence that in the presence of G-CSF, there is an upregulation of the vacuolar 
H-ATPase (Gottlieb et al., 1995). Considering the above literature, it is possible that rapid 
internalisation of CD63 from the cell surface to lysosomal compartment, due to the use of 
anti-CD63 antibodies, results in the possible fail to internalise the H,K-ATPase and vacuolar 
H-ATPase to the intracellular compartment. The overall effect seen would be more protons 
being pumped out preventing intracellular acidification, an early step in the apoptosis 
program. It is possible that co-incubation of GM-CSF and anti-CD63 antibodies targeted the 
same process and as a result a more prominent reduction in neutrophil apoptosis, however 
not significant, was seen with both in comparison to the GM-CSF alone. 
My results show that although there is good CD63 protein expression, as indicated by 
western blotting, the flow cytometry experiments failed to show a CD63 protein surface 
expression on unstimulated neutrophil. There are a number of studies that show, however, 
that neutrophils have low CD63 protein expression on the plasma membrane, with the 
majority of the protein being localized in the primary granules (Beinert et al., 2000; El Azreq 
et al., 2010; Tohami et al., 2004; Zhang et al., 2007). Although flow cytometry analysis failed 
to show CD63 protein expression on unstimulated neutrophil cell surface, stimulation of 
neutrophils with S. aureus resulted in the detection of CD63 when compared to JC1 control 
(Figure 3.9). Our results are in accordance with the literature since, in the presence of other 
degranulation stimuli, the same effect is seen. For instance, HL-60 cell incubation with 
zymosan results in CD63 recruitment to the phagocytic cup while fMLP incubation increases 
CD63 expression to the surface (Nordenfelt et al., 2009). This suggest that the anti-CD63 
antibody clone used in the experiments can detect CD63. Though low CD63 surface 
expression of the unstimulated neutrophils correlated with possibly a false positive signal 
resulting from JC1 isotype antibody binding to the high amounts of Fc receptors that 
neutrophils express on their surface, resulting in inadequate detection of the tetraspanin 
on neutrophil surface in this thesis. Although studies show CD63 expression on 
unstimulated neutrophil surface, additional experiments would need to be done to show 
this in our model system. To reduce the false positive signal future experiments could use 
human serum to block the Fc receptors. 
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Similarly, the flow cytometry CD63 expression data obtained showed that a conclusion 
could not be reached about CD63 upregulation on cell surface with age. This could be also 
due to the high amounts of Fc receptors that neutrophils express on their surface that 
would allow JC1 isotype antibody binding to these receptors and give a false positive signal. 
In vitro study conducted by Beinert et al., 2000 showed that CD63 expression increases on 
cell surface with age. However, in the study the authors used gentamicin to inhibit 
neutrophil apoptosis for 48 hours. Gentamicin can affected the internal gene transcription 
as well as translation and expression of protein potentially resulting in skewed results (Healy 
et al., 2002). 
An in depth understanding of CD63 role in neutrophil survival could be achieved by deleting 
the CD63 gene in neutrophils. However, neutrophils have a very short life and are 
genetically intractable. To get around this problem, PLB-985, a myeloid-leukemia cell line, 
can be differentiated into cells that are functionally similar to neutrophils and express CD63+ 
granules (Pivot-Pajot et al., 2010). As a consequence, studying CD63 function in neutrophil 
survival can be done by knocking down the tetraspanin using small interfering RNA (siRNA). 
Furthermore, PLB-985 can be used to fine tune experiments that would otherwise require 
large neutrophil numbers and are limited by blood availability. For instance, to understand 
what survival pathway CD63 feeds into, CD63 interacting partners could be studied. Pull-
down or immunoprecipitation assays, which require more protein and are difficult to 
optimise with primary neutrophils due to high number of degrading proteases, is more 
feasible with differentiated PLB-985 due to readily availability in high numbers and lower 
levels of proteases. Alternatively, neutrophils fromCD63 knockout mice could be obtained, 
albeit at the time of the study this was not possible due to mice breeding problems. 
Alternatively CD63 role in neutrophil survival can be investigated in vitro by overexpressing 
the tetraspanin. CD63 is highly expressed in neutrophil granules but overexpressing CD63 
could have a different effect on neutrophil survival (Cham et al., 1994). Despite the fact that 
neutrophils cannot be manipulated in this way, previous studies conducted by our group 
showed that neutrophils can be stably transfected with lentivirus encoding a dominant 
negative protein to overexpress and study the protein of interest (Dick et al., 2009). This 
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technique can be used to induce neutrophils CD63 overexpression to investigate its 
function. 
The effects of CD63 on neutrophil survival has only been studied in this thesis in an in vitro 
model or by using ex vivo patient samples. However, in vitro models present limitations due 
to inability of seeing a more integrated global effect as seen with an in vivo model. To put 
the data in a more clinical context and to understand better the role of CD63 in neutrophil 
survival, in vivo studies using mice or zebrafish models must be done. Considering that 
mouse and human DNA is 95% similar, the mouse is a suitable model for studying 
neutrophils. CD63 knock-out mice that could be used in our study were previously obtained 
by knocking out the two CD63 gene copies on C57BL/6J background mice (Schroder et al., 
2009). A similar strain is also commercially available (Taconic, n.d.). Moreover, an 
elastase/LPS induced mouse model of COPD could also be used in conjunction with anti-
CD63 antibodies to study the role of CD63 in an in vivo model, giving a more clinical context 
of the tetraspanin role (Ganesan et al., 2012). When considering the zebrafish model, the 
human and zebrafish CD63 proteins are 62.2% similar with comparable key features: 3 
glycosylation identical sites in the EC2 domain and the C-terminus internalisation motif 
(Trikic et al., 2011). However, complete knock-down using morpholinos of CD63 in zebrafish 
was shown to result in impaired hatching of the embryos (Trikic et al., 2011). At present, 
Sanger institute is working on a stable line with a nonsense mutation to be available in the 
near future, that will probably overcome the hatching problem noticed by Trikic et al., 2011 
(Welcome trust Sanger institute, 2017) Furthermore, when selecting an appropriate in vivo 
model to confirm this study, it should be considered the CD63 knockout mouse model did 
not demonstrate any severe physiological changes as seen in the zebrafish model. This 
indicates perhaps that mammals have more redundancy in the tetraspanin network where 
if a tetraspanin is absent or malfunctioning, other tetraspanins could compensate for its 
function. 
The findings presented in this chapter show for the first time that CD63 plays a role in 
constitutive neutrophil apoptosis, independent of small levels of PBMCs contamination. In 
addition, neutrophils from COPD patients showed similar apoptosis results to age matched 
HC controls when incubated with anti-CD63 antibodies. Protein analysis data did not show 
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a difference in protein expression, failing to hint toward a potential mechanism. All things 
considered, the results allow for many questions to be opened about the mechanism of 
CD63-dependent regulation of neutrophil apoptosis. 
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Chapter 4: A role for CD151 in neutrophil interactions with S. aureus 
and other respiratory pathogens 
4.1. Introduction 
4.1.1. Neutrophil defence against pathogens 
Phagocytosis is one of the most important processes by which neutrophils protect the host 
from invading pathogens. It involves pathogen engulfment and activation of the 
downstream processes involved in pathogen killing. To do this, neutrophils recognise 
conserved pathogen structures via pathogen recognition receptors described in detail in 
Chapter 1 (Schymeinsky et al., 2007; Takeuchi and Akira, 2010). The neutrophils ingest the 
pathogen through a zipper model, forming a phagocytic cup which seals to form the 
phagosome. Fusion of granules to the phagosome forms the phagolysosome, which is 
progressively acidified and exposed to antimicrobial components and ROS, ultimately 
resulting in bacterial death (Borregaard and Cowland, 1997b; Groemping and Rittinger, 
2005; Swanson, 2008). S. aureus, as well as other pathogens have evolved mechanisms to 
evade recognition by neutrophils and escape from the phagolysosome (Bera et al., 2005; 
Bestebroer et al., 2007; Bestebroer et al., 2009; Haas et al., 2005; Haas et al., 2008; Laarman 
et al., 2012; Malachowa et al., 2011; Mishra et al., 2011; Prat et al., 2006; Prat et al., 2009). 
It is therefore important to study the mechanisms underpinning neutrophil phagocytosis, 
which may ultimately reveal novel therapeutic strategies for patients with life threatening 
and/or chronic infections. 
4.1.2 The involvement of tetraspanins in phagocytosis 
Previous studies have shown that tetraspanins play a role in bacterial phagocytosis 
(Artavanis-Tsakonas et al., 2011; Artavanis-Tsakonas et al., 2006; Chang and Finnemann, 
2007; Noda et al., 2013). For instance, CD81, via the αvβ5 integrin, has a role in retinal 
pigment epithelial phagocytosis of photoreceptor segment fragments (Chang and 
Finnemann, 2007). In dendritic cells, CD82 is recruited to phagosomes containing fungi and 
bacteria, prior to their fusion with the lysosomes, but its role in this process is yet to be 
elucidated (Artavanis-Tsakonas et al., 2011). The same group has previously shown CD63 
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dependent recruitment of the Cryptococcus neoformans to the acidified phagolysosome 
(Artavanis-Tsakonas et al., 2006). Furthermore, CD9 was shown to be part of the 
macrophage efferocytosis pathway (Noda et al., 2013). The role of tetraspanins in 
neutrophil phagocytosis has not been investigated. 
4.1.2. Evidence of tetraspanins role in S. aureus adhesion 
S. aureus interacts with host cells by mechanisms that may involve tetraspanins. Assays 
showed that the strong CD9 and CD151 interaction with β1 integrins can mediate S. aureus-
fibronectin adhesion while CD9 interaction with heat shock protein 70 (Hsp70) and αVβ3 
integrin is able to mediate S. aureus intestinal cell adhesion via Hsp70 (Dziewanowska et al., 
2000; Guerrero and Moreno, 2012; Peddibhotla et al., 2013; Rubinstein et al., 1994; Yauch 
et al., 2000). Additionally, CD9 binds to fibronectin in intestinal cells, a S. aureus adhesion 
component, but it also promotes shedding fibrinogen receptor on platelet cells to prevent 
S. aureus adhesion via it (Guerrero and Moreno, 2012; Hato et al., 1988; Piroth et al., 2008). 
Previous data from Dr. Lynda Partridge and Prof. Peter Monk groups also showed that CD9, 
CD63 and CD151 are involved in S. aureus adhesion to epithelial cells through an unknown 
mechanism (Green et al., 2011). A recent paper by Virreira Winter et al., showed that 
ADAM10 bound and internalised less S. aureus pore-forming toxin α hemolysin when cells 
were deficient in TSPAN14 (Virreira Winter et al., 2016).  
The studies, although CD9 oriented, suggest a role for tetraspanins in S. aureus interaction 
with host cells and potential subversion of host defences. However, none of these studies 
explore the role of tetraspanins in neutrophil interaction with S. aureus. As a result the 
hypothesis investigated in this chapter is that tetraspanins play a role in the interaction with 
S. aureus and possibly other respiratory pathogens. The first aim of the project was to 
identify the tetraspanin(s) involved in S. aureus interactions using different anti-tetraspanin 
antibodies. The second aim was to see if this tetraspanin(s) is involved in modulating 
neutrophil interactions with different S. aureus strains or other Gram positive/negative 
respiratory pathogens. Lastly, I proceeded to investigate the mechanism by which this 
tetraspanin(s) modulates neutrophil interaction with S. aureus or other respiratory 
pathogens. 
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4.2. Results 
4.2.1 Neutrophil interaction with HK S. aureus increases with MOI 
Neutrophils are professional phagocytes that readily phagocytose S. aureus (Odell and 
Segal, 1991). To validate the interaction range of S. aureus, neutrophils were incubated for 
2 hours with heat-killed (HK) S. aureus at MOI of 2.5, 5, 10 and 20. The phagocytic index (PI) 
was calculated to account for the percentage of neutrophils that phagocytose bacteria, but 
also the number of bacteria each cell has phagocytosed. Light microscopy analysis showed 
that interaction with HK S. aureus increased with MOI, reaching a mean±SD of 529.5±128.1 
at MOI20 (Figure 4.1). Light microscopy does not discriminate between phagocytosed and 
surface bound bacteria therefore in all experiments where the technique is used the results 
will be referred to as showing a neutrophil-bacterial interaction. 
4.2.2. Anti-CD151 antibodies inhibit neutrophil interaction with HK S. aureus 
Results from the groups of Dr. Lynda Partridge and Prof. Peter Monk, as well as others show 
that tetraspanins are involved in S. aureus adhesion and interaction with epithelial cells 
(Dziewanowska et al., 2000; Green et al., 2011; Ventress et al., 2016; Virreira Winter et al., 
2016). With the exception of Tohami et al., 2004 who showed that neutrophils from patients 
with pneumonia and urinary tract infections express reduced levels of CD81 and CD82, the 
role of tetraspanins in neutrophil bacterial infections has not been investigated. To explore 
this, neutrophils were incubated for 1 hour with anti-tetraspanin antibodies directed 
against CD9, CD37, CD63 and CD151 at 10µg/ml. These tetraspanins are expressed at higher 
levels, but are not restricted to myeloid cells and therefore good candidates for study in this 
context. Media and JC1 IgG1 isotype (10µg/ml) were used as controls. HK S. aureus MOI20 
was then added for a further 2 hours. Photomicrograph of JC1 control (Figure 4.2A) 
incubated neutrophils showed the presence of S. aureus within phagosomes. Phagocytic 
index quantification showed a significant difference between JC1 and anti-CD151 
antibodies (517.71±135.6 Mean±SD in JC1 control and 402.66±132.7 Mean±SD in anti-
CD151 antibody incubated neutrophils (Figure 4.2B)). Antibodies to CD9, CD37 and CD63 
were without effect. Expression of individual phagocytic index in a table (Figure 4.2C) shows 
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variation of PI between donors. Overall, the data indicates a potential role for CD151 in 
neutrophil interaction with HK S. aureus and this was explored in further experiments. 
4.2.3. Anti-CD151 antibodies inhibit neutrophil interaction with HK S. aureus at 10 µg/ml 
Since anti-CD151 antibodies inhibited neutrophil interactions with HK S. aureus, their 
working concentration was further refined to determine the optimal use. To do this, 
neutrophils were incubated for 1 hour with JC1 isotype control (10µg/ml) and low (0.5-
1µg/ml) (Figure 4.3A) or high (5-20µg/ml) (Figure 4.3B) concentrations of anti-CD151 
antibodies. HK S. aureus MOI10 was added for a further 2 hours. While the low 
concentrations of anti-CD151 antibodies had no effect on reducing neutrophil interaction 
with HK S. aureus, the higher concentration of 10µg/ml significantly reduced neutrophil 
interaction with HK S. aureus. Although, 20µg/ml of anti-CD151 antibodies led to a visible 
reduction in phagocytic index, this was not significantly different, probably due to variations 
in the results obtained with that concentration. For this reason, 10µg/ml of anti-CD151 
antibodies was used in all further experiments. 
4.2.4. Different anti-CD151 antibody clones inhibit neutrophil interaction with HK S. 
aureus 
To confirm further that CD151 plays a role in neutrophil interactions with HK S. aureus, a 
commercially available anti-CD151 was compared to the in-house antibody used above. 
Neutrophils were incubated for 1 hour with anti-CD151 antibodies (10µg/ml) or their 
equivalent isotype controls (10µg/ml), followed by a 2 hour incubation with HK S. aureus at 
MOI10. Phagocytic index counts indicate a significant reduction in interaction of neutrophils 
with HK S. aureus when both anti-CD151 antibody clones were used, by comparison to their 
equivalent isotype controls (Figure 4.4). These results confirm further the involvement of 
CD151 in neutrophil phagocytosis of HK S. aureus.  
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Figure 4.1: Evidence of increased neutrophil interaction with HK S. aureus with MOI. 
Plasma/Percoll-pure neutrophils were incubated for 2 hours with HK S. aureus at MOI 2.5, 
5, 10 and 20. Phagocytosis was assessed by light microscopy. Data from 4 different 
experiments is expressed as mean±SD. 
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C . Donor Media JC1 CD9 CD37 CD63 CD151
D1 439.82 391.28 403.78 322.82 298.54 278.26
D2 721.67 533.95 461.89 442.23 542.05 437.44
D3 319.68 444.66 433.01 497.52 458.12 320.8
D4 682.51 700.98 672.9 724.42 664.96 574.14
Mean±SD 540.92±193.1 517.71±135.6 492.89±122.3 496.75±168.4 490.92±153.8 402.66±132.7
Figure 4.2: The effect of different anti-tetraspanin antibodies on neutrophil interaction 
with HK S. aureus. 
Freshly isolated neutrophils from venous blood of healthy volunteers by plasma/Percoll 
centrifugation were cultured for 1 hour with media or 10µg/ml of anti-tetraspanin 
antibodies against CD9, CD37, CD63 and CD151 or JC1 isotype control, followed by a 2 hour 
incubation with HK S. aureus at MOI20. Neutrophil interaction with S. aureus was assessed 
by light microscopy. A) Photomicrograph of neutrophil interaction with HK S. aureus in the 
presence of JC1 isotype control. Neutrophils-black arrow, HK S. aureus in the 
phagolysososme- red arrow. Scale bar 10µm. B) Phagocytic index of the data from 4 
independent repeats is expressed as mean±SD. Statistical analysis carried out by one-way 
ANOVA with Bonferroni's post-test (*p<0.05). C) Table showing different phagocytic index 
rates obtained from the donors in the presence of different anti-tetraspanin antibodies. 
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Figure 4.3: Anti-CD151 antibodies inhibit neutrophil interaction with HK S. aureus at 
10µg/ml. 
Freshly isolated neutrophils from venous blood of health volunteers by plasma/Percoll 
centrifugation were incubated for 1 hour with JC1 isotype control (10µg/ml) and low (0.5-
1µg/ml) (A) or high (5-20µg/ml) (B) concentrations of anti-CD151 antibodies followed by a 
2 hour incubation with HK S. aureus at MOI10. Neutrophil interaction with HK S. aureus was 
assessed by light microscopy. Data from 4 (A) and 5 (B) independent experiments is 
expressed as mean±SD. Statistical analysis carried out by one-way ANOVA with Bonferroni's 
post-test with repeated measures (**p<0.01). 
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Figure 4.4: Commercially available and in house obtained anti-CD151 antibodies inhibit 
neutrophil interaction with HK S. aureus. 
Freshly isolated neutrophils from venous blood of health volunteers via plasma/Percoll 
centrifugation were incubated for 1 hour with anti-CD151 antibodies or isotype controls 
(10µg/ml), either obtained in house by Dr. Lynda J. Partridge or commercially available from 
Biolegend, followed by a 2 hour incubation with HK S. aureus at MOI10. Neutrophil 
interaction with S. aureus was assessed by light microscopy. Data from 6 independent 
donors is expressed as mean±SD. Statistical analysis carried out by one-way ANOVA with 
Bonferroni's post-test with repeated measures (*p<0.5, **p<0.01). 
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4.2.5. Anti-CD151 antibodies inhibit neutrophil interaction with HK S. aureus at MOI5 
and 10 and at 60 and 120 minutes post incubation 
I next wanted to determine the potential of anti-CD151 antibodies in inhibiting neutrophil 
interaction with HK S. aureus across a range of MOIs and time points. Neutrophils were 
incubated for 1 hour with JC1 isotype control or anti-CD151 antibody at 10µg/ml followed 
by a further 2 hour incubation with HK S. aureus at MOI1, 2.5, 5 or 10 (Figure 4.5A) or by a 
30, 60 or 120 minute incubation with HK S. aureus at MOI10 (Figure 4.5B). Neutrophil 
interactions with HK S. aureus was significantly inhibited at all MOIs and time points, 
reaching statistical significance at MOI5 and 10 (Figure 4.5A) and after 60 and 120 minutes 
(Figure 4.5B). 
4.2.6. Anti-CD151 antibodies inhibit neutrophil interaction with HK S. aureus WT and JE2 
strains 
There are over a thousand strains of S. aureus with some being more pathogenic than others 
(van Belkum and Melles, 2009). To show the role for CD151 was not restricted to a single 
strain (SH1000-WT), the USA300 background (JE2) was also tested. Considering that S. 
aureus SH1000-WT is predominantly a laboratory strain, the most common community-
associated MRSA clinical isolate USA300, has increased pathogenicity and potentially 
altered mechanism of cell entry (Kennedy et al., 2008; Strobel et al., 2016). Neutrophils 
were incubated for 1 hour with JC1 isotype control or anti-CD151 antibodies at 10µg/ml, 
followed by a 2 hour incubation with JE2 and WT strains of HK S. aureus at MOI10. 
Interaction of both strains of S. aureus with neutrophils was significantly inhibited in the 
presence of anti-CD151 antibodies (Figure 4.6). This indicates that CD151 is not restricted 
to a single strain of S. aureus. 
4.2.7. Anti-CD151 antibodies inhibit interaction of live S. aureus with neutrophils 
So far, only heat inactivated strains of S. aureus were used. However, heat inactivation of 
bacteria can change the structural proteins and lipoproteins on the surface of the cell and 
therefore may alter rates of phagocytosis. In addition, the bacteria is no longer able to 
secrete factors that may ordinarily prevent engulfment (Ingmer and Brondsted, 2009; 
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Kumar, 2015). As a result, to elucidate further the role of CD151 in S. aureus interaction 
with neutrophils, the cells were incubated for 1 hour with anti-CD151 antibodies and JC1 
isotype control (10µg/ml) followed by a 45 minute incubation with live S. aureus at MOI5. 
Interaction of neutrophils with live S. aureus was significantly inhibited with anti-CD151 
antibodies (Figure 4.7) when compared to JC1 control. 
4.2.8. Anti-CD151 antibodies do not inhibit interaction of HK S. pneumoniae with 
neutrophils at any MOI tested or any incubation time points used 
Neutrophils are equipped to protect a wide variety of respiratory pathogens that are often 
associated with pneumoniae and cause serious and often fatal exacerbations in people 
suffering from chronic inflammatory disease (Craig et al., 2009; Eldika and Sethi, 2006). 
Consequently, CD151 involvement in neutrophil interaction with another Gram positive 
respiratory pathogens, S. pneumoniae, was investigated. Neutrophils were incubated for 1 
hour with JC1 isotype control or anti-CD151 antibody at 10µg/ml followed by a 2 hour 
incubation with opsonised HK S. pneumoniae at MOI 5, 10 or 20 (Figure 4.8A-C) or by a 30, 
60, 120 or 180 minute incubation with opsonised HK S. pneumoniae at MOI10 (Figure 4.8D). 
Light microscopy shows a similar S. pneumoniae load in JC1 isotype treated neutrophils 
(Figure 4.8A) and anti-CD151 antibody treated cells (Figure 4.8B). A zoomed in 
photomicrograph shows S. pneumoniae as purple rods arranged in a chain structure inside 
clear phagolysosomes. Neutrophil interaction with HK S. pneumoniae was not significantly 
different in the presence of anti-CD151 antibodies compared to JC1 control at any of the 
MOI used (Figure 4.8C) or after any of the incubation time point employed (Figure 4.8D). 
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Figure 4.5: Anti-CD151 antibodies significantly inhibit neutrophil interaction with HK S. 
aureus at MOI5 and 10 and at 60 and 120 minutes post incubation. 
Freshly isolated neutrophils from venous blood of health volunteers via plasma/Percoll 
centrifugation were incubated for 1 hour with JC1 isotype control or anti-CD151 antibodies 
at 10µg/ml (Figure 4.5 A, B) followed by a 2 hour incubation with HK S. aureus at MOI 1, 2.5, 
5 or 10 (Figure 4.5 A) or by a 30, 60 or 120 minutes (mins) incubation with HK S. aureus at 
MOI 10 (Figure 4.5 B). Neutrophil interaction with S. aureus was assessed by light 
microscopy. Data from 5 (A) or 4 (B) independent donors is expressed as mean±SD. 
Statistical analysis carried out by one-way ANOVA with Bonferroni's post-test with repeated 
measures (*p<0.5, **p<0.01). 
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Figure 4.6: Anti-CD151 antibodies inhibit neutrophil interaction with JE2 and SH1000 (WT) 
strains of HK S. aureus. 
Plasma/Percoll-purified neutrophils were incubated for 1 hour with JC1 isotype control or 
anti-CD151 antibodies at 10µg/ml, followed by a 2 hour incubation with JE2 or SH1000 (WT) 
strains of HK S. aureus at MOI10. Neutrophil interaction with both S. aureus strains was 
assessed using light microscopy. Data from 4 different donors is expressed as mean±SD 
(one-way ANOVA with Bonferroni's repeated measures post-test (*p<0.05)). 
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Figure 4.7: Anti-CD151 antibodies inhibit neutrophil interaction with live S. aureus.  
Freshly isolated neutrophils from venous blood of health volunteers via plasma/Percoll-
centrifugation were incubated for 1 hour with media, anti-CD151 antibodies and JC1 isotype 
control (10µg/ml) followed by a 45 minute incubation with live S. aureus at MOI 5. 
Neutrophil interaction with S. aureus was assessed by light microscopy. Data from 11 
independent donors is expressed as mean±SD. Statistical analysis carried out by one-way 
ANOVA with Bonferroni's post-test with repeated measures (*p<0.5). 
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Figure 4.8: The effect of anti-CD151 antibodies on neutrophil interaction with different 
MOI of HK S. pneumoniae and after different incubation times. 
Freshly isolated neutrophils from venous blood of health volunteers via plasma/Percoll 
centrifugation were incubated for 1 hour with JC1 isotype control or anti-CD151 antibodies 
at 10µg/ml (A-D) followed by a 2 hour incubation with opsonised HK S. pneumoniae at 
MOI5, 10 or 20 (A-C) or by a 30, 60, 120 or 180 mins incubation with opsonised HK S. 
pneumoniae at MOI 10 (D). Neutrophil interaction with S. pneumoniae was assessed by light 
microscopy. Photomicrographs of neutrophil interaction with HK S. pneumoniae at MOI10 
in the presence of JC1 isotype control (A) and anti-CD151 antibodies (B). Enlarged area 
depicting HK S. pneumoniae in the clear phagolysosomes (B). C, D) Data from 3 independent 
donors is expressed as mean±SD. Statistical analysis carried out by one-way ANOVA with 
Bonferroni's post-test with repeated measures. 
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4.2.9. Anti-CD151 antibodies do not inhibit neutrophil interaction with live S. pneumoniae  
As stated above, bacterial heat inactivation can damage cellular structures, resulting in 
altered neutrophil phagocytosis. To elucidate further the role of CD151 in neutrophil 
interaction with S. pneumoniae, live bacteria was used. Neutrophils were incubated for 1 
hour with media, anti-CD151 antibodies (10µg/ml) and JC1 isotype control (10µg/ml). 
Opsonised live S. pneumoniae MOI10 was added for a further 1 hour. Neutrophil interaction 
with live S. pneumoniae was not significantly inhibited with anti-CD151 antibodies (Figure 
4.9), compared to the control, confirming further that CD151 does not play a role in 
neutrophil interaction with S. pneumoniae. 
4.2.10. Anti-CD151 antibodies have no impact on S. aureus-induced cell death 
S. aureus can result in rapid neutrophil lysis following phagocytosis via the production of 
cell lysis factors such as staphylococcal α-phenol soluble modulins, γ-hemolysin and panton 
valentine leukocidin (PVL) (Cribier et al., 1992; Kobayashi et al., 2010; Konig et al., 1997; 
Surewaard et al., 2013; Voyich et al., 2005). Considering that anti-CD151 antibodies inhibit 
S. aureus phagocytosis by neutrophils, I hypothesise that the antibodies will also reduce the 
S.-aureus-induced cell death. ToPro-3 is a vital dye that intercalates between double 
stranded DNA when cells become permeable, making it a good tool to investigate 
neutrophil lysis (Babiychuk et al., 2008; Cantinieaux et al., 2004; Solito et al., 1998; 
Vanhooijdonk et al., 1994). Neutrophils were incubated for 1 hour with media, JC1 isotype 
control (10µg/ml) or anti-CD151 antibodies (10µg/ml) followed by a 2.5 hour incubation 
with live S. aureus at MOI5. Neutrophils were then stained with ToPro-3 and analysed by 
flow cytometry. FSC/SSC dot plots allowed gating of cells from debris (Figure 4.10A). RL1-A 
histogram showed a total right shift in ToPro-3 positivity. Lysed cells represent the positive 
(+ve) control while unstained and stained media incubated neutrophils represent the 
negative controls. Co-incubation of S. aureus with media, JC1 isotype and anti-CD151 
antibodies indicated a moderate increase of ToPro-3+cells (Figure 4.10B). % ToPro-3+ cell 
calculation indicated no difference in cell lysis between the media, JC1 and anti-CD151 
antibodies incubated neutrophils with S. aureus (Figure 4.10C). The results indicate similar 
neutrophil cell lysis in both anti-CD151 antibody incubated cells and controls. 
- 143 - 
 
 
Figure 4.9: Effect of anti-CD151 antibodies on neutrophil interaction with live S. 
pneumoniae. 
Freshly isolated neutrophils from venous blood of health volunteers via plasma/Percoll 
centrifugation were incubated for 1 hour with media, JC1 isotype control or anti-CD151 
antibodies (10µg/ml) followed by a 1 hour incubation with opsonised live S. pneumoniae 
MOI 10. Neutrophil interaction with S. pneumoniae was assessed by light microscopy. Data 
from 3 independent donors is expressed as mean±SD. Statistical analysis carried out by one-
way ANOVA with Bonferroni's post-test with repeated measures. 
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Figure 4.10: Effect of anti-CD151 antibodies on S. aureus-induced cell death. 
Plasma/Percoll isolated neutrophils from venous blood of healthy volunteers were 
incubated for 1 hour with media, JC1 isotype control (10µg/ml) or anti-CD151 antibodies 
(10µg/ml) followed by a 2.5 hours incubation with live S. aureus at MOI5. Permeability was 
assessed by ToPro-3 staining. Unstained, media stained and lysed cells are representative 
of negative and positive (+ve) controls. A.) FSC/SSC dot plot of neutrophil separation from 
debris. B) RL1-A histogram representative of ToPro-3+ fluorescence, obtained using Attune 
flow cytometer. C) % ToPro-3 positive cells quantification of neutrophils obtained under 
different conditions. Data expressed from 4 independent donors as mean±SD. 
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4.2.11. Trypan Blue quenches S. aureus (WT chr-GFP) GFP fluorescence with increased 
MOI 
There is no knowledge if anti-CD151 antibodies inhibit S. aureus adhesion or internalisation 
by neutrophils. To test this, a biochemical method can be used to test between the two 
categories. Such a method uses trypan blue (TB) to quench FITC or GFP fluorescence of 
extracellular bacteria (Nuutila and Lilius, 2005). To probe the suitability of this method to 
distinguish between intracellular and extracellular bacteria in our experiments, neutrophils 
were incubated with live S. aureus (WT chr-GFP) at MOI 5, 10 or 20 for 45 minutes. To 
determine the right amount of TB required and TB incubation time, cells were incubated 
with TB at either 1:4 (0.1% TB) or 1:2 (0.2% TB) dilutions for 1 minute or 15 minutes. FSC/SSC 
dot plots show cell separation from debris (Figure 4.11 A-C). FL1-H histograms right shift 
show gain of S. aureus (WT.chr-GFP) fluorescence (Figure 4.11 D-F). TB quenching of GFP 
fluorescence is seen as a decrease in the fluorescence intensity peak and a left shift on the 
FL1-H axis. Little FL1-H left fluorescence shift with an MOI5 of S. aureus (WT.chr-GFP) was 
seen when using the two TB dilutions and incubation times (Figure 4.11D). By contrast, 
when an MOI10 of S. aureus (WT.chr-GFP) (Figure 4.11E) or MOI20 (Figure 4.11F) was used, 
a noticeable left shift fluorescence change is seen. Neutrophil incubation with S. aureus 
(WT.chr-GFP) MOI20 and MOI10 showed the most profound fluorescence quenching when 
TB was used at 1:2 dilution for 15 minutes. For this reason, in future experiments TB was 
used at 1:2 dilution for 15 minutes. 
4.2.12. TB fluorescence quenching technique cannot be used to accurately differentiate 
between internalised and surface attached S. aureus (WT.chr-GFP) when neutrophils are 
incubated with anti-CD151 antibodies 
As previously described, S. aureus neutrophil incubation can result in spontaneous cell lysis 
following phagocytosis. If this were to happen when neutrophils were incubated S. aureus 
(WT.chr-GFP), TB would gain entry in the cells and quench internal bacteria fluorescence 
leading to skewed results. To account for this leakage, ToPro-3 was used as a marker for cell 
lysis (Vanhooijdonk et al., 1994). Media control neutrophils were incubated for 1 hour at 
37°C/ 5%CO2 or 4°C while JC1 isotype control (10µg/ml) or anti-CD151 antibody (10µg/ml) 
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neutrophil incubation was done for 1 hour at 37°C/ 5%CO2. Live S. aureus (WT chr-GFP) 
MOI10 was then added for a further 45 minutes to the cells. TB at 1:2 dilutions for 15 
minutes and ToPro-3 (1:10,000) were added to neutrophils prior to the analysis. FSC/SSC 
dot plots show cell separation from debris (Figure 4.12A-E). FL1-H histogram indicates a left 
shift upon GFP fluorescence quench by TB (Figure 4.12F) while FL4-H histogram indicates a 
right shift upon ToPro-3+ staining of lysed cells (Figure 4.12G). A 4°C neutrophil negative 
control was used, showing a peak in the FL1-H and FL4-H unstained region of the axis (<101). 
At 4°C neutrophils metabolic functions are reduced resulting in impaired phagocytosis 
(Magnusson and Holst, 1998). The FL1-H histogram shows a low, similar mean fluorescence 
intensity (MFI) reduction between equivalent anti-CD151 antibody and control conditions 
when TB is used (Figure 4.12F). Conversely, ToPro-3 positivity indicates a right FL4-H shift in 
all 37°C S. aureus (WT chr-GFP) incubated neutrophil conditions (Figure 4.12G). The results 
obtained therefore indicate that S. aureus (WT chr-GFP) induces cell lysis in all of the 
conditions used, making the use of TB fluorescent quenching technique unsuitable to 
distinguish between neutrophils internalised and surface-bound bacteria in our 
experimental model. 
4.2.13. Optimisation of HK S. aureus staining with Alexa Fluor 647 and pHrodo dyes 
Light microscopy is considered a gold standard technique to count bacteria that interacts 
with neutrophils, however phagocytosed and adherent bacteria cannot be distinguished 
due to sample viewing from one focal point. In vivo work conducted using a zebrafish model 
showed that by co-conjugating S. aureus with pHrodo and Alexa Fluor 647, phagocytosed 
and neutrophil surface adherent S. aureus can distinguish and quantified, making it a 
suitable technique to understand better the role of CD151 in S. aureus interaction with 
neutrophils (Ellett et al., 2015). PHrodo is a pH sensitive dye that only fluoresces in an acidic, 
phagolysosomal environment (3-6 pH) while Alexa Fluor 647 is a highly stable dye, visible 
an acid- alkaline environment (Aziz et al., 2013; Ellett et al., 2015). Additionally, pHrodo (Ex 
-560nm, Em -585nm) and Alexa Fluor 647 (Ex -650nm, Em -665nm) dyes have well separated 
emission spectra, allowing their simultaneous usage. 
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To test this, neutrophils were initially incubated with HK S. aureus MOI10 pre-stained for 
either pHrodo or Alexa Fluor 647, following the published protocol of Ellett et al., 2015. The 
neutrophil cell membrane was then stained using PKH67 cell tracker. Cells were then 
cytocentrifuged and fixed on glass slides. Analysis of fluorescent images show that there 
appears to be a good staining of the HK S. aureus with both dyes (Figure 4.13). However 
bacterial numbers are low with no more than 10 pHrodo or Alexa Fluor 647 stained S. aureus 
per image. This indicates the possibility of bacterial loss during the staining process. 
Thus, the bacteria loss was investigated to determine if it could be reduced by using 1% BSA 
or 1% FBS during the S. aureus dye washing steps by supplementing the washing buffers 
with either of the compounds (Bulard et al., 2012; Ellett et al., 2015). As seen from Figure 
4.14, there is more Alexa Fluor 647 and pHrodo stained HK S. aureus when 1% BSA 
supplemented washing buffers were used when compared to the condition where 1% FBS 
supplemented washing buffers were used. This indicates that by using 1% BSA in the 
washing buffers bacteria yield is increased. As a result, all future S. aureus staining with 
pHrodo were conducted using 1% BSA in the washing buffers. 
4.2.14. Alexa Fluor 647 stained HK S. aureus poor visualisation via fluorescent microscopy 
Following the bacterial staining optimisation process, the effect of anti-CD151 antibody 
usage on neutrophil HK S. aureus internalisation and adhesion was investigated using S. 
aureus co-stained for Alexa Fluor 647 and pHrodo. Neutrophils were pre-incubated for 1h 
with JC1 control or anti-CD151 antibodies at 10µg/ml, followed by a 45 minute incubation 
with HK S. aureus MOI10 stained for both pHrodo (red) and Alexa Fluor 647 (green). The 
well separated emission spectra of the Alexa Fluor 647 and pHrodo dyes makes them 
suitable to be used in conjunction. Alexa Fluor 647 fluorescence will be seen on all bacteria 
regardless of them being phagocytosed or not while pHrodo will fluoresce only in an acidic, 
phagolysosomal environment. Co-staining with the two dies (yellow) would show 
phagocytosed bacteria while adherent/internalised only bacteria will be visualised via the 
Alexa Fluor 647 (green) specific channel. Fluorescent microscopy merge images showed 
that overall there are fewer HK S. aureus present in the presence of anti-CD151 antibodies 
when compared to JC1 control (Figure 4.15). However, there are visibly less Alexa Fluor 647 
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stained HK S. aureus when compared to the pHrodo stained bacteria (Figure 4.15). This 
indicates that probably the Alexa Fluor 647 staining of HK S. aureus is not uniformly 
distributed on all bacteria. 
To test for this, unstained (Figure 4.16A) or stained bacteria for both pHrodo and Alexa Fluor 
647 dyes (Figure 4.16B) were run through the LSRII flow machine. The Blue 610/20 
histogram shows a small right shift in pHrodo+ fluorescence while the Red 660/20 histogram 
shows a prominent right shift in Alexa Fluor 647+ fluorescence, indicative of a uniform 
staining of the HK S. aureus cells with the Alexa Fluor 647 dye. This indicates the possibility 
of other factors being involved which do not allow visualisation of Alexa Fluor 647 stained 
bacterial cells using fluorescent microscopy. Due to this consideration, further fluorescent 
microscopy experiments were conducted using only the pHrodo stain. 
4.2.15. Significant inhibition of neutrophil phagocytosis of live S. aureus but not of HK S. 
aureus in the presence of anti-CD151 antibodies, as shown by fluorescent microscopy 
PHrodo stained S. aureus was used to probe if there is less phagocytosed S. aureus in the 
presence of anti-CD151 antibody when compared to JC1 control. Freshly isolated 
neutrophils were incubated for 1 hour with media, JC1 isotype control (10µg/ml) or anti-
CD151 antibodies (10µg/ml), followed by a 30 minutes incubation with pHrodo pre-stained 
live S. aureus MOI5 (Figure 4.17 and Figure 4.19A) or by by a 45 minute incubation with 
pHrodo pre-stained HK S. aureus MOI10 (Figure 4.18 and Figure 4.19B). The neutrophil cell 
membrane was then stained with PKH67 cell tracker dye. Fluorescent microscopy images 
showed that in the presence of anti-CD151 antibodies there appears to be less pHrodo 
stained live S. aureus in neutrophils compared to the controls (Figure 4.17) but similar 
pHrodo stained HK S. aureus levels in neutrophils from the controls or incubated with anti-
CD151 antibodies (Figure 4.18). Quantification of the images, using Fiji program with an 
algorithm designed by Dr. Darren Robinson, showed similar results with significant less 
pHrodo stained live S. aureus with anti-CD151 antibodies compared to the controls (Figure 
4.19A) but with visible but not significant difference in HK S. aureus levels between anti-
CD151 antibody incubated neutrophils and JC1 control (Figure 4.19B). 
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Figure 4.11: Effect of TB fluorescence quenching on different MOI of live S. aureus (WT 
chr-GFP). 
Plasma/Percoll isolated neutrophils from venous blood of healthy volunteers were 
incubated with live S. aureus (WT chr-GFP) at MOI 5, 10 or 20 for 45 minutes. The cells were 
then incubated with TB at either 1/4 or 1/2 dilutions for 1 minute or 15 minutes. A-C) 
FSC/SSC dot plot of neutrophils incubated with MOI5 (A), MOI10 (B) or MOI20 (C) of live S. 
aureus (WT chr-GFP), separated from debris. D-F) FL1-H histograms of neutrophils 
incubated with MOI5 (D), MOI10 (E) or MOI20 (F) of S. aureus (WT chr-GFP), representing 
GFP+ FL1-H right shift in fluorescence: red- neutrophil+ S. aureus (WT chr-GFP), blue- 
neutrophil+ S. aureus (WT chr-GFP)+ 1/4TB for 1 minute, orange- neutrophil+ S. aureus (WT 
- 150 - 
 
chr-GFP)+1/4 TB for 15 minutes, light green- neutrophil+ S. aureus (WT chr-GFP)+1/2 TB for 
1 minute, dark green- neutrophil+ S. aureus (WT chr-GFP)+1/2 TB for 15 minutes. Black 
segmented line delimitation between unstained and stained peaks. Data obtained from 
single experiment. 
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Figure 4.12: Anti-CD151 antibodies effect on S. aureus (WT chr-GFP) fluorescence 
quenching by TB. 
Plasma/Percoll isolated neutrophils from venous blood of healthy volunteers were 
incubated for 1 hour with media at 37°C/ 5%CO2 or 4°C or with JC1 isotype control (10µg/ml) 
or anti-CD151 antibodies (10µg/ml) at 37°C/ 5%CO2. Live S. aureus (WT chr-GFP) at MOI10 
was then added to the cells for a further 45 minutes. Cells were stained with TB at 1/2 
dilutions for 15 minutes and ToPro-3 just before analysis. A-E) FSC/SSC dot plots of: 
neutrophils only (A), neutrophil+ S. aureus (WT chr-GFP) 4°C (B) neutrophil+ S. aureus (WT 
chr-GFP) 37°C/ 5%CO2 (C), neutrophil+ S. aureus (WT chr-GFP) + JC1 37°C/ 5%CO2 (D), 
- 152 - 
 
neutrophil+ S. aureus (WT chr-GFP)+anti-CD151 antibodies 37°C/ 5%CO2 (E). F-G) FL1-H and 
FL4-H histogram representative of right shift on GFP+ FL1-H fluorescence (F) or ToPro-3+ 
FL4-H fluorescence (G) of neutrophils incubated with S. aureus (WT chr-GFP): 
F) red- neutrophils  , light blue- neutrophil+S. aureus (WT chr-GFP) 4°C, orange- neutrophil+ 
S. aureus (WT chr-GFP) 4°C + TB, light green- neutrophil+ S. aureus (WT chr-GFP) 37°C/ 
5%CO2, dark green- neutrophil+ S. aureus (WT chr-GFP) 37°C/ 5%CO2+ TB, light purple- 
neutrophil+ S. aureus (WT chr-GFP) + JC1 37°C/ 5%CO2, dark purple- neutrophil+ S. aureus 
(WT chr-GFP) + JC1 37°C/ 5%CO2+ TB, dark blue- neutrophil+ S. aureus (WT chr-GFP) +anti-
CD151 antibodies 37°C/ 5%CO2, yellow- neutrophil+ S. aureus (WT chr-GFP) +anti-CD151 
antibodies 37°C/ 5%CO2+ TB. 
G)red- neutrophils + ToPro-3, light blue- neutrophil+S. aureus (WT chr-GFP) 4°C, orange- 
neutrophil+ S. aureus (WT chr-GFP) 4°C + ToPro-3, light green- neutrophil+ S. aureus (WT 
chr-GFP) 37°C/ 5%CO2, dark green- neutrophil+ S. aureus (WT chr-GFP) 37°C/ 5%CO2+ 
ToPro-3, light purple- neutrophil+ S. aureus (WT chr-GFP) + JC1 37°C/ 5%CO2, dark purple- 
neutrophil+ S. aureus (WT chr-GFP) + JC1 37°C/ 5%CO2+ ToPro-3, dark blue- neutrophil+ S. 
aureus (WT chr-GFP) +anti-CD151 antibodies 37°C/ 5%CO2, yellow- neutrophil+ S. aureus 
(WT chr-GFP) +anti-CD151 antibodies 37°C/ 5%CO2+ ToPro-3. 
Data obtained from single experiment. 
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Figure 4.13: Visualisation of neutrophils incubated with HK S. aureus stained with Alexa 
Fluor 647 and pHrodo 
Freshly isolated neutrophils were incubated for 45 minutes with Alexa Fluor 647 or pHrodo 
stained HK S. aureus MOI10 followed by neutrophil membrane staining with PKH67 cell 
tracker. The cells were then fixed on glass slides using 4% paraformaldehyde and nucleus 
stained for DAPI. The slides were then imaged using Olympus upright epifluorescence 
system with 100x oil immersion. Photomicrographs of infected and non-infected cells: 
Nucleus- blue; neutrophil membrane- green; Alexa Fluor 647 HK S. aureus - magenta; red 
pHrodo HK S. aureus -red. Data obtained from single experiment. Images were adjusted to 
reduce blurriness and enhance contrast using Fiji program. 
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A .
B .
 Figure 4.16: HK S. aureus staining with Alexa Fluor 647 and pHrodo. 
Unstained (A) or co-stained HK S. aureus for Alexa Fluor647 and red pHrodo (B) were 
analysed using the LSRII flow cytometer. FSC/SSC dot plot of HK S. aureus log scale. Blue 
610/20-A histogram is indicative of a right shift in pHrodo+ cells while the Red660/20-A 
histogram indicates a right shift in Alexa Fluor 647+ cells. Data obtained from single 
experiment. 
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Figure 4.17: The use of anti-CD151 antibodies results in less pHrodo stained live S. aureus 
in neutrophils. 
Live S. aureus was stained with pHrodo using washing buffers containing 1% BSA. Freshly 
isolated neutrophils were incubated for 1 hour with media, JC1 isotype control (10µg/ml) 
or anti-CD151 antibodies (10µg/ml), followed by a 30 minute-incubation with pHrodo 
stained live S. aureus MOI5. Neutrophil membrane was stained for PKH67 cell tracker 
followed by centrifugation, neutrophil fixing on glass slides using 4% paraformaldehyde and 
nucleus staining for DAPI. The cells were then imaged using the Olympus upright 
epifluorescence system with 60x oil immersion. Photomicrographs of infected and non-
infected cells: Nucleus- blue; neutrophil membrane- green; pHrodo live S. aureus -red. Data 
representative of 4 independent experiments. Images were adjusted to reduce blurriness 
and enhance contrast using Fiji program. 
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Figure 4.18: The use of anti-CD151 antibodies does not show less pHrodo stained HK S. 
aureus in neutrophils. 
HK S. aureus was stained with pHrodo using washing buffers containing 1%BSA. Freshly 
isolated neutrophils were incubated for 1 hour with media, JC1 isotype control (10µg/ml) 
or anti-CD151 antibodies (10µg/ml), followed by a 30 minute incubation with pHrodo 
stained HK S. aureus MOI10. Neutrophil membrane was stained for PKH67 cell tracker 
followed by centrifugation, neutrophil fixing on glass slides using 4% paraformaldehyde and 
nucleus staining for DAPI. The cells were then imaged using the Olympus upright 
epifluorescence system with 60x oil immersion: nucleus- blue; neutrophil membrane- 
green; pHrodo live S. aureus -red. Data representative of 4 independent experiments. 
Images were adjusted to reduce blurriness and enhance contrast using Fiji program. 
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Figure 4.19: Anti-CD151 antibodies significantly inhibit neutrophil interaction with 
pHrodo stained live S. aureus but not with HK S. aureus. 
Plasma/Percoll purified neutrophils from venous blood of healthy volunteers were 
incubated for 1 hour with media, JC1 isotype control or anti-CD151 antibodies at 10µg/ml, 
followed by a 30 minute incubation with live pHrodo pre-stained S. aureus at MOI5 (A) or 
by a 45 minute incubation with pHrodo pre-stained HK S. aureus at MOI10. Neutrophil 
interaction with pHrodo stained S. aureus was visualised using upright epifluorescence 
microscope. Data was assessed using Fiji program with the algorithm designed by Dr. Darren 
Robinson to count the bacteria. Data from 4 independent donors is expressed as mean±SD. 
Statistical analysis carried out by one-way ANOVA with Bonferroni's post-test with repeated 
measures (**p<0.01, ns-nonsignificant). 
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4.2.16. Anti-CD151 antibodies promote significantly less internalisation of live S. aureus 
by neutrophils 
Another technique that can differentiate between adherent and internalised bacteria is the 
gentamicin protection assay and this was used to understand better S. aureus- neutrophil 
interaction in the presence of anti-CD151 antibodies (Vaudaux and Waldvogel, 1979). 
Neutrophils were incubated for 1 hour with JC1 isotype control (10µg/ml) or anti-CD151 
antibodies (10µg/ml) followed by a 45 minute incubation with live S. aureus at MOI5. The 
extracellular and cell surface bacteria were then killed using gentamicin followed by cell 
lysis for estimation of the intracellular CFU. Results show that S. aureus internalisation by 
neutrophils was significantly inhibited with anti-CD151 antibodies when compared to JC1 
control (Figure 4.20), supporting further the hypothesis that CD151 plays a role in 
neutrophil interaction with S. aureus. 
4.2.17. The use of anti-CD151 antibodies results in inability of neutrophils to internalise 
and kill live S. aureus 
S. aureus internalisation and killing by neutrophils is often a fast process (Lu et al., 2014; 
Nielsen et al., 1995). To understand this process further when using anti-CD151 antibodies, 
a later time point was included in the gentamicin protection assay. Neutrophils were 
incubated for 1 hour with JC1 isotype control (10µg/ml) or anti-CD151 antibodies (10µg/ml) 
followed by a 45 minute incubation with live S. aureus at MOI5. Extracellular and cell 
adherent bacteria were killed with gentamicin for 30 minutes and then cultures were either 
lysed or incubated for a further 75 minutes in media containing gentamicin, before 
neutrophil lysis for estimation of the intracellular CFU. Cytospins were also made 45 
minutes post S. aureus addition and after the extracellular and cell adherent bacteria were 
killed. There is significantly less S. aureus with JC1 control condition at second time point 
compared to the first one indicating intracellular killing of S. aureus over time (Figure 4.21A). 
By contrast, the CFU/ml in the anti-CD151 antibody condition showed an inconsistent, 
nonsignificant trend between the two time points, indicating a possible donor dependent 
killing of S. aureus over time in the presence of anti-CD151 antibody (Figure 4.21B). In 
addition, while significantly less S. aureus was seen at 75 minutes with anti-CD151 
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antibodies when compared to JC1 control, after 120 minutes there were similar viable S. 
aureus rates in the JC1 control and anti-CD151 antibody incubated neutrophils (Figure 
4.21C). Phagocytic index count showed significantly less S. aureus in anti-CD151 incubated 
cells when compared to JC1 control after 45 minutes and with similar JC1 and anti-CD151 
antibody PI 75 minutes post incubation (Figure 4.21D).  
4.2.18. Anti-CD151 antibodies do not inhibit live NTHi internalisation by neutrophils 
Only Gram positive bacteria have been used to this point to understand CD151 involvement 
in respiratory pathogenic bacteria-neutrophil interactions. As a result, the respiratory Gram 
negative pathogen NTHi, which often promotes exacerbation and COPD progression, was 
further used to study CD151 function in neutrophil-bacteria interactions (Eldika and Sethi, 
2006; Patel et al., 2002). Neutrophils were incubated for 1 hour with media, JC1 isotype 
control (10µg/ml) or anti-CD151 antibody (10µg/ml) followed by 1 hour incubation with live 
NTHi MOI10. Extracellular and cell adherent bacteria were killed using gentamicin before 
neutrophils were lysed for intracellular CFU estimation. Light microscopy could not be 
conducted to determine the phagocytic index, because of the small size of NTHi. No 
significant NTHi internalisation differences were seen between JC1 and anti-CD151 
antibody incubated neutrophils (Figure 4.22). 
4.2.19. Anti-CD151 antibodies effect on MDMs internalisation and killing of S. aureus 
Macrophages are professional phagocytes that can engulf S. aureus, however their ability 
to completely kill the bacteria is low and poorly understood (Jubrail et al., 2016). 
Considering that CD151 appears to play a role in S. aureus phagocytosis by neutrophils, I 
hypothesised that the tetraspanin also plays a role in macrophage phagocytosis of S. aureus. 
To test this, MDMs differentiated for 14 days were incubated for 1 hour with JC1 isotype 
control (10µg/ml) or anti-CD151 antibodies (10µg/ml). The cells were then incubated with 
live S. aureus for 1 hour on ice followed by a further 1 hour at 37°C/ 5%CO2. The extracellular 
and cell adherent bacteria were killed with gentamicin for 30 minutes followed by cell lysis 
(2h time point on the graph) or maintained in low gentamicin dose for a further 1.5 hours 
(4h time point on the graph). MDMs lysis was then conducted for intracellular CFU 
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estimation. There is no significant change at 2 hours between anti-CD151 antibody 
incubated MDMs and media or JC1 controls (Figure 4.23A). In the JC1 control, there is 
significantly less S. aureus at 4 hours compared to the 2 hour-time point (Figure 4.23B). By 
contrast, no significant changes were seen between the two time points when anti-CD151 
antibody was used (Figure 4.23C). Furthermore, the variation in MDMs donor response with 
anti-CD151 antibody indicates a possible donor specific response when the antibody is used. 
The data is, however, insufficient to conclude if CD151 has a role in MDMs internalisation 
and killing of S. aureus.  
4.2.20. CD151 is expressed at protein level in neutrophils 
Considering that there is some debate in the literature about CD151 expression by 
neutrophils with one study saying that neutrophils do not express CD151 while another 
showing low expression of the tetraspanin in neutrophils (Sincock et al., 1997; Tohami et 
al., 2004), CD151 expression at the neutrophil protein level was explored. Neutrophil whole 
cell lysates from 3 independent donors were subjected to SDS-PAGE and immunostained 
with the anti-CD151 antibody. The staining confirmed CD151 expression in all 3 donors at 
the expected band of 30-32kDa (Figure 4.24.), indicating CD151 presence in neutrophils. 
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Figure 4.20: Anti-CD151 antibodies inhibit neutrophil internalisation of live S. aureus. 
Freshly isolated neutrophils from venous blood of healthy volunteers via plasma/Percoll 
centrifugation were incubated for 1 hour with JC1 isotype control (10µg/ml) or anti-CD151 
antibodies (10µg/ml) followed by a 45 minute incubation with live S. aureus at MOI5. 
Following gentamicin killing of extracellular and cell adherent bacteria, neutrophils were 
lysed for intracellular CFU estimation. Data obtained from 7 independent donors. Statistical 
analysis carried out by paired t-test (*p<0.05). 
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Figure 4.21: Anti-CD151 antibodies effect on neutrophil internalisation and killing of S. 
aureus. 
Freshly isolated neutrophils from healthy volunteers via plasma/Percoll centrifugation were 
incubated for 1 hour with JC1 isotype control (10µg/ml) or anti-CD151 antibodies (10µg/ml) 
followed by 45 minute incubation with live S. aureus at MOI5. (A-C) Extracellular and cell 
adherent bacteria were killed with gentamicin for 30 minutes (75 minutes on the graph)and 
then cultures were either lysed or incubated for a further 75 minutes (120 minutes on the 
graph) in media containing gentamicin, before neutrophil lysis for estimation of the 
intracellular CFU. D) Light microscopy cytospins count 45 minutes post S. aureus addition 
and after the extracellular bacteria was killed (75 minutes on the graph). A-D) Data from 6 
independent donors is expressed as Mean±SD. A-B) Statistical analysis carried out by paired 
t-test on JC1 incubated neutrophils (A) and anti-CD151 incubated neutrophils (B).C-D) 
Statistical analysis carried out by one-way ANOVA with Bonferroni's post-test with repeated 
measures (*p<0.5, ***p<0.001).  
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Figure 4.22: The effect of anti-CD151 antibodies on neutrophil internalisation of live NTHi. 
Freshly isolated neutrophils from healthy volunteers via plasma/Percoll centrifugation were 
incubated for 1 hour with media, JC1 isotype control (10µg/ml) or anti-CD151 antibodies 
(10µg/ml) followed by 1 hour incubation with live NTHi MOI10. Extracellular and cell 
adherent bacteria were killed with gentamicin followed by cell lysis for intracellular CFU 
estimation. Data from 5 independent donors is expressed as mean±SD. Statistical analysis 
carried out by one-way ANOVA with Bonferroni's post-test with repeated measures. 
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Figure 4.23: Anti-CD151 antibodies effect on MDMs internalisation of live S. aureus. 
A-C) Freshly isolated PBMCs from healthy volunteers via plasma/Percoll centrifugation were 
differentiated into MDMs for 2 weeks. On the 14th day the cells were incubated for 1 hour 
with media, JC1 isotype control (10µg/ml) or anti-CD151 antibodies (10µg/ml). The cell 
were subsequently incubated with live S. aureus MOI5 for 1 hour on ice followed by a 
further one hour incubation at 37°C/ 5%CO2. The extracellular and cell adherent bacteria 
were then killed using gentamicin for 30 minutes followed by cell lysis (2h time point on the 
B-C graphs) or by a further 1.5 MDM maintenance in low gentamicin dose (4h time point on 
the B-C graphs). MDMs lysis was then conducted for intracellular CFU estimation. A-C) Data 
from 4 independent donors is expressed as mean±SD. A) Statistical analysis carried out by 
one-way ANOVA with Bonferroni's post-test with repeated measures. B-C) Statistical 
analysis carried out by paired t-test on JC1 incubated MDMs (B) and anti-CD151 antibody 
incubated MDMs (C) (*p<0.5). 
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Figure 4.24: CD151 protein expression by neutrophils. 
Whole cell lysates from freshly isolated neutrophils from three donors were run on 12% 
SDS-PAGE gel. Protein extracted from 2X106 neutrophils of each donor was loaded on each 
lane and probed for CD151 (1:600). CD151 expression is seen at 30-32kDa. Red line 
represents the expected molecular weight of CD151. 
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4.2.21. Quantification of CD151 expression on neutrophil surface cannot be accurately 
done 
CD151 is mainly expressed on neutrophil surface as well as cytoplasmic compartments 
(Baldwin et al., 2008; Berditchevski et al., 2001). Considering the changes in neutrophil 
interaction with S. aureus in the presence of anti-CD151 antibodies, I speculated that these 
changes are due to CD151 recruitment to cell surface upon infection. To investigate this, 
neutrophils were incubated for 15 minutes with media or HK S. aureus at MOI10. The Fc cell 
surface receptors were then blocked for 15 minutes with 10% goat serum. The cells were 
then stained with primary JC1 isotype control or anti-CD151 antibodies at 10µg/ml for 20 
minutes followed by a further 20 minute incubation with a similar amount of FITC labelled 
secondary anti-mouse IgG antibody. Unstained and secondary only antibody negative and 
positive controls were used. FSC/SSC dot plots showed a right and upwards shift of 
neutrophils in the presence of HK S. aureus, indicative of neutrophil activation and 
interaction with the bacteria (Figure 4.25A). FL1-H histogram indicates right fluorescence 
shift upon FITC labelling. The right shift in the FITC+ FL1-H florescence for infected and 
noninfected cells is decreased in anti-CD151 antibody incubated neutrophils when 
compared to their equivalent JC1 controls (Figure 4.25B). A secondary antibody only right 
shift in FITC+ FL1-H florescence is also seen, indicative of secondary antibody nonspecific 
binding (Figure 4.25B). 
To eliminate the background noise due to binding of the secondary antibody, the above 
experiment was repeated using JC1 isotype control and anti-CD151 antibodies (10µg/ml) 
that were conjugated with Alexa Fluor 488. FSC/SSC dot plots show a right and upwards 
shift of neutrophils in the presence of HK S. aureus, indicative of neutrophil activation and 
interaction with the bacteria (Figure 4.26A). FL1-H histogram showed a similar right shift in 
the Alexa Fluor488+ FL1-H florescence in infected or noninfected neutrophils when 
incubated with anti-CD151 antibody or JC1 control (Figure 4.26B). The small fluorescence 
peak in all conditions indicates the possibility that the antibodies have failed to properly 
stain. 
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As a consequence, investigation of conjugation potency between CD151 antibody and Alexa 
Fluor 488 dye was done using HEC-1-B epithelial cell line. This line stably expresses high 
levels of CD151 on the cell surface(Green et al., 2011). HEC-1-B were blocked for 15 minutes 
with 10% goat serum. The cells were then incubated on ice with Alexa Fluor 488 JC1 isotype 
control, non-conjugated anti-CD151 antibodies, Alexa Fluor 488 anti-CD151 antibodies at 
10µg/ml or 5µl of commercially available APC isotype and anti-CD151 antibodies for 30 
minutes. The cells incubated with non-conjugated anti-CD151 antibodies were incubated 
further for 30 minute on ice with the same amount, to the primary antibody, of FITC labelled 
secondary anti-mouse IgG antibody. The commercially available APC antibodies were used 
as positive controls. FSC/SSC dot plots shows HEC-1-B separation from debris (Figure 4.27A). 
FL1-H histogram right shift indicates Alexa Fluor 488 and FITC gain of fluorescence (Figure 
4.27B). Only a slight, right shift in Alexa Fluor 488+ FL1-H fluorescence can be seen with the 
Alexa Fluor 488 pre-stained anti-CD151 antibody when compared to the more prominent 
right shift in FITC+ FL-1 fluorescence of cell incubated with primary anti-CD151 followed by 
FITC labelled secondary antibodies (Figure 4.27B). FITC labelled secondary antibodies 
produced no nonspecific binding in HEC-1-B cells. The results therefore indicate poor 
labelling of the anti-CD151 antibody with Alexa Fluor 488. FL4-H histogram shows a slight 
right shift in APC+ fluorescence with anti-CD151 antibody when compared to the isotype 
control (Figure 4.27C). A high APC fluorescence right shift is however seen with the isotype. 
Considering that the APC labelled commercially available antibodies give a better binding 
signal and there is no need for secondary antibody that could result in nonspecific binding, 
CD151 externalisation in infected and noninfected neutrophils was investigated further 
using these antibodies. Neutrophils were incubated for 15 minutes with media or HK S. 
aureus at MOI10 followed by a 30 minute incubation with commercially available, 
conjugated APC isotype control or anti-CD151 antibodies at 10µg/ml. FSC/SSC dot plots 
show a right and upwards shift of neutrophils in the presence of HK S. aureus, indicative of 
neutrophil activation and interaction with S. aureus. (Figure 4.28A). FL4-H histogram shows 
a bigger, right shift in APC+ fluorescence with the isotype control conditions when compared 
to the equivalent anti-CD151 incubated cells (Figure 4.28B). This section failed to accurately 
quantify CD151 expression on neutrophil surface.  
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4.2.22. Investigation of PI4-K type II protein expression in neutrophils incubated with 
different S. aureus MOI and time points  
CD151 was shown to have a strong interaction with the 55kDa PI4-K type II protein (Yauch 
and Hemler, 2000). PI4-K type II forms a stable complex with α3β1 and CD151 to promote 
cell migration in epithelial cell lines (Yauch et al., 1998). PI4-K type II is involved in PtdIns(4)P 
synthesis, a precursor of the phagosome shaping lipids PtdIns(4,5)P2, PtdIns(3,4,5)P3 and 
Ins(3,4,5)P3, but it also has an important role in endosome and vesicle trafficking due to its 
AP-3 sorting motif (Craige et al., 2008; Wang et al., 2007). These data suggest that CD151 
may promote a PI4-K type II dependent neutrophil interaction with S. aureus, that could 
result in uptake of the bacteria via phagolysosome cup formation or via its trafficking inside 
the cell via the PI4-K type II AP-3 sorting motif. To investigate this, neutrophils were 
incubated with HK S. aureus at MOI 20 for 15, 30, 60, 120, 180 or 240 minutes (Figure 4.29A). 
Neutrophils were also incubated with HK S. aureus at MOI 2.5, 5, 10, 20 and opsonised HK 
S. pneumoniae at MOI 10, 20, 40 for 2 hours (Figure 4.29B). S. aureus and PLB-985 were 
used as controls. Neutrophil, S. aureus and PLB-985 whole cell lysates were subjected to 
SDS-PAGE and immunostained with the anti-PI4-K type II antibody. PLB-985 cells present a 
band at 55kDa, indicative of PI4-K type II protein expression (Figure 4.29A). The various 
incubation time points and MOI of neutrophils with HK S. aureus present consistent, 
multiple bands ranging from 45-75kDa (Figure 4.29A, B). Clear bands can be seen when an 
MOI2.5 of HK S. aureus WT is used, showing binding of the antibody at about 38, 52 and 
60kDa but not at 55kDa (Figure 4. 29B). Neutrophil HK S. pneumoniae incubation, on the 
other hand, showed no bands on the blot when probed for PI4-K type II (Figure 4.29B). 
Phagocytic index numbers under each lane show, however, variation in S. aureus numbers. 
A single band at 35kDa is seen in the neutrophil only lane. Unphosphorylated p38 control 
shows similar protein loading amounts for neutrophils incubates with S. aureus and more 
in neutrophil only lane and neutrophils with HK S. pneumoniae. Antibodies used for 
interrogating PI4-K type II expression in the two blots were purchased from different 
companies, both showing high amounts of non-specific binding. 
- 175 - 
 
4.2.23. PI4-K type II expression cannot be confirmed in neutrophils when using different 
strains of HK S. aureus 
Looking at the section above, most of the non-specific PI4-K type II binding pattern appears 
to be due to HK S. aureus proteins. As a consequence, a HK S. aureus protein A (SpA) mutant 
was used to try to reduce some of the non-specific binding. This mutant was chosen since 
protein A is one of the most abundant proteins S. aureus produces (Forsgren and 
Nordstro.K, 1974). Neutrophils were incubated with HK S. aureus WT or SpA at MOI 10 or 
20 for 2 hours (Figure 4.30A). The effect of anti-CD151 antibodies on PI4-K type II expression 
in neutrophils incubated with Spa was also probed by pre-incubating for 1 hour the 
neutrophils with JC1 isotype control or anti-CD151 antibodies at 10µg/ml followed by a 2 
hour incubation with HK S. aureus SpaA or HK S. pneumoniae or beads at MOI10 (Figure 
4.30B). Neutrophil and S. aureus whole cell lysates were subjected to SDS-PAGE and 
immunostained with the anti-PI4K type II antibody. Figure 4.30A shows non-specific binding 
with HK S. aureus WT from 23-80kDa while with SpA mutant the non-specific binding is seen 
from 45-80kDa. A similar band pattern is seen with the anti-CD151 antibodies when 
neutrophils are incubated with S. aureus but no bands are seen in the presence of S. 
pneumoniae or beads (Figure 4.30B). Phagocytic index numbers indicate good neutrophil S. 
aureus interaction rates but due to lack of unphosphorylated p38 control, even protein load 
between conditions could not be confirmed (Figure 4.30A). In Figure 4.30B there appears 
to be overall less protein expressed in JC1 control incubated neutrophils with SpA compared 
to anti-CD151 incubated cells and media control. However unphosphorylated p38 protein 
loading control confirms less protein loading in that lane compared to the others. PI4-K type 
II probing indicates that although less bands are seen with neutrophils incubated with SpA 
mutant, the non-specific binding in the 55kDa region is not eliminated making it hard to 
distinguish the protein expression changes between conditions. 
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Figure 4.25: Flow cytometry analysis of CD151 expression on neutrophil surface. 
Neutrophils were incubated for 15 minutes with media or HK S. aureus at MOI10. The cells 
were blocked for 15 minutes with 10% goat serum. Neutrophils were then stained with 
primary JC1 isotype control or anti-CD151 antibodies at 10µg/ml for 20 minutes followed 
by a further 20 minute incubation with an equivalent amount of FITC labelled secondary 
anti-mouse IgG antibodies. Unstained and secondary antibody only were used as negative 
controls. A) FSC/SSC dot plot of neutrophils under different conditions with the 
delimitations from contaminating cells and debris. B) FL1-H histogram indicative of a right 
shift in FITC+ FL1-H fluorescence of neutrophils under different conditions: red-unstained 
neutrophils, blue-neutrophils+ secondary antibodies only, orange- neutrophils+ JC1 isotype 
control, light green-neutrophils+ HK S. aureus+ JC1 isotype control, dark green- neutrophils+ 
anti-CD151 antibodies, purple- neutrophils+ HK S. aureus+ anti-CD151 antibodies. Data 
obtained from single experiment. 
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Figure 4.26: Flow cytometry analysis of CD151 expression on the surface of neutrophils 
using Alexa Fluor 488 conjugated anti-CD151 antibodies. 
Neutrophils were incubated for 15 minutes with media or HK S. aureus at MOI10. The cells 
were then stained with conjugated Alexa Fluor 488 JC1 isotype control or anti-CD151 
antibodies at 10µg/ml for 30 minutes. Unstained neutrophils were used as negative control. 
A) FSC/SSC dot plot of neutrophils under different conditions with the delimitations from 
contaminating cells. B) FL1-H histogram with a right shift in Alexa Fluor 488+ FL1-H 
fluorescence of neutrophils under different conditions: red-unstained neutrophils, blue-
neutrophils+ JC1 isotype control, orange- neutrophils+ HK S. aureus+ JC1 isotype control, 
green- neutrophils+ anti-CD151 antibodies, purple- neutrophils+ HK S. aureus+ anti-CD151 
antibodies. Data obtained from single experiment. 
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Figure 4.27: Flow cytometry analysis of CD151 expression on the surface of HEC-1-B using 
different anti-CD151 antibodies. 
HEC-1-B cells were blocked for 15 minutes with 10% goat serum. A 30-minute incubation 
was then conducted with Alexa Fluor 488 JC1 isotype control, unstained anti-CD151 
antibodies, Alexa Fluor 488 anti-CD151 antibodies at 10µg/ml or 5µl APC isotype and APC 
anti-CD151 antibodies. A further 30 minute incubation with FITC labelled secondary anti-
mouse IgG antibodies was conducted where unstained anti-CD151 antibodies were used. 
A) FSC/SSC dot plot of HEC-1-B cells under different conditions with the delimitations from 
contaminating cells. B) FL1-H histogram of right shift in FITC/Alexa Fluor 488+ FL1-H 
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fluorescence: red-unstained HEC-1-B, blue-secondary FITC-labeled antibodies only stained 
HEC-1-B, orange- anti-CD151 antibodies+ secondary FITC labeled antibodies HEC-1-B, light 
green- Alexa Fluor 488 prestained JC1 isotype, dark green- Alexa Fluor 488 prestained anti-
CD151 antibodies. C) FL4-H histogram of right shift in APC+ FL4-H fluorescence C) red-
unstained HEC-1-B, blue-APC prestained isotype, orange- APC prestained anti-CD151 
antibodies. Data obtained from single experiment. 
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Figure 4.28: Flow cytometry analysis of CD151 neutrophil surface expression using 
commercially available conjugated anti-CD151 antibodies. 
Neutrophils were incubated for 15 minutes with media or HK S. aureus at MOI10. A further 
30-minute incubation was done with 5µl of commercially available, conjugated APC isotype 
control or anti-CD151 antibodies. Unstained neutrophils were used as negative control. A) 
FSC/SSC dot plot of neutrophils under different conditions B.) FL4-H histogram indicating 
right shift in APC+ FL4-H fluorescence of neutrophils under different conditions: red-
unstained neutrophils, blue-neutrophils+ JC1 isotype control, orange- neutrophils+ HK S. 
aureus+ JC1 isotype control, light green- neutrophils+ anti-CD151 antibodies, dark green- 
neutrophils+ HK S. aureus+ anti-CD151 antibodies. Data representative of three 
experiments. 
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Figure 4.29: Determination of PI4-K type II protein expression in neutrophils incubated 
with HK S. aureus WT. 
Neutrophils were incubated with HK S. aureus WT at MOI 20 for 15min, 30 min, 1 hour, 2 
hours, 3 hours or 4 hours (A) or with HK S. aureus WT at MOI 2.5, 5, 10, 20 or opsonised S. 
pneumoniae at MOI 10, 20, 40 for 2 hours (B). Whole cell lysates from neutrophils incubated 
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as above, HK S. aureus WT (MOI20) or PLB-985 (gifted by Dr. Pranvera Sadiku) were run on 
12% SDS-PAGE gel. Protein extracted from 2X106 neutrophils, 40x106 HK S. aureus WT and 
1x106 PLB-985 were loaded on each lane and probed for PI4-K type II (1:600). HK S. aureus 
WT lysed cells were used as control. Blot (A) was probed with a Sigma antibody while blot 
(B) was probed with an Abcam antibody. The Colorplus prestained protein ladder was used 
for the 2 blots. Red arrow is indicative of the expected 55kDa molecular weight of PI4-K type 
II in neutrophils. Probing for unphosphorylated p38 (1:2000) was used as control for even 
protein load. Where available, the phagocytic index from light microscopy analysed 
cytospins was indicated under the blots. Blots obtained from single experiments. 
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Figure 4.30: Determination of PI4-K type II protein expression in neutrophils incubated 
with HK S. aureus SpA. 
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Neutrophils were incubated with HK S. aureus WT or SpA at MOI10 or 20 for 2 hours (A) or 
pre-incubated for 1 hour with JC1 isotype control or anti-CD151 antibodies at 10µg/ml 
followed by a 2 hour incubation with HK S. aureus SpA or S. pneumoniae at MOI20 or the 
equivalent to the bacteria MOI20 of beads (B.). Whole cell lysates extracted from 2X106 
neutrophils, 40x106 HK S. aureus WT or SpA were loaded on each lane on a 12% SDS-PAGE 
gel and probed for PI4-K type II (1:600). HK S. aureus WT or SpA mutant lysed cells were 
used as controls. Blot (A) was probed with Abcam antibody and the prestained Colorplus 
protein ladder was used while blot (B.) was probed with an Abgent antibody and the 
Geneflow prestained protein ladder was used. The red arrow indicates the expected 55kDa 
molecular weight of PI4-K type II in neutrophils. Probing for p38 (1:2000) was used as 
control for even protein load. Where available, phagocytic index obtained from each 
condition by light microscopy was indicated underneath. Blots obtained from single 
experiments. 
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4.2.24. Anti-CD151 antibodies do not significantly inhibit interaction of neutrophils with 
SRCO11 and SRCO12 S. aureus mutants 
CD151 is known to interact with β1 integrins, proteins involved in the binding of the 
extracellular matrix protein-fibronectin (Jonsson et al., 1991; Yauch et al., 2000). This 
protein is regularly used by S. aureus to adhere to cells (Jonsson et al., 1991; Piroth et al., 
2008). Considering this, I propose that CD151 modulates neutrophil interaction with S. 
aureus by supporting the formation of a putative CD151-integrin-fibronectin complex to 
facilitate S. aureus adhesion to neutrophils. To test this, two fibronectin binding mutants, 
SRCO11 and SRCO12 on the S. aureus WT background were used (See Section 2.4.1. for 
details on the strains). Neutrophils were incubated for 1 hour with media, JC1 isotype 
control or anti-CD151 antibodies at 10µg/ml followed by a 45 minute incubation with S. 
aureus WT or the fibronectin mutants SRCO11 and SRCO12 at MOI 5. Statistical analysis of 
the data showed that there is significant reduction of neutrophil interaction with S. aureus 
WT in the presence of anti-CD151 antibodies (Figure 4.31). Although there is reduction in 
neutrophil interaction with SRCO11 and SRCO12 mutants in the presence of anti-CD151 
antibodies, this reduction is not significant. 
4.2.25. Effect of anti-CD151 and anti-β1 antibodies on neutrophil interaction with S. 
aureus 
As previously presented, a very stable interaction is known to be formed between α3β1 
integrin and CD151 (Yauch et al., 1998). However, the CD151-α3β1 integrin role in the 
context of neutrophil interaction with S. aureus has not been investigated yet. To test this, 
neutrophils were incubated for 1 hour with media or with JC1 isotype control, anti-CD151 
(10µg/ml) or β1 integrin (5µg/ml) antibodies. This was then followed by a 30 minute 
incubation with live S. aureus at MOI5. The 5µg/ml of anti- β1 integrin antibody was used 
since previous optimisation experiments showed better inhibition of neutrophil interaction 
with S. aureus compared to 10µg/ml of the antibody (Appendix IV). Statistical analysis of 
the data showed significant reduction of neutrophil interaction with live S. aureus when 
neutrophils were incubated separately with anti-CD151 or anti-β1 integrin antibodies but 
not when they were co-incubated with both antibodies (Figure 4.32). 
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Figure 4.31: Effect of anti-CD151 antibodies on neutrophil interaction with live S. aureus 
WT and fibronectin mutants SRCO11 and SRCO12. 
Plasma/Percoll-purified neutrophils from venous blood of healthy volunteers were 
incubated for 1 hour with media, JC1 isotype control or anti-CD151 antibodies at 10µg/ml 
followed by a 45 minute incubation with live S. aureus WT or fibronectin mutants SRCO11 
and SRCO12 at MOI5. Neutrophil interaction with the different bacterial strains was 
assessed by light microscopy. Data from 7 independent donors is expressed as mean±SD. 
Statistical analysis carried out by one-way ANOVA with Bonferroni's post-test with repeated 
measures (*p<0.5). 
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Figure 4.32: Effect of anti-CD151 and anti-β1 integrin antibodies on neutrophil interaction 
with S. aureus. 
Plasma/Percoll isolated neutrophils from venous blood of healthy volunteers were 
incubated for 1 hour with media, JC1 isotype control, anti-CD151 antibodies at 10µg/ml 
or/and anti-B1 integrin at 5µg/ml followed by a 30minute incubation with live S. aureus at 
MOI5. Neutrophil interaction with live S. aureus was assessed by light microscopy. Data 
from 5 independent donors is expressed as mean±SD. Statistical analysis carried out by one-
way ANOVA with Bonferroni's post-test with repeated measures (*p<0.5). 
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4.3. Discussion 
In this chapter I have shown for the first time that tetraspanins have a potential role in 
neutrophil interaction with the important clinical pathogen S. aureus. Light microscopy 
indicated that CD151 may play a role in neutrophil interaction with different strains of S. 
aureus, but not with S. pneumoniae or NTHi. No role for CD151 was shown in MDMs 
interactions with S. aureus, although this was a single experiment and this hypothesis would 
need more rigorous testing. Gentamicin protection assays and fluorescent microscopy data 
further strengthened the findings by showing less S. aureus internalisation in anti-CD151 
antibody treated neutrophils. Moreover, results indicate no cumulative role for anti-CD151 
and anti-β1 antibodies in reducing neutrophil phagocytosis of S. aureus. The overall data 
suggest, therefore, a putative role for CD151 in modulating neutrophil S. aureus 
phagocytosis. 
Anti-CD151 antibodies reduced neutrophil interactions with S. aureus WT and JE2 strains. 
No role was shown for CD9, CD63 and CD37. A collective role was shown for CD9, CD63 and 
CD151 in modulating S. aureus interactions in epithelial cells (Green et al., 2011). It is 
possible that the collective antibody use against the tetraspanins mentioned above, would 
result in a more profound decrease in neutrophil interaction with S. aureus compared to 
the single antibody use, though more research must be conducted. Furthermore, 
investigations in this thesis were conducted using only two strains of S. aureus. A 
comprehensive understanding of CD151 therapeutic implication in neutrophil-S. aureus 
interactions, would require, however, the use of more S. aureus clinical isolates and possibly 
other Staphylococcus strains. 
Results in this chapter show no role for CD151 in neutrophil interaction with NTHi and S. 
pneumoniae. These results are not surprising. Unlike S. aureus, S. pneumoniae was 
opsonised prior to neutrophil incubation suggesting the use of phagocytic receptors by the 
bacteria to enter the cells. Neutrophils from mice poorly phagocytose Haemophilus 
influentzae, which is in accordance with the 4-5% NTHi internalisation rate by neutrophils 
seen in this thesis (Tay et al., 2015). Taken together, this suggests that S. pneumoniae and 
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NTHi are most probably not internalised by neutrophils using the same mechanism 
employed for S. aureus internalisation. 
The MDMs gentamicin protection assay results showed no change in S. aureus 
internalisation in the presence of anti-CD151 antibodies. However, the variable results with 
anti-CD151 antibodies seen in MDMs killing of S. aureus indicate that perhaps CD151 may 
play a role in MDMs killing of the bacteria. To confirm this, more rigorous investigations 
would need to be conducted. Although to date it is known that monocytes express CD151 
at the plasma membrane and cytoplasmic level, there is no evidence in the literature for 
CD151 involvement in macrophage/monocyte-bacterial interactions (Tohami et al., 2004). 
The flow cytometry CD151 expression data indicates that CD151 expression on the 
neutrophil cell surface could not be quantified accurately. Incubation of neutrophils with 
pre-stained antibodies, obtained in house or commercially, showed a marked nonspecific 
binding of the JC1 isotype control, even after serum blocking of Fc receptors. When using 
the HEC-1-B positive control cell line, CD151 detection was possible with both the in house 
anti-CD151 antibody, probed with a secondary antibody, and with the pre-stained 
commercial antibody, although the effect was more moderate. Furthermore binding of the 
JC1 isotype or secondary antibody only controls was, unlike in neutrophils, similar to the 
unstained baseline control, which is possibly due to the high level of Fc receptors on the 
neutrophil surface (Hostoffer et al., 1993; Sengelov et al., 1994). In addition, the literature 
suggests that neutrophils have low CD151 expression, most of which being localised in the 
intracellular compartment in the endosomes, late endosomes and lysosomes with small 
amounts on cell surface (Sincock et al., 1999; Tohami et al., 2004). Considering this, high 
surface levels of Fc receptor could hinder accurate CD151 detection. Though in this thesis 
CD151 expression could not be detected on neutrophil surface, considering the literature 
neutrophils would be expected to have low levels of CD151 on their surface. It is possible 
that the experimental design was not sensitive enough to detect the tetraspanin or a 
different technique would need to be used to demonstrate CD151 presence on neutrophil 
cell surface. At the same time, considering this thesis results, the hypothesis that 
neutrophils do not have CD151 on their surface cannot be excluded. Future experiments 
could include human serum to attempt to reduce the JC1 nonspecific binding or employ a 
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different technique, such as fluorescent microscopy, to probe for CD151 presence on 
neutrophil surface. 
To determine if the anti-CD151 antibodies affected the internalisation or adhesion of S. 
aureus to neutrophils, Trypan Blue was used to initially to distinguish between internalised 
and surface bound bacteria due to its ability to quench the external bacteria fluorescence. 
However, ToPro-3 staining indicated that it is an unsuitable method due to neutrophil lysis 
which most probably resulted in Trypan Blue cell entry. The unsuitability of the technique 
is contrasting previous findings, where the method was used successfully to discriminate 
between internalised and cell-surface bacteria (Nuutila and Lilius, 2005; Santos et al., 2015). 
One of the reasons for cell lysing is the high toxicity of Trypan Blue which may have affected 
cell viability. However, detrimental cell toxicity with Trypan Blue has only been determined 
30 minutes post incubation, a much longer time compared to the experiments conducted 
in this thesis (Awad et al., 2011). Therefore, it can be speculated that S. aureus neutrophil 
incubation could have rendered cells more susceptible to lysis allowing Trypan Blue cell 
entry and internal bacteria fluorescence quench. 
Consequently, fluorescent microscopy was used to investigate this hypothesis. Significantly 
less pHrodo stained live S. aureus was seen with anti-CD151 antibodies compared to the 
control. Since pHrodo fluoresces only at an acidic pH, the results indicate that less S. aureus 
is phagocytosed in the presence of anti-CD151 antibodies (Aziz et al., 2013). Attempts to 
co-stain S. aureus with both pHrodo and Alexa Fluor 647 dyes resulted in poor visualisation 
of Alexa Fluor 647 stained bacteria. Alexa Fluor 647 stained bacteria were found to be 
fluorescent by flow cytometry suggesting the staining procedure was successful. Co-
visualusation of the two dyes is also possible, as indicated by in vivo studies conducted in 
zebrafish model (Ellett et al., 2015). It is possible that the microscope used could have 
photobleached quite rapidly the Alexa Fluor 647 dye, resulting in poor visualisation of the 
dye. 
Gentamicin protection assays further confirm that less S. aureus is internalised by 
neutrophils with anti-CD151 antibodies. The results also show that the bacteria were not as 
effectively killed with the anti-CD151 antibody, as shown by the comparable bacterial load 
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between the two time points. The differential internalisation effectiveness was initially 
proposed to be due to differential cell lysis rates between conditions, a hypothesis 
disproved by similar %ToPro-3 cell staining between conditions. A role for CD151 in the 
endocytosis of a foreign pathogen was demonstrated in the context of cervical cancer 
(Scheffer et al., 2013). Human papillomavirus type 16 (HPV16)-CD151 complexes were seen 
to be endocytosed in endosomes in a clathrin-independent mechanism, in a process that 
required TEMs (Spoden et al., 2008). A similar mechanism could be seen in this context. 
CD151 may be involved in S. aureus internalisation by promoting fusion of late and early 
endosomes with the phagosome to aid in its sealing and maturation. Alternatively, CD151 
can be endocytosed via the clatherin-dependent pathway, due to its tyrosine-based sorting 
motif, by interacting with AP-2 (Sincock et al., 1999; Winterwood et al., 2006). However, 
the close proximity of the motif to the plasma membrane can constrain stericaly the 
interaction with AP-2, suggesting a clatherin-independent internalisation of the protein 
being most probable (Rohrer et al., 1996). Fusion of CD151 with early and late endosomes 
can be probed, using fluorescent microscopy technique, by conducting co-localisation 
studies looking at S. aureus and CD151 co-localisation with Rab5, Rab7 stained early and 
late endosomes. This mechanism could also require TEMs formation to bring in close 
proximity other CD151 binding partners to facilitate this process. Integrins are known to be 
involved in pathogen uptake as a result of their ability to initiate signalling to promote actin 
rearrangement upon activation (Dupuy and Caron, 2008). CD151 can form stable 
interactions with many integrins to modulate cellular processes, including α3, α6 and β1 
(Hong et al., 2012b; Lammerding et al., 2003; Nishiuchi et al., 2005; Puklin-Faucher and 
Sheetz, 2009; Takeda et al., 2007). In glioblastoma cells the CD151-integrin complex is 
required for AKT phosphorylation and downstream signalling following migration, while in 
epithelial cells CD151 promotes multimolecular complexes formation in the membrane by 
promoting α3β1/ α6β1 interaction with the GTPases Ras, Rac1, Cdc42 (Hong et al., 2012a; 
Tilghman et al., 2016). As described in Chapter 1, CD151-dependent signalling activation is 
dependent on the cellular context. Therefore, considering that GTPases are involved in 
neutrophil cytoskeletal rearrangements and AKT is involved in neutrophil response to S. 
aureus, the use of the anti-CD151 antibodies could have altered integrin interactions to 
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disrupt either of the pathways (Arbibe et al., 2000; Liu et al., 2013; Zhong et al., 2003). 
Kinase and GTPase activation can be probed using commercially available kits such as the 
LISA activation assay kits to detect GTPase activation. Moreover, the separate incubation of 
neutrophils with the anti-CD151 and β1 blocking antibodies resulted in significant reduction 
of neutrophil interaction with S. aureus while antibody co-incubation showed similar 
interaction rates to the control. This lack of the cumulative effect with the antibodies may 
be due to the steric antibody inhibition when CD151 and β1 integrin are in close proximity. 
This is highly probable since the anti-CD151 antibody used in this study, 14A2, is presumed 
to disrupt the tetraspanin interaction with the α3, β1 and β4 integrin chains (Geary et al., 
2001; Yamada et al., 2008). This is due to the α3 region of the α3β1 integrin and the anti-
CD151 antibody binding domains recognising two overlapping epitopes in the EC2 region of 
the tetraspanins (Berditchevski et al., 2001; Yamada et al., 2008; Yauch et al., 2000). Though 
disruption of integrin –CD151 interaction by the antibodies could explain the reduced 
neutrophil phagocytosis of S. aureus, more research must be conducted to confirm this. 
Further investigations using light microscopy showed decreased, but non-significant, 
neutrophil interaction with fibronectin mutants in the presence of anti-CD151 antibodies 
when compared to the control. The fibronectin mutants (See section 2.4.1.) were used due 
to lack of ability to bind to fibronectin. This result possibly indicates that fibronectin may 
not be involved in mediating a CD151 dependent neutrophil S. aureus interaction. However, 
before this hypothesis is excluded I consider that more investigations need to be done by 
using a different technique. For instance, neutrophil, fibronectin and S. aureus WT and 
mutants triple staining can allow visualisation of the interaction and bacterial 
internalisation outcome with or without the anti-CD151 antibodies. It is possible that 
fibronectin may still be involved in this process, considering the lack of significant inhibition 
with anti-CD151 antibodies. Moreover, S. aureus adhesion to fibronectin may be also 
facilitated by other tetraspanins. TEMs association can orchestrate many cellular processes 
including cell migration, signalling in immune complexes and viral cell entry (Levy and 
Shoham, 2005b; Mantegazza et al., 2004; Spoden et al., 2008). CD151-CD9, CD151-CD81 
homodimers can be found in cell plasma membrane (Kovalenko et al., 2004). For example, 
CD9 can interact with fibronectin binding integrins and Hsc70 receptor, exploited by S. 
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aureus to adhere and gain entry into host cells (Guerrero and Moreno, 2012; Wilkinson et 
al., 1995). Most recently, CD9 was shown as a potential therapeutic target against S. aureus 
adhesion to epithelial cells (Ventress et al., 2016). CD9 can therefore promote S. aureus 
adhesion to neutrophils and potentiate the phagocytic process. However, anti-CD9 
antibodies were without effect suggesting that the tetraspanin may not be involved in the 
process. Nonetheless, CD81 is required for Listeria monocytogenes bacteria entry into 
epithelial cell (Tham et al., 2010). CD81 can form complexes with fibronectin binding 
integrins such as α4β1 found on neutrophil surface (Pereira et al., 2001; Serru et al., 1999; 
van den Berg et al., 2001). The function of this tetraspanin was not probed in our model 
system but evidence suggests investigative potential. 
CD151 can interact with PI4-K type II and bring into close proximity the α3β1 integrin to 
facilitate cell migration (Yauch et al., 1998). Therefore, activation of PI4-K type II upon 
neutrophil interaction with S. aureus was investigated by western blotting. Despite using 
different antibodies, time points, MOI and strains of S. aureus, change in PI4-K type II 
expression between conditions could not be seen in neutrophils due to the presence of 
nonspecific bands. PI4-K type II expression could not be seen in neutrophils incubated with 
S. pneumoniae or beads. Less nonspecific binding was seen when neutrophils were 
incubated with S. aureus SpaA mutant compared to WT. However, the high number of 
nonspecific bands seen with both S. aureus strains in the 55kDa expected region of PI4-K 
type II, indicates unsuitability of the technique to study the kinase expression. Alternative 
techniques could be used to study the interaction such as co-immunoprecipitation, 
although the high amount of nonspecific binding seen with the antibodies can lead to the 
precipitation of artefact proteins, as well as nuclear magnetic resonance (NMR). NMR would 
be a more desirable technique since it is highly sensitive and transient protein interactions 
can be detected. 
As described in Chapter 3, the anti-tetraspanin antibodies could potentially alter neutrophil 
functions not only via their interaction with the target but also via their Fc region that could 
interact with the Fc receptors on adjacent neutrophils (Murphy, 2012; Porges et al., 1994). 
In this chapter only anti-CD151 antibodies were used to show a reduced neutrophil-S. 
aureus interaction. Therefore, to test in future experiments if the Fc region of the antibodies 
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alter neutrophil-S. aureus interactions by interacting with Fc receptors on adjacent cells, 
CD151 Fab fragments would need to be tested in parallel with the antibody. This experiment 
was not attempted in this thesis due to lack of availability of the CD151 Fab fragments. 
Moreover, reduced S. aureus interaction with neutrophils could be due to Staphylococcal 
SpA protein binding to the IgG region of the anti-CD151 antibody and preventing bacterial 
adhesion to the neutrophil and subsequent phagocytosis (Forsgren and Nordstro.K, 1974). 
Phagocytic index obtained from light microscopy samples (Figure 4.30A) showed less 
neutrophil interaction of S. aureus SpA mutant when compared to the WT strain. Although 
this is a single experiment and more thorough investigation would need to be conducted, 
this light microscopy data suggests that SpA protein-Fc anti-CD151 antibody region 
interaction does not take place or is not required to reduce neutrophil-S. aureus 
interactions.  
Similar to Chapter 3 description, neutrophils are genetically intractable limiting the tools 
available to investigate CD151 function in mediating neutrophil interaction with S. aureus. 
Previous research conducted in our group showed, however, the suitability of lentivirus 
vectors to overexpress proteins in neutrophils (Dick et al., 2009). This technique can 
therefore be used to overexpress CD151 in neutrophils, generally seen at low levels, to 
investigate CD151 overexpression effects in neutrophil-S. aureus interactions. For further 
experiments, CD151 role in neutrophil-S. aureus interactions would need to be interrogated 
using a more amenable in vitro model or, for a more clinically-related context, using an in 
vivo system. PLB-985 cell line once differentiated have similar morphology and function to 
that of primary neutrophils (Pivot-Pajot et al., 2010). Therefore, PLB-985 cells are a good in 
vitro model to conduct CD151 knockdown to probe further S. aureus-neutrophil 
interactions.  
The CD151 human and mouse homologs are 93% similar, the highest similarity of all 
tetraspanins, indicating that the mouse can be used as a suitable model to study the 
tetraspanin (Fitter et al., 1998). The four transmembrane regions, the N-glycosylation sites, 
the 15 cysteine residues as well as the EC2 domain are also highly conserved between the 
two species (98% and 89% identity) (Hasegawa et al., 1997). In vivo CD151 knockout mouse 
models were developed by different laboratories to investigate CD151 functions in different 
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illnesses (Sachs et al., 2006; Takeda et al., 2007; Wright et al., 2004). However, none of the 
groups looked at the role of CD151 in an infectious model. The use of mice to study the role 
of CD151 in neutrophil interaction with S. aureus could however give inaccurate results. 
According to the protein database bank, mice contain a protein of unknown function that 
has the extracellular domain 57% identical to the CD151 one, called BAB22942 (Hemler, 
2001). What is more, the 11-amino-acid motif in the EC2 domain of CD151 is identical to 
the unknown protein one, differing by 2 amino acids (RDHASNIYKVE- RAHPSNIYKVE) 
(Berditchevski et al., 2001). It is possible that this protein would have similar or 
complementary function to that of CD151. Furthermore tetraspanins are known to form 
TEMs where they often play redundant function, making it difficult for single tetraspanin 
function investigation (Huang et al., 2005). It is highly possible that CD151 knockout in the 
mouse would result in function compensation by other tetraspanins. 
CD151 role in neutrophils have not yet been investigated using in vivo zebrafish knockout 
model. The Sanger institute initiative was to have a CD151 zebrafish mutant with a 
nonsense mutation by the end of 2016, however the fish are not available yet. A CD151 
knockout zebrafish has been developed in the past two years by Katherine Marsay, a PhD 
student in Dr. Lynda Partridge group. The fish line is stable but it is yet to be phenotyped 
before CD151 implication in neutrophil interaction with S. aureus is investigated. 
Using different molecular and biochemical methods, I showed for the first time a correlation 
between tetraspanin CD151 and neutrophil internalisation of S. aureus. Interestingly, no 
role for CD151 was determined for neutrophil interaction with NTHi or S. pneumoniae. 
These results confirm further the role of tetraspanins in pathogen cell interactions. 
However, the result needs to be understood further with additional experiments. 
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Chapter 5: Final Discussion 
5.1. Thesis summary 
In this thesis I have demonstrated for the first time that tetraspanins are involved in 
modulating two key neutrophil functions: survival and phagocytosis. 
In chapter 3 I demonstrated using morphology and biochemical methods that anti-CD63 
antibodies and Fab fragments inhibit constitutive neutrophil apoptosis. Interestingly, 
neutrophils from individual subjects varied in their responsiveness to anti-CD63 antibodies 
yet western blot analysis showed no variation between donors or time points. Contrary to 
the literature, flow cytometry analysis did not show a conclusive result of CD63 up-
regulation on the neutrophil surface over time. My results also demonstrate that 
neutrophils from age matched healthy controls and COPD patients have similar apoptosis 
inhibition rates in the presence of anti-CD63 antibodies. 
In chapter 4 I showed that anti-CD151 antibodies reduce neutrophil interactions with S. 
aureus but not with S. pneumoniae or NTHi. Fluorescent microscopy with pHrodo labelled 
bacteria suggest that anti-CD151 antibodies reduce phagocytosis of S. aureus as opposed 
to just adherence. Gentamicin protection assays confirmed a reduction in S. aureus 
internalisation. Attempts to investigate changes in CD151 expression on neutrophil surface, 
using a panel of in-house and commercially-available antibodies, failed to show any change 
in CD151 expression between the two conditions. Subsequent functional assays showed no 
cumulative role for anti-CD151 and β1 antibodies in reducing neutrophil interaction with S. 
aureus nor indicated a clear requirement for fibronectin in the process. 
5.2. Major findings and impact 
5.2.1. CD63 role in neutrophil survival 
CD63 is a highly abundant lysosomal protein, often recruited to the plasma membrane upon 
neutrophil activation (Cham et al., 1994; Hatskelzon et al., 1993; Lopez et al., 1995; Nishibori 
et al., 1993). CD63 is part of the tetraspanin molecular facilitator group, with roles in diverse 
cellular functions (Horejsi and Vlcek, 1991; Yanez-Mo et al., 2009). In this thesis, I have 
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shown for the first time that CD63 is involved in modulating neutrophil apoptosis. 
Interestingly, CD63-mediated regulation of neutrophil apoptosis was proven to be donor 
dependent, with some donor cells experiencing profound apoptosis inhibition with anti-
CD63 antibodies while others were without effect. Although no overall change in protein 
expression was seen between the two groups, the differential tetraspanin surface 
expression was not investigated and doing this may reveal clues about whether CD63 
trafficking/recycling may play a role in mediating apoptosis. Age, gender, diet or 
environment can also potentially alter neutrophil survival results, but the study ethics did 
not allow us to collect and report on these characteristics (Spitzer and Zhang, 1996). 
Neutrophils isolated from COPD patients also demonstrated a delay in apoptosis in the 
presence of anti-CD63 antibodies, which suggests this pathway is not dysregulated in this 
disease. These results are in contrast with the literature, where decreased CD63 expression 
was seen in the COPD cohort (Zhang et al., 2007). Age variability is often linked to changes 
in results outcome, being positively correlated to changes in neutrophil function in the 
elderly population (Hazeldine et al., 2014; Panda et al., 2009). Moreover, COPD prevalence 
is in 45+ age group (Doucet et al., 2016). Taken together, discrepancies between my current 
and Zhang et al. results may be due to the age matching of the healthy controls with COPD 
patients in this thesis while Zhang et al. used a much younger control group to match with 
the COPD patients. 
The study adjoins another function to CD63 in neutrophils, to the already known one of cell 
migration and protein granule transport, suggesting that the tetraspanin may be more of a 
global regulator of neutrophil processes (Kallquist et al., 2008; Skubitz et al., 1996; Trikic et 
al., 2011).  
5.2.2. CD151 role in neutrophil S. aureus interactions 
Neutrophils are fundamentally important in the defence against S. aureus (Odell and Segal, 
1991; Quie et al., 1967). It is well documented that tetraspanins are involved in pathogen 
trafficking and adhesion to different cell types (Monk and Partridge, 2012). In this thesis I 
have shown for the first time that CD151 is involved in neutrophil interaction with S. aureus. 
This adds to the current knowledge that S. aureus uses tetraspanins for attachment to cells 
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and induce cytotoxicity, as shown by studies conducted on epithelial cells (Green et al., 
2011; Ventress et al., 2016; Virreira Winter et al., 2016). CD151 was indeed part of the TEMs 
involved in S. aureus adhesion to epithelial cells, along with CD9. However, our results did 
not indicate a role for CD9 in this context, suggesting perhaps that tetraspanin function is 
cell type dependent. CD151 has not been widely studied in bacterial interactions with host 
cells, however work conducted using HPV16 indicated a role for CD151 in viral endocytosis 
(Scheffer et al., 2013). Taken together, this indicates that CD151 has putative adhesion and 
trafficking abilities in this context, although more studies must be conducted to fully 
understand this in the neutrophil. Interestingly, CD151 had a specific role for S. aureus 
internalisation but not for S. pneumoniae and NTHi. This finding suggests a potential 
specificity of the tetraspanin for S. aureus, making it a good therapeutic target for this 
pathogen, albeit much research using different bacteria is needed to confirm this. 
Moreover, it may also be speculated that CD151 may act as a gateway for S. aureus 
infection. Although this hypothesis needs further research, there is evidence that S. aureus 
α-hemolysin uses TSPAN14 on epithelial cells to induce cytotoxicity (Virreira Winter et al., 
2016). Taken together, the study presents for the first time CD151 role in specific neutrophil 
phagocytosis of S. aureus. 
5.3. Therapeutic potential 
Persistence of neutrophils in the lung, concomitant with a delay in apoptosis and an inability 
to clear intruding pathogens, has long been associated with increased COPD severity 
(Damiano et al., 1986; Hoenderdos and Condliffe, 2013; Nadel, 1991; Redinbo, 2014; Zhang 
et al., 2012). Current therapies in COPD inflammation mostly treat symptoms and fail to 
stop disease progression. These treatments often include bronchodilators such as β2-
adrenoreceptor agonists and glucocorticoids. Both bronchodilators encourage an 
inflammatory phenotype with β2-adrenoreceptor agonists failing to inhibit neutrophil 
survival while glucocorticoids have been shown to promote increased neutrophil lifespan 
(Anderson et al., 2014; Burgon et al., 2014; Liles et al., 1995; Meagher et al., 1996). 
Tetraspanins have already been proposed as therapeutic targets, mainly in infections and 
cancer (Cozens and Read, 2012; Haeuw et al., 2011; Hassuna et al., 2009; Hemler, 2008; 
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Murayama et al., 2015; Ventress et al., 2016). Antibody targeting of the two highly 
expressed tetraspanins in cancer, CD9 and CD151, was demonstrated to reduce tumour cell 
growth (Haeuw et al., 2011; Murayama et al., 2015). At the same time, anti-CD81 antibodies 
can prevent hepatitis C virus entry in hepatocytes by stopping adhesion of its E2 protein to 
the tetraspanin (Bertaux and Dragic, 2006). Most importantly, anti- S. aureus adhesion 
therapies are showing great preliminary promise in the context of S. aureus adhesion to 
epithelial cells (Ventress et al., 2016). The study showed that nanomolar levels of short 
peptides that were derived from the sequence of CD9 EC2 domain are effective in reducing 
S. aureus adhesion to epithelial cells and 3D tissue skin model (Ventress et al., 2016). This 
demonstrates therapeutic targeting potential for these tetraspanins.  
Before consideration is given for tetraspanins as therapeutic targets to modulate neutrophil 
functions, I consider there are some questions that need to be answered. Neutrophils are 
required for an effective defence against invading microorganisms, and compromising 
immunity by inducing apoptosis may have deleterious effects for the host. This is 
particularly important for patients with chronic lung disease, who are frequently colonised 
with pathogens. Therefore, the choice of therapeutic treatment and delivery must take into 
account these factors. My data suggests that the use of anti-CD63 antibodies inhibit 
neutrophil apoptosis in COPD patients, suggesting the unsuitability of these antibodies to 
use as therapeutics in this context. However, CD63 ability to internalise antibodies makes it 
an useful target to deliver drugs or RNAi therapeutics, when conjugated with the antibodies, 
to alter cellular functions including targeting neutrophil apoptosis through a different 
pathway (Barrio et al., 1998). This approach has already been proposed in cancer therapy 
(Barrio et al., 1998). Moreover, if CD63 is demonstrated to associate with TEMs to modulate 
neutrophil survival, physical disruption of these association can be conducted to alter cell 
function. Acyl transferases are required for protein palmitoylation, an important process 
for protein assembly into TEMs, therefore targeting the relevant acyl transferases could 
disrupt TEMs interactions (Charrin et al., 2002; Mitchell et al., 2006). 
Although more research needs to be conducted, the results obtained so far suggest that 
CD151 appears to be a good therapeutic target since its function seems to be restricted only 
to neutrophil phagocytosis of S. aureus. Neutrophils are professional phagocytes, and unlike 
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epithelial cells, S. aureus phagocytosis and killing is their main function. Thus a natural 
question we may need to address in future work is if we want to inhibit neutrophil 
phagocytosis of S. aureus and what would be the overall effects. As discussed in chapter 1, 
neutrophil can kill S. aureus with a vast array of proteolytic enzymes and ROS production 
released within the phagolysosome. Equally, S. aureus has evolved many mechanisms to 
evade killing by neutrophils including the ability to use neutrophils as a gateway for 
infection by surviving and replicating within the cytoplasm (Fraunholz and Sinha, 2012; 
Gresham et al., 2000; Grosz et al., 2014). The next step would thus be to understand if 
CD151 promotes S. aureus entry via the phagolysosomal pathway or if it is exploited by the 
bacteria to gain entry, survive and replicate within neutrophils. These are questions that 
require further understanding before tetraspanin targeting for therapeutics is considered. 
The last thing that needs to be considered is the effect that tetraspanin targeting on 
neutrophils would have on the surrounding tissues. Tetraspanins are ubiquitously 
expressed in many tissues, aiding to conduct a multitude of processes, therefore targeting 
one cell may have negative effect on the surrounding tissues (Charrin et al., 2014). CD151 
has an important role in the normal function of alveolar epithelial cells by maintaining 
adhesion strength of the basement membrane, its loss resulting in pulmonary fibrosis in 
mice (Tsujino et al., 2012). Therefore, if a CD151 containing spray therapeutic would be 
used in the lungs, in addition to reducing neutrophil S. aureus load, it could also promote 
bacterial entry in the organism by reducing basement membrane strength in the 
surrounding tissues. Consequently, experiments using in vivo models, such as mice, would 
play a vital role in determining the therapeutic potential and toxicological drawbacks of 
targeting tetraspanins on neutrophils. 
5.4. Study limitations 
A confounding variable of this study is the method employed to attain a purified neutrophil 
population from whole blood. The Percoll purification process can result in cell activation, 
although historically it has been shown to be less activating compared to other methods 
(Venaille et al., 1994). Additional variation that could result as well in cell activation can be 
introduced by different phlebotomists and scientists handling the blood (Wehlin et al., 
- 201 - 
 
1998). However, a switch from round to an elongated cell morphology as well as neutrophil 
aggregation, as seen in a haemocytometer chamber, is usually indicative of cell activation. 
Moreover, as described above, donor age variability is often linked to variation in the results 
outcome due to the neutrophil differential response to stimuli (Hazeldine et al., 2014; 
Panda et al., 2009). 
Another limiting factor in this study is that neutrophils are short lived in culture and 
genetically intractable. Thus, the experimental techniques used to probe their functions in 
this thesis were limited. Ideally I would have wanted to knockdown CD63 and CD151 in 
neutrophils to confirm the antibodies functions. 
5.5. Future work 
5.5.1. Studies on CD63 effect on neutrophil survival 
There is a body of evidence that shows TEMs modulate various cell functions, including cell 
apoptosis (Kuhn et al., 2007). Future work will involve investigating CD63 TEMs formation 
to see which co-factors localise with CD63 and whether TEMs formation is required for 
neutrophil apoptosis to take place. CD63 association in TEMs can be initially investigated 
using a panel of anti-tetraspanin antibodies, followed by high resolution fluorescent 
microscopy co-localisation studies of these complexes, due to their small size of only several 
nm (Grove, 2014; Zuidscherwoude et al., 2015). Cholesterol depletion assays with methyl-
β-cyclodextrin would also be a good technique to investigate CD63-partner protein 
interactions (Pierini et al., 2003; Yang et al., 2012). Methyl-β-cyclodextrin can disrupt, 
however, cellular actin having the potential to disrupt additional cellular functions (Kwik et 
al., 2003). 
As described in chapter 3 discussion, CD63 could regulate neutrophil survival by potentially 
disrupting intracytoplasmic signalling by affecting kinases, such as PKCδ and PI4-K type II, 
trafficking to the plasma membrane. Alternatively, the tetraspanin can regulate one of the 
Bcl-2 family members protein expression by promoting a signalling pathway activation, as 
seen in acute myelogenous leukemia cells where CD82 can regulate the expression of 
BCL2L12 via STAT5/AKT signalling (Nishioka et al., 2015). A next step in this process would 
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be to interrogate CD63 function in the above processes. Western blot can be used to 
determine signalling molecule activation, such as PKCδ, PI4-K type II and AKT, or by 
conducting fluorescent microscopy co-localisation studies or pull-down assays to probe 
CD63 interaction with the signalling molecules. 
Here, I showed that neutrophil apoptosis reduction rates are similar in both healthy control 
and COPD populations with anti-CD63 antibodies, irrespective of overall CD63 protein 
expression. This is an interesting result considering it has been demonstrated that CD63 
mRNA and plasma membrane protein level is reduced in COPD patients compared to HC 
(Zhang et al., 2007). Alternatively, neutrophil survival, from cells isolated from the sputum 
of COPD patients, can be investigated in the presence of anti-CD63 antibodies to see if the 
effect is different to circulating cells. 
5.5.2. Further investigating the role of CD151 in phagocytosis of S. aureus.  
 As described above, it is possible that S. aureus uses CD151 to gain entry into neutrophils. 
While S. aureus is not strictly an intracellular pathogen, there is emerging evidence that this 
pathogen is able to survive and even replicate within the neutrophil cytoplasm and 
therefore may use the cell as a niche (Fraunholz and Sinha, 2012; Gresham et al., 2000; 
Grosz et al., 2014). To determine the function of the tetraspanin, CD151-S. aureus 
interactions could be investigated in the presence of the anti-tetraspanin antibodies using 
gentamicin protection assay or flow cytometry to screen a library of S. aureus mutants 
lacking candidate adhesion proteins or virulence factors, such as sar global regulator 
(Cheung et al., 1992). Moreover, time lapse super-resolution microscopy techniques could 
allow visualisation of S. aureus entering the neutrophil, from which it can be identified 
whether CD151 is required for bacteria binding or/and internalisation by neutrophils during 
this process. Moreover, CD151 TEMs formation to modulate neutrophil interaction with S. 
aureus can be investigated as described in the section above. 
5.6. Conclusion 
Chronic inflammatory diseases such as COPD are an increasing medical and economic 
burden, and are still poorly treated. Neutrophils are key cells in the pathophysiology of 
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chronic inflammation and I have investigated two elements of neutrophil behaviour, 
apoptosis and phagocytosis, because these form the foundation from which neutrophils 
perform important immune functions and contribute to inflammation. I have described 
previously undefined roles for the tetraspanins, CD63 and CD151 in apoptosis and 
phagocytosis, which not only adds to our knowledge of the mechanisms underpinning key 
neutrophil functions, but may also open up potential opportunities for therapeutic 
strategies in the future. 
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 Appendix I: 
 
1mg/ml Hemin  
Reagents Quantities 
Hemin powder 0.05g 
NaOH 5ml 
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 Appendix II: 
 
Phosphate lysis buffer (500µl) 
Reagents Volume (µl) 
Phosphatase inhibitor cocktail (PI) (1:100 dilution) 
(Merckmillipore, Watford, UK) 
5 
Phenylmethanesulfonyl fluoride (PMSF) (100mM) 
(Sigma-Aldrich, Poole, UK) 
5 
dH2O 
(Baxter, Newbury, UK) 
490 
 
2X SDS-PAGE loading dye (10ml) 
Reagents Concentration in buffer Volume 
1M Dithiothreitol (DTT) 
(Sigma-Aldrich, Poole, UK) 
0.1M 1ml 
20% Sodium dodecyl sulfate (SDS) 
(Fisher Scientific, Loughborough, UK) 
4% 2ml 
100% Glycerol 
(Fisher Scientific, Loughborough, UK) 
20% 2ml 
0.5M Tris HCl (pH6.8) 
(Fisher Scientific, Loughborough, UK) 
0.0625M 1250µl 
0.2% Bromophenol Blue 
(Sigma-Aldrich, Poole, UK) 
0.004% 200µl 
dH2O - 3.55ml 
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Stacking gel (1.5mm plates) 
Reagents 1 gel 2 gel 3 gel 4 gel 
Water 3ml 6ml 9ml 12ml 
40% Acrylamide 620l 1240l 1860l 2480l 
0.5M Tris pH 6.8 
(Bio Rad Laboratories, Hercules, California) 
1260l 2520l 3780l 5040l 
20% SDS 25l 50l 75l 100l 
20% APS 50l 100l 15l 200l 
TEMED 5l 10l 15l 20l 
 
10X Running Buffer 
Reagents Quantities 
Glycine 
(Fisher Scientific, Loughborough, UK) 
190g 
Tris Base 
(Fisher Scientific, Loughborough, UK) 
30.3g 
20% SDS 50ml 
dH2O to 1 litre 
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Resolving gel (1.5mm plates) 
12% Resolving gel reagents 1 gel 2 gels 3 gels 4 gels 
Water 6.6ml 9.9ml 13.2ml 16.5ml 
40% Acrylamide 
(Geneflow, Lichfield, UK) 
4.4ml 6.8ml 9ml 11.3ml 
1.5M Tris pH 8 
(Bio Rad Laboratories, Hercules, California) 
3.8ml 5.7ml 7.6ml 9.5ml 
20% SDS 75l 112.5l 150l 187.5l 
20% APS 
(Sigma-Aldrich, Poole, UK) 
150l 225l 300l 375l 
TEMED 
(Geneflow, Lichfield, UK) 
6l 9l 12l 15l 
 
Transfer Buffer 
Reagents Quantities 
Glycine 145g 
Tris Base 29g 
dH2O to 800ml 
Note: For experimental use, the Transfer buffer was diluted using a 1:2:7. ratio of Transfer 
buffer:methanol:water. 
 10X TBS 
Reagents Quantities 
Tris-HCl 1M pH 8.0 100ml 
Sodium Chloride (NaCl) 
(Fisher Scientific, Loughborough, UK) 
97.3g 
Water to 1000ml 
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 10 X TBS-Tween 
Reagents Quantities 
Tris-HCl 1M pH 8.0         100ml 
 NaCl 97.3g 
Tween-20 
(VWR chemical, Fontenay-sous-bois, France) 
5ml 
Water to 1000ml 
 
Primary and secondary antibody dilutions 
 Antibody  Dilutions 
Primary JC1 isotype    1:600 
Primary anti-CD63 1:600 
Primary anti-CD151 1:600 
Primary anti-phosphatidylinositol 4-kinase (PI4-K) type II 
(Sigma-Aldrich, Poole, UK; Abcam, Cambridge, UK; Abgent, San Diego, CA) 
1:600 
Primary anti-unphosphorylated P38 
(Cambridge Bioscience, Cambridge, UK) 
1:2000 and 
1:4000 
Secondary polyclonal goat anti-mouse 
(Dako, Cambridge, UK) 
1:2000 
Secondary polyclonal goat anti-rabbit 
(Dako, Cambridge, UK) 
1:1000 
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Appendix III: 
 
To make 4%PFA, 5g PFA was dissolved in 50 ml water, followed by the addition of 1ml of 
1M NaOH. The mixture was stirred at 65°C until dissolved. It was then topped with 10ml of 
10x PBS. The pH was adjusted to 7.4 by adding 1M hydrochloric acid (HCl). The 4%PFA was 
made by our in house technician Mrs. Catherine J. Cooke.  
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Appendix IV: Plasma/Percoll pure neutrophils were incubated for 20 hours with media JC1 
IgG1 isotype control (10µg/ml) and anti-B1 antibodies at 5 and 10 µg/ml. Phagocytic index 
was assessed using light microscopy. Data obtained from single experiment. 
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